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Stellingen 
behorende bij het proefschrift 
The lin1c of asthma outcome with AMP responsiveness and 
airway pathology 
1. Complete remissie van astma bestaat (dit proefschrift) 
2. Het fenotype van astma dient uitgebreid te worden met het 
AMP profiel ( dit proefschrift) 
3. Stoppen met roken lijkt ook vanuit pulmonaal oogpunt 
zinvol bij astma, maar geeft (nog) geen garanties voor de 
toekomst ( dit proefschrift) 
4. De kunst is om de eosinofiele inflammatie op tijd te 
ontdekken omdat dit geassocieerd is met versnelde 
achteruitgang van longfunctie (dit proefschrift) 
5. Versterkte luchtweggevoeligheid voor AMP is een geschikte 
indicator en provocator voor eosinofiele inflammatie (dit 
proefschrift) 
6. Na het bereiken van Well Controlled astma, lijkt er geen 
basis te zijn om nog voor Total Control te gaan (dit 
proefschrift) 
7. Klinische controle van astma heeft een fundament gekregen 
( dit proefschrift) 
8. Om klinisch verder te komen, gaan we met het onderzoek 
juist verder van de dagelijkse kliniek af 
9. Open deuren dienen ook evidence based te zijn 
10. Het verschil tussen stilstand en beweging is op een foto 
moeilijk te onderzoeken 
11. Als de sleutel voor behandelsucces zich in de handen van de 
patient bevindt, is het de uitdaging voor de dokter om het 
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THE NATURAL COURSE OF ASTHMA 
Asthma is a chronic inflammatory disorder of the airways associated with airway 
obstruction that is often completely reversible. Chronic asthmatic disease may lead to 
important morbidity and may have a large impact on quality of life. These complications 
are most likely the result of an inflammatory process in the airways underlying the 
clinical presentation of asthma. As a result of activation of inflammatory cells, an array 
of mediators and cytokines are produced and/or released, causing bronchoconstriction, 
vasodilatation, plasma exudation, mucus hypersecretion and activation of sensory 
nerves, all contributing to the clinical presentation of asthma. Simultaneously this 
ongoing inflammatory process may result in structural changes in the airways, such 
as subepithelial fibrosis, hyperplasia of airway smooth muscle cells, and angiogenesis. 
Ultimately these processes may lead to irreversible lung damage in some (but not all) 
asthmatics. This has indeed been found after long-term follow up of asthmatics, resulting 
in irreversible airflow limitation(l-4) 
Next to deterioration of disease over time, there may also occur asthma remission over 
time. This can occur both in a subset of adult and childhood asthma (3;5), meaning 
that these patients have normal lung function, and no clinical symptoms while not using 
asthma medication. This state has been defined as clinical or symptomatic asthma 
remission(4-7). However, since bronchial hyperresponsiveness is still present in the 
majority of patients with clinical or symptomatic remission(4-7), this suggests that the 
underlying disease process is not yet cured. This is supported by the observation that 
the bronchoalveolar lavage (BAL) fluid contains increased levels of eosinophils in some 
asthmatic children without current symptoms and medication for the last 12 months, 
when compared to healthy controls(8). Furthermore, higher numbers of eosinophils, 
T cells, mast cells and higher expression of IL-5 were found in the airway mucosa of 
patients with clinical remission, when compared to healthy controls(9). 
Given the persistence of bronchial hyperresponsiveness and elevated markers of 
pulmonary inflammation, despite the asymptomatic status in this group of patients, 
the definition of complete asthma remission has been introduced. This definition also 
includes absence of bronchial hyperresponsiveness as an additional criterium to the 
asymptomatic status(4;5). So far no studies have investigated pulmonary inflammation 
in this subset of asymptomatic patients and assessed if these subjects are really "cured" 
from their asthma. 
DETERMINANTS FOR PROGRESSION OR REMISSION OF ASTHMA 
Still little is known with respect to risk factors that determine progression or remission of 
asthma. It has been suggested in several studies that progression to persistent airway 
obstruction is more closely related to the duration of asthma than to age itself(1;2;10). 
Previous studies have revealed multiple risk factors for an accelerated FEV1 decline 
(15-50 ml/year) in asthma: low baseline lung function (FEV1 % predicted)(11-13), less 
reversibility to f32-agonists(2; 10), more severe bronchial hyperresponsiveness(12; 14), 
smoking(15), increased mucus production(16), male gender(17), and smoking (16) 
The pathological processes underlying the accelerated FEV1 decline in asthma are 
unknown. Several suggestions for the underlying pathological process come from cross­
sectional studies demonstrating an association between the above described risk factors 
and markers of airway remodeling and/or inflammation. For example, low baseline lung 
function has been associated with increased airway wall thickness(18). A more severe 
BHR has been associated with thickening of the subepithelial basement membrane(19), 
and with subepithelial fibrosis(20). Increased mucus production has been associated with 
hyperplasia and hypertrophy of epithelial goblet cells(21) and with increased presence of 
submucosal mucous glands(21). Also, an association has been shown between accelerated 
FEV1 and higher blood eosinophil numbers and decline in adult asthma patients(22). 
Not all asthmatics show this excess decline. Panhuysen et al investigated which factors 
contribute to outgrowing of asthma, which may occur in up to 25 % in the group of adult 
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asthma patients(S). Disappearance of asthma was associated with younger age and 
with less severe airway obstruction at first testing(S). In line, disappearance of airway 
hyperresponsiveness was associated with younger age and with both less severe airway 
obstruction at first testing and with a shorter untreated period of asthma(S). Grol et al 
investigated the outcome of asthma in children, and confirmed that a better lung function 
in childhood was associated with remission of asthma at young adulthood(3). 
The above mentioned risk factors for progression of asthma suggest that an accelerated 
FEV1 decline in asthma indeed results from ongoing inflammatory and remodeling 
processes in the airways. Furthermore, risk factors for remission of asthma support 
the hypothesis that early (sub)epithelial and inflammatory factors in the airway wall 
already determine whether patients may outgrow the disease. Probably, a combination 
of environmental and genetic risk factors plays a role in the ongoing process of airway 
inflammation and remodeling, consequently leading to the clinical progression or 
remission of asthma. More studies are needed to disentangle the causative factors. For 
an accurate assessment of the (lack of) decline in FEV1, it is very important to take the 
three phases in the development of FEV1 into account, i.e. initial growth, followed by a 
plateau phase, and after the age of± 30 years decline of FEV1(23;24). 
AIRWAY INFLAMMATION 
Asthmatic airway inflammation is characterised by a complex interplay of resident cells 
(epithelial and dendritic cells, fibroblasts, nerves, endothelial cells) and inflammatory 
cells (eosinophils, mast cells, macrophages, T-lymphocytes). Asthmatic inflammation 
contributes to the airway obstruction that is caused by inhalation of allergens. Allergen 
inhalation typically induces both an early response, with airway obstruction within 10 
minutes, and a late response that usually is associated with airway obstruction after 
8-24 hours. The early asthmatic reaction following inhaled allergen provocation is mast­
cell dependent. Mast cells secrete mediators like histamine, prostaglandin D2, and 
leukotriene C4, which are capable of inducing bronchoconstriction, mucus secretion, 
and mucosal edema. Mast cells in asthma localize in the airway smooth muscle (ASM), 
airway mucous glands, and bronchial epithelium. In these locations, mast cells may 
contribute to the development of ASM hypertrophy and hyperplasia, may facilitate 
the ongoing immunologic response (antigen presentation, Th2 differentiation and IgE 
synthesis), and may have consequences on epithelial function. Also, in post-mortem 
studies, mast cells have been associated with mucous gland hyperplasia and the mucus 
gland secretion(25). 
It is suggested that a structurally and functionally defective airway epithelium 
underlies abnormal responses to inhaled stimuli in asthma. These abnormal responses 
enhance signalling between the airway epithelium and underlying structural and 
immune cells. Eventually, this promotes a microenvironment that facilitates allergic 
sensitization, supports different types of inflammation, and predisposes the airways to 
exacerbations(26). The inflammatory cascade is thought to start with the presentation 
of an allergen by a dendritic cell to Th2 lymphocytes. This activates Th2 lymphocytes 
resulting in an asthma-characteristic release of IL-4 and IL-5 cytokines. This ultimately 
leads to allergen-specific IgE production by B cells and the recruitment, proliferation 
and maturation of the asthma-specific effector cell, the activated eosinophil. Activated 
eosinophils may release mediators like eosinophil-derived neurotoxin (EDN), major basic 
protein (MBP) and eosinophil cationic protein (ECP) that are cytotoxic and damaging 
to the airway epithelium. This damage to the airway epithelial may initiate a chronic 
inflammatory state of the airway wall. Thl lymphocytes may contribute to chronicity 
and to the effector phase in allergic disease. Thl lymphocytes increase IFN-y and TNF-a 
levels which promote activation and apoptosis of epithelial cells associated with epithelial 
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Chronic asthma is characterized by enhanced epithelial-mesenchymai communication in response to inhaled stimuli. The continuous release of 
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Chronic airway inflammation underlies the structural and irreversible changes of the 
airways. Several immunological mechanisms may contribute to the consolidation of 
airway inflammation(28;29). The bronchial epithelium of asthmatics seems to become 
fragile and to loose its protective properties. Increased expression of CD44 suggests 
that the bronchial epithelium transforms into a chronic repair phenotype with enhanced 
presentation of epidermal growth factor ligands to their receptors. Eventually, the 
bronchial epithelium becomes a continuous source of proinflammatory products as well 
as growth factors that drive airway wall remodeling(29). 
AIRWAY REMODELING 
Morphometric studies in post-mortem or resected lung specimens have confirmed that 
the airway walls of subjects with fatal and non-fatal asthma are thicker than those of 
non-asthmatics. Other studies have shown a significant correlation between increased 
airway wall thickness and irreversible airway obstruction{Boulet, 1995 221 /id}. The 
structural changes that are associated with increased airway wall thickness and chronic 
airway obstruction are: 
• Goblet cell hyperplasia and/or epithelial metaplasia(21) 
• Thickened lamina reticularis or subbasement membrane(20;30;31) 
• Submucosal collagen deposition(32) 
• Smooth muscle hyperplasia and hypertrophy(33;34) 
• Mucous gland hyperplasia(35) 
• Increased vascularity(36) 
• Small airway and parenchymal changes(37;38) 
ASTHMA AND SMOKING 
The prevalence of cigarette smoking among adults with asthma is surprisingly high. In a 
15-year follow-up study in Denmark the prevalence of current smoking in subjects with 
asthma (mean age 52 years) was 71 %, while in subjects without asthma this was 62% 
(p<0.001)(16). In The Netherlands, the prevalence of cigarette smoking in a cohort of 
young asthmatics with a mean age of 24. 7 years was 33%(39) which is comparable to 
the general population at that time. 
The clinical outcome of asthma is negatively affected by cigarette smoking. Asthmatic 
smokers have more severe asthma symptoms than non-smoking asthmatics(40), a 
higher frequency of asthma attacks(16), more hospital admissions( 41;42), accelerated 
lung function decline(16; 16) and increased asthma mortality(43). 
Cigarette smoking has negative effects on the lung in non-asthmatic subjects, causing 
increased airway inflammation, i.e. increased neutrophil, macrophage and CDS+ 
lymphocyte numbers in BAL(44-47) and increased inflammatory cell numbers in the 
bronchial wall, such as neutrophils, eosinophils, macrophages and mast cells(45;47;48). 
Moreover, cigarette smoking has been associated with features of increased remodeling, 
such as increased tenascin and laminin deposition under the basement membrane, in 
non-asthmatic subjects(48). 
At present, the underlying pathological processes of smoke-induced deterioration of 
asthma are largely unknown. As smokers are often excluded in asthma studies to prevent 
co-existence of chronic obstructive pulmonary disease, only a few studies have presented 
results with respect to the effects of smoking on asthmatic inflammation. These few 
studies showed that cigarette smoking has an impact on inflammation by increasing the 
number of neutrophils( 49 ;50) and IL-8 levels(50) in sputum and by increasing bronchial 
metaplasia, neutrophil elastase and IFN-y and intra-epithelial IL-8 in biopsies(51;52). 
Also white blood cell numbers are increased in asthmatic smokers(49;50). 
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MARKERS OF PULMONARY INFLAMMATION 
Bronchial hyperresponsiveness tests are regarded to be markers of airway inflammation. 
Traditionally, bronchial hyperresponsiveness is measured with methacholine or histamine; 
both are direct stimuli since they exert their effect directly on airway smooth muscle cell 
receptors. One study investigated a treatment strategy in which changes in treatment 
were based on regularly performed hyperresponsiveness tests to methacholine on top of 
the Global INiative for Asthma (GINA) guidelines(53). As a consequence of this strategy 
the dose of inhaled corticosteroids was almost doubled in the hyperresponsiveness 
arm versus GINA arm. As expected, this increased dose of inhaled corticosteroids was 
associated with clinically relevant improvements in respiratory symptoms, with less 
airway obstruction, with less hyperresponsiveness to methacholine, and with decreased 
airway inflammation and airway remodeling. A limitation to this study protocol may 
be that bronchial hyperresponsiveness to methacholine has a limited sensitivity to 
inflammatory changes after adjusting the dose of inhaled corticosteroids. The increase 
in the doubling dose of methacholine was only 1.1 in the hyperresponsiveness arm after 
2 years of treatment. This limited sensitivity probably contributes to the higher dose of 
inhaled corticosteroids in the hyperresponsiveness arm and may limit the option of a step 
down regime by titrating corticosteroid doses. 
Another stimulus to measure bronchial hyperresponsiveness is Adenosine 5'­
MonoPhosphate (AMP). AMP is an indirect stimulus, since it is thought to act via the 
release of inflammatory mediators from mast cells. It has been suggested that the 
response to AMP better reflects eosinophilic inflammation in asthma than the response to 
direct stimuli. The level of PC20 AMP was predominantly predicted by the percentage of 
sputum eosinophils in a cross-sectional study(54). In addition, the extent of corticosteroid­
induced improvement in PC20 AMP was solely related to the level of reduction in airway 
inflammation as reflected by reduced numbers of sputum eosinophils, lymphocytes, 
epithelial cells, and exhaled NO(55). Furthermore, bronchial hyperresponsiveness to AMP 
has been shown to respond more rapidly to treatment with inhaled corticosteroids than 
a challenge with a direct stimulus, with changes in PC20 AMP values already detectable 
after 1 week of treatment and returning to near-baseline levels after 1-week treatment 
discontinuation. In contrast, significant changes in PC20 methacholine are only detectable 
after 4 weeks of treatment and no significant changes are found after 4 weeks treatment 
discontinuation( 56). 
Measuring exhaled Nitric Oxide (NO) has been found useful in assessing and monitoring 
of airway inflammation. Previous studies have found an association between exhaled NO 
levels and asthma severity(57;58). Also treatment with inhaled corticosteroids leads to 
lower exhaled NO levels(59). However, in the same study, exhaled NO did not correlate 
with airway mucosal eosinophilia and conventional markers of asthma control(59). A 
recent review of 5 studies showed that treatment guided algorithms based on exhaled 
NO did not reduce the frequency of asthma exacerbations, in contrast to algorithms 
based on sputum eosinophils (60). Only one study with exhaled NO guided therapy 
showed that the maintenance ICS dose could be reduced according to NO levels (61). 
As mentioned above, induced sputum has also been used to monitor asthma inflammation 
during treatment. Green et al. measured eosinophils in induced sputum and adjusted 
inhaled corticosteroid levels according to eosinophil numbers, targeting a level of 1 and 
3%. Sputum based medication adjustments led to fewer (severe) asthma exacerbations 
and hospital admissions compared to the control group. In both groups, the doses 
of inhaled corticosteroids used were similar(62). In another study, data on asthma 
exacerbations was compared between treatment guided on eosinophils in induced sputum 
and on clinical data. With sputum guided treatment the time to the first exacerbation was 
longer (by 213 days), the relative risk ratio for an asthma exacerbation was lower (by 
49%), and the number of exacerbations needing prednisone was reduced (5 versus 15) 
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when compared to the control group. This strategy did not improve the frequency of non­
eosinophilic exacerbations, which were the most common exacerbations(63). Recently, 
the same group showed, in a pilot study of 20 patients, that a treatment strategy aiming 
at normalising sputum eosinophils also reduced mucosal inflammatory cells and MUCSA 
expression in bronchial biopsies in patients with mild to moderate asthma. However, 
no effects on airway remodeling were found as measured by subepithelial collagen 
deposition(64). 
ASSESSING CONTROL OF ASTHMA 
The GINA guidelines of 2006 emphasized the importance of asthma control, focusing on 
the level of impairment, the patient's future risk of exacerbations, loss of lung function 
and drug side-effects. 
The GOAL (Gaining Optimal Asthma control) study in 2004 aimed at achieving optimal 
control by applying strictly the aims of asthma treatment as defined by GINA in 2002. 
Optimal-control and well-control of asthma in this study were composite measures based 
on respiratory symptoms at day and night, use of rescue medication, peak expiratory flow 
rate, exacerbations, emergency visits and treatment-related adverse effects(65). These 
variables are easy to measure and applicable worldwide. Indeed many patients without 
control of their asthma improved to well-control or optimal-control levels after stepwise 
increase in the dose of fluticasone or fluticasone combined with salmeterol(66). 
Several questionnaires have been developed to measure asthma control. One of the 
questionnaires is the 7 items asthma control questionnaire (ACQ), which has been 
validated in a 9-week observational study in 50 adults with symptomatic asthma(67). 
The reliability of the ACQ was very high in patients with stable asthma (intra class 
correlation coefficient 0.90). The questionnaire responded significantly to changes in 
asthma control. Furthermore, high correlations were shown with asthma related quality 
of life (AQLQ questionnaire)(68), general health status, and other asthma symptoms. 
A drawback of the ACQ is that it requires measurement of peak expiratory flow, which 
could limit its use because a peak flow meter may not always be available or may not be 
properly used. To exclude the need for peak flow measurements, the short version of the 
ACQ was introduced which showed similar reliability(69). 
More recently the asthma control test (ACT) was introduced as an alternative questionnaire 
for quick assessment of uncontrolled asthma(70). The ACT scores 5 items and an overall 
agreement between ACT and the specialist's rating ranged from 71 % to 78% depending 
on the cut-off points used(70). Longitudinally, responsiveness of the ACT to changes in 
asthma control and lung function was demonstrated with significant correlations between 
changes in ACT scores and changes in specialists' ratings (r=0.44, P<.001), ACQ scores 
(r=-0.69, P<.001), and percent predicted FEV1 values (r=0.29, P<.001)(71). An ACT 
score of 19 or less provided optimum balance of sensitivity (71 %) and specificity (71 %) 
to detect uncontrolled asthma(71). Thus, the ACT seems to be a useful tool in the clinical 
setting to identify patients with uncontrolled asthma and to follow patients' progress with 
treatment. 
Only a few studies have investigated associations between assessment of the level of 
asthma control by questionnaires and the severity of airway inflammation. Quaedvlieg 
et al showed that higher numbers of sputum eosinophils and more severe bronchial 
hyperresponsiveness to methacholine, but not higher exhaled NO levels, were associated 
with uncontrolled asthma as scored with the ACQ(72). Other studies found correlations 
between asthma questionnaires and exhaled NO (73) and inflammatory markers in 
induced sputum(74;75). 
So far, no studies have investigated the relationship between the level of asthma control 
as assessed by questionnaires and airway inflammation in bronchial biopsies. Such 
studies are highly needed to investigate whether there is a direct link between subjective 




AIMS OF THE STUDIES 
1. To investigate if airway inflammation and remodeling are absent in asthma patients 
meeting the criteria of complete asthma remission ( Chapter 2 and 3). 
2. To investigate differences in airway inflammation and remodeling between 
adenosine-5'-monophoshate responsive and unresponsive asthmatics (Chapter 4). 
3. To investigate differences in airway inflammation and remodeling between 
remission and progression of asthma (Chapter 5). 
4. To investigate the underlying pathological process of smoke-induced deterioration 
of asthma (Chapter 6.) 
5. To investigate the relationship between clinical markers of asthma control with both 
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CHAPTER 2 
ABSTRACT 
Background : T he definition of "clinical asthma remission" is based on absence of 
symptoms and use of medication. However, in the majority of these subjects airway 
inflammation is still present when measured . In the present study we investigated 
whether "complete asthma remission", additionally defined by the absence of bronchial 
hyperresponsiveness ( B H R) and the presence of a normal lung function, is associated 
with the absence of airway inflammation. 
Methods : Patients with a former diagnosis of asthma and a positive histamine provocation 
test were re-examined to identify subjects with complete asthma remission (no asthma 
symptoms or medication, PC20 histamine > 32 mg/ml, FEV1 > 90% predicted). Patients 
with PC20 histamine :5 32 mg/ml were defined as current asthmatics and were divided in 
two groups, i.e. asthmatics with and without BH R to adenosine S'monophoshate (AMP). 
Sputum induction was performed 1 week before and 1 hour after AMP provocation. 
Sputum induction and AMP provocation were previously shown to be sensitive markers 
of airway inflammation. 
Results : Seven patients met criteria for complete asthma remission. Twenty-three were 
current asthmatics, including twelve without hyperresponsiveness to AMP. Subjects 
with complete asthma remission showed no AMP-induced sputum eosinophilia (median 
(range) 0.2 (0 - 4.6)% at baseline and 0.2 (0 - 2.6)% after AMP). After AMP, current 
asthmatics had a significant increase in sputum eosinophils ( 0. 5  (0 - 26.0)% at baseline 
and 2.6 (0 - 32.0) % after AMP), as had the subgroup of current asthmatics without 
hyperresponsiveness to AMP (0. 2  (0 - 1.8)% at baseline and 1. 3 (0 - 6. 3)% after 
AMP) . 
Conclusions: Subjects with complete asthma rem1ss1on, in contrast to subjects with 
current asthma, do not respond with eosinophilic inflammation in sputum after AMP 
provocations. T hese data lend support to the usefulness of the definition of complete 
asthma remission. 
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BACKGROU N D  
Asthma symptoms may diminish over time in a subgroup of patients and sometimes 
even disappear completely. The loss of asthma symptoms in the absence of need for 
pulmonary medication has been defined as "clinical or symptomatic asthma remission"(l-
4). However, the majority of patients with clinical or symptomatic remission still shows 
bronchial hyperresponsiveness (BHR) (1-4), suggesting that the disease asthma is not 
yet cured. 
This is supported by the observation that the broncho alveolar lavage (BAL) fluid contains 
increased levels of eosinophils in some asthmatic children with clinical asthma remission, 
when compared to healthy controls(S). Furthermore, higher numbers of eosinophils, T 
cells, mast cells and expression of IL-5 were found in the airway mucosa of patients with 
clinical remission than in healthy controls(6). 
Given the persistent presence of airway inflammation and BHR despite the asymptomatic 
status, it is likely that a more strict definition is required to signify whether an individual 
really is "cured" from asthma and can be regarded to have complete remission. The 
definition of clinical asthma remission has therefore previously been extended to 
"complete asthma remission", also including absence of BHR and normal lung function 
(FEV1>90%predicted) (1,4). A 25-year follow up study of 181 asthma patients, initially 
aged 13-44 years, all diagnosed with a positive bronchial hyperresponsiveness test to 
histamine and clinical asthma symptoms according to ATS criteria, showed a prevalence 
of clinical remission and complete remission of 40% and 11 % respectively by the age 
of 38-69 years(!). In another follow up study, 119 allergic asthmatic children were 
retested after 30 years and 52% were in clinical remission and 22% in complete asthma 
remission(4). To our knowledge, it has not been investigated so far whether asthmatic 
airway inflammation is objectively absent in this subgroup of subjects with complete 
asthma remission. 
We have previously shown that adenosine S'monophosphate (AMP) provocation induces 
sputum eosinophilia in asthma patients with and without inhaled steroid use(7) . We 
considered this as an interesting tool to investigate airway inflammation, because the 
recruitment process of eosinophils after an AMP challenge indicates the presence of an 
active inflammatory response. 
The present study was set up to investigate whether such an inflammatory response 
indeed is absent and cannot be induced in subjects with complete asthma remission. To 
this aim we compared inflammatory cells 1 week before and 1 hour after AMP provocation 
in induced sputum from subjects with complete remission and from patients with current 
asthma. Since not all asthmatics are responsive to AMP, we divided these subjects in an 
AMP responsive and a non-responsive group. These subgroups enabled us to additionally 
study the dose-response effect op AMP on sputum eosinophil numbers. 
M ETHODS 
SUBJECTS 
Non-smoking asthma patients aged between 18 and 70 years, without oral or inhaled 
corticosteroids were recruited. All patients originated from research cohorts investigated 
earlier by our research group and all had a doctor's diagnosis of asthma and a 
documented PC20 histamine � 32 mg/ml in the past(4;8-10). All patients had to be 
able to expectorate sputum after inhalation of hypertonic saline. In order to compare the 
effects of the highest cumulative dose of AMP (639.99 mg) on the influx of inflammatory 
cells in induced sputum, current asthma patients were divided in those with a negative 
and a positive AMP provocation test. Current asthma in these patients was proven by 
a positive bronchial hyperresponsiveness test to histamine. Patients were considered 
to have no asthma symptoms when they answered negatively on questions regarding 
cough and sputum in wintertime, dyspnea, wheeze and asthma attacks in the last three 
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years. T he study protocol was approved by the local medical ethics committee; all 
participants gave their written informed consent. 
Patients were assigned to 3 different groups according to the following criteria: 
• Complete asthma remission: former diagnosis of asthma, PC20 AMP > 320 
mg/ml and PC20 histamine > 32 mg/ml, FEV1 % predicted > 90%, no 
asthma symptoms, no asthma medication. 
• Current asthma with a negative PC20 AMP: former diagnosis of asthma, PC20 
AMP > 320 mg/ml, PC20 histamine :5 32 mg/ml. 
• Current asthma with a positive PC20 AMP : former diagnosis of asthma, PC20 
AMP :5 320 mg/ml. 
STUDY DESIG N 
Patients visited the hospital twice. At the first visit lung function, blood collection 
and sputum induction were obtained. T he second visit followed after 1-2 weeks and 
included AMP provocation test and sputum induction 1 hour after the final dose of 
AMP. In patients with a negative AMP provocation (dose AMP > 320 mg/ml) bronchial 
hyperresponsiveness to histamine was measured > 1 week later. To facilitate 
comparison with historical data on bronchial hyperresponsiveness to histamine, the 
maximum provocative dose of histamine in the present study was also set at 32 mg/ 
ml (with 30-seconds tidal breathing method, a dose that is comparable with 8 mg/ml 
in the 2-minute tidal breathing method). 
QUESTIONNAIRE 
T he Dutch version of the British Medical Research Council's standard questionnaire 
was used( 11). Patients were considered asymptomatic if they answered negatively on 
questions regarding coug h, sputum, dyspnea, wheeze and asthma attacks 
LUNG FUNCTION 
FEVl was measured with a calibrated water-sealed spirometer according to 
standardized guidelines(12; 13). Reversibility of the FEV1 %predicted was measured 
after administration of 400 µg of salbutamol. Provocation tests were performed with 
a method adapted from Cockcroft and coworkers(14; 15). After 2-min tidal breathing 
and an initial nebulized saline challenge, subjects inhaled doubling concentrations AMP 
(0.04 to 320 mg/ml) at 5-min intervals. Bronchial hyperresponsiveness to histamine 
was tested as reported previously(8), using 30-seconds tidal breathing and doubling 
concentrations ranging from 0 .13 to 32 mg/ml. 
SPUTUM INDUCTION AND SPUTUM PROCESSING 
Sputum was induced by inhalation of hypertonic saline aerosols as previously 
described(13). Hypertonic saline ( 5%) was nebulized over 3 consecutive periods 
of 5 min. Whole sputum samples were processed according to the method of Fahy 
and colleagues with some modifications(13;16). Sputum cell cytospins were stained 
with May Grunwald Giemsa ( MGG) and cell differentials from in total 600 viable, non 
squamous cells were assessed in a blinded fashion. Sputum was not scored if the 
percentage of squamous cells was > 80 percent or the total number of non-squamous 
cells was < 600. Number of sputum drop-outs because of 80 % squamous cells were 
6 at baseline and 0 after AMP, drop outs because of < 600 non-squamous cells were 
2 at baseline and 4 after AMP. Additionally, no sputum could be induced in 8 patients 
at baseline and 6 after AMP. 
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HISTAMINE E LISA 
A histamine ELISA was purchased from IBL (Hamburg, Germany) for quantitative 
detection of histamine in sputum supernatant. All reagents were provided in the kit. 
The protocol was as follows: the acetylated samples, controls and standards are 
pipetted into a 96-wells plate. After adding enzyme conjugate and histamine antiserum 
the plate was incubated for 3 hours on an orbital shaker. After washing TMB substrate 
solution was added to each well and incubated for 20 minutes. The substrate reaction 
was stopped and the optical density was measured at 450nM. 
ALLERGIC PARAMETERS 
The concentration of eosinophilic cationic protein (ECP) in sputum was measured using 
a fluoroenzyme immunoassay (lmmunoCAP ECP, Pharmacia, Uppsala, Sweden). Total 
serum IgE (IU/L) was measured by a solid-phase immunoassay (VIDAS total IgE kit, 
BioMerieux, Marcy l'Etoile, France). The Phadiatop screening test was performed on 
the ImmunoCap system according to the instructions of the manufacturer (Phadia AB, 
Sweden). Results were presented as quotients (fluorescence of the serum of interest 
divided by the fluorescence of a control serum). Positive Phadiatop was defined as 
patient serum/control serum > 1. 
STATISTICS 
All analyses were performed using SPSS (version 16.0; SPSS Inc, Chicago, IL, USA). 
Non-parametric tests were used for analysis. Wilcoxon signed rank test was used 
for paired testing within groups between measurements at baseline and after AMP 
provocation. Mann-Whitney U test was used for testing differences between groups. 
Two tailed p-values of < 0.05 were considered statistically significant. 
RESULTS 
PATIENT CHARACTERISTICS 
47 patients were enrolled in the study. 17 patients were excluded from analysis 
because they were not able to produce sputum both before and after AMP provocation 
or because the quality of sputum was too low to allow analysis. 3 of the excluded 
subjects had complete asthma remission and 14 current asthma. The included and 
excluded groups did not differ statistically regarding age, sex, FEV1 %pred, reversibility 
of FEV1, allergy and blood eosinophils. From the included patients, 7 patients met the 
inclusion criteria for complete asthma remission and were compared with 23 current 
asthma patients. Of these current asthmatics 11 had a positive PC20AMP (PC20 AMP 
� 320 mg/ml) and 12 had a negative PC20 AMP (PC20 AMP > 320 mg/ml, but a PC20 
Histamine � 32 mg/ml) (table 1). FEV1 % predicted in subjects with complete asthma 
remission was significantly higher than in patients with current asthma. Atopy was 
most frequent in asthmatics with a positive PC20AMP, significantly more frequent than 
in current asthmatics with a negative PC20 AMP and subjects in complete asthma 
remission 
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� TABLE I: PATIENT CHARACTERISTICS 
Sex (M/F) 
Age (years) 
FEV 1 (% predicted) 
PC20 AMP (mg/ml) 
Cumulative AMP dose (mg) 
PC20 Histamine (mg/ml) 
Reversibility FEV 1 (%) 
IgE (IU/L) 
Positive Phadiatop (n (%)) 




53 .0 (32-67) 




4.59 ( 1 .76 - 9.72) 
47 (7- 1 66) 
3 (43f 
0. 1 2  (0.09-0.24) 





97 (76- 1 3 1 ) 
>320 (0.02 - >320) 
639.99 (0.02 -639.99) 
N.A. 
5 .42 (-2.98- 26.7) 
66 ( 1 1 -558) 
15 (65) 
0. 1 5  (0.03-0.35) 
Current asthma 
Negative Positive 
PC20 AMP PC20 AMP 
(n= 1 2) (n=l 1 )  
6/6 8/3 
47.5 (35-70) 48.0 (38 -62) 
96.2 (76.2 - 1 23) 96.5 (84.8 - 1 3 1 )  
>320 1 2.0 (0.02 - 1 74) 
639.99 39.99 (0.02 - 639.99) 
1 6.9 (2.5 - 32.0) N.A. 
3 . 1 5  (-2 .98 - 1 2.2i 9 .40 ( 1 .76 - 26.7) 
6 1  ( 14 - 246) 78 ( 1 1 -558) 
5 (42i 1 0  (9 1 )  
0. 1 1  (0.03 - 0.35) 0. 1 7  (0.07 - 0.25) 
Definition of abbreviations: PC20 AMP = provocative concentration of adenosine 5 'monophoshate causing a 20% fall in 
FEY 1 ; reversibility FEY 1 = change in FEY 1 , expressed as increase in percentage predicted normal value after 400 µg of Salbutamol; Positive Phadiatop = specific IgE' s in patient serum/control serum > 1 ;  n = number; N .A. = not available. 
* p :S 0.05 versus current asthma total group. 
+ p :S 0.05, ++ p :S 0.0 1 versus current asthma PC20 AMP positive. 
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SPUTUM DATA 
COMPLETE ASTHMA REMISSION VERSUS 
CURRENT ASTHMA 
At baseline, total sputum cell count, 
macrophage, neutrophil, lymphocyte and 
eosinophil differential counts were similar 
in all investigated groups (table 2). After 
AMP provocation, sputum eosinophils did 
not increase in subjects with complete 
asthma remission in contrast to patients 
with current asthma, resulting in a 
significantly higher percentage eosinophils 
post AMP challenge in the current asthma 
groups (figure 1). Similar trends were 
observed for sputum ECP, i .e. median 
(range) levels before and after AMP were 
16.0 (2.5 - 170.0) and 14.8 (2.6 - 63. 7), 
respectively, in the group with complete 
asthma remission and 36.3 (6.0 - 2467 .0) 
and 47.3 (9.0 - 1628.0) in the group 
with current asthma. Histamine levels in 
sputum supernatant were comparable in 
the group with complete asthma remission 
and with current asthma. Median (range) 
levels before and after AMP provocation 
were 13.4 (2.8 - 29.8) ng/ml and 12.4 
(4.0 - 137.0) ng/ml, respectively, in the 
group with complete asthma remission, 
and 9.8 (0.2 - 38.0) ng/ml and 8.4 (3.0 
- 30.5) ng/ml in the group with current 
asthma. 
AMP provocation had little effect on the 
other inflammatory cells. Analysis with 
absolute sputum cell numbers showed 
comparable results with sputum cell 
percentages, however data are not 
presented because of differences in total 
cell numbers between groups. 
Figure I 
Changes in sputum eosinophil % from baseline to 
post-AMP provocation in subjects with complete 
asthma remission, current asthma patients with a 
negative AMP provocation and current asthma pa­
tients with a positive AMP provocation. Data are pre­
sented in a semi-log plot to optimize visualization of 
minor and major changes. 
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A M P  POSITIVE VERSUS A M P  N EGATIVE SUBJ ECTS WITH CU RRENT ASTH MA 
Allergy was more frequently present in current asthmatics with a positive than with 
a negative AMP provocation test (table 1). Sputum eosinophils increased significantly 
after AMP provocation in current asthma patients, even in those without AMP 
responsiveness (figure 1). However, the increase in sputum eosinophils after AMP 
provocation was significantly higher in AMP positive subjects (table 2). Also higher 
ECP levels were observed in AMP positive current asthma patients, i.e. median levels 
before and after AMP were 41.6 (11 .9 - 262.0) µg/1 and 62.2 (15 .2 - 467.0) µg/1 ,  
respectively, compared to 32. 3 (6.0 - 2467.0) µg/1 and 37.8 (9.0 - 1628.0) µg/1 in 
AMP negative current asth ma patients. Histamine levels in sputum supernatant were 
comparable in AMP positive and AMP negative subjects with current asthma. Median 
(range) levels before and after AMP were 11.0 (4.8 - 38.0) ng/ml and 9 .1 (4.9 - 28.0) 
ng/ml, respectively, in the AMP positive group, and 9.5 (0 .2 - 28.8) ng/ml and 8. 3 
( 3. 0  - 30.5) ng/ml in the AMP negative group. 
DISCUSSION 
To our knowledge, this is the first study investigating sputum inflammation in subjects 
meeting the criteria for complete asth ma remission. Our definition of complete 
asth ma remission also includes a normal lung function and absence of bronchial 
hyperresponsiveness in addition to the absence of asthma symptoms and medication, 
which was previously defined as clinical asthma remission. Sputum inflammation at 
baseline and the response after AMP provocation was compared between subjects 
with current asthma and complete asthma remission. Levels of sputum eosinophils at 
baseline and blood eosinophils were not significantly different between these groups. 
However, we demonstrate that AMP provocation increases the number of sputum 
eosinophils in current asthmatics, yet not in those with complete asthma remission. 
Similar trends were observed for ECP. T his thus suggests that the latter group indeed 
has outgrown their asthma and eosinophils are not in a primed state. 
T he present study shows the usefulness of measuring hyperresponsiveness and FEVl 
in recognizing subjects with complete asthma remission. Several studies have shown 
that a clinical definition based on the absence of asthma symptoms and no use of asthma 
medication is insufficient to definitely assess that asthma is cured. Many of these subjects 
still show features of persistent asth ma, such as presence of hyperresponsiveness 
and/or a low lung function( l-4) or ongoing airway inflammation(5;6). T he concept 
of complete asthma remission has previously been introduced as an alternative to 
the definition of clinical asthma remission. Complete asthma remission is defined by 
the combined absence of asthma symptoms, asth ma medication, airway obstruction, 
and bronchial hyperresponsiveness(1;4). In the present study, we investigated the 
concept of complete asthma remission in more detail by measuring inflammatory cells 
in induced sputum before and after AMP provocation in subjects meeting the criteria 
for complete asthma remission. T he finding that sputum eosinophils do not increase 
significantly after AMP provocation in these subjects supports the hypothesis that they 
are free of airway inflammation. Indeed, eosinopils that are characteristic of asthma 
are not attracted to the airways upon provocation with a stimulus that does attract 
these cells in patients with persistent asthma, even when similar doses of AMP are 
being inhaled. 
T his study also demonstrates that sputum induction after AMP provocation gives 
more information than sputum induction at baseline alone. After all, the differences 
between asthma remission and current asthma would not have been recognized if 
only baseline sputum measurements had been compared, especially since all asthma 
patients had stable disease without using inhaled steroids. We can speculate about 
the underlying mechanisms that are responsible for the differences observed. 
Apparently the immunological mechanisms involved in recruiting eosinophils into the 
airway lumen differs between subjects with complete asthma remission and patients 
with current asthma. It is possible that immunologically primed mast cells may have 
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TABLE II: SPUTUM BEFORE AND AFTER AMP PROVOCATION 
Complete remission 
(n=7) 




0.6 (0. 1 - 2.9) 
0.2 (0. 1 - 1 .4) 8 
-0.5 (- 1 .5 - 0.0) 
Squamous cells (%) 
Baseline 23.8 (5.3 - 67.0) 
After AMP 41 .5 (9.0 - 49.0) 
Change 14.0 (-26.2 - 22.2) 
Neutro hils (o/� 
At baseline 62.2 (1 8.9 - 77.6) 
After AMP 48. 1 (1 5.0 - 90.4) 
Change -3 .9 (-37.9 - 58. 1 )  
MacroP,hages (%) 
At baseline 35.8 (19.9 - 77. 7) 
After AMP 49. 1 (8.9 - 84.2) 
Change 1 1 .2 (-56.7 - 41 .3) 
Eosinophils (%) 
At baseline 0.2 (0.0 - 4.6) 
After AMP 0.2 (0.0- 2.6)*· m 





2.2 ( 1 .4 - 7.3) 
0.3 (0.0 - 2.5)*' U, 8• § 
- 1 .8 (-7.0 - 0.7) 
Total group 
(n=23) 
0.3 (0. 1 - 2.3) 
0.3 (0. 1 - 3.0) 
0.0 (-1 .7 - 1 .5) 
2 1 .3 (0.8 - 70.3) 
1 7.5 (0.5 - 64.5) 
-2.0 (-25.8 - 27.0) 
55.2 (19.8 - 94.5) 
59.0 (22.3 - 96.8) 
-3.2 (-35.1 - 68.0) 
32.7 (5.3 - 76.4) 
29.2 (3.0 - 72.5) 
1 .2 (-65. 1  - 28.6) 
0.5 (0.0 - 25. 7) 
2.6 (0.0 - 32.0)° 8 o 
1 .4 (-2.3 - 13.7) 
1 .9 (0.0 - 6.9) 
1 .3 (0.0 - 6. 1 )  





0.4 (0. 1 - 2.3) 
0.4 (0.2 - 3.0) 
0. 1 (- 1 . 1  - 1 .5) 
19.2 (0.8 - 70.3) 
1 9.9 (0.5 - 64.5) 
- 1 . 1  (-1 6.5 - 27.0) 
56.8 (20. 7 - 94.5) 
7 1 .3 (25.7 - 96.8) 
-0.4 (-29.5 - 68.0) 
40.0 (5.3 - 76.4) 
23. 1  (3 .0 - 72.5) 
0.0 (-65. 1  - 28.6) 
0.2 (0.0 - l .8)H 
1 .3 (0.0 - 6.3)m, o 
0.7 (-0.5 - 6. Ii  
2.0 (0.2 - 6.9) 
0.8 (0.0 - 6.1) 
-0.4 (-4.2 - 3.8) 
Positive 
PC20 AMP 
(n=l 1 )  
0.3 (0.2 - 2. 1 )  
0.3 (0. 1 - 0.8) 
0.0 (- 1 .7 - 0.2) 
2 1 .3 (4.7 - 43 .3) 
1 7.5 (1.7 - 24.5) 
-2.0 (-25.8 - 1 0.6) 
55.2 (19.8 - 93.6) 
52.7 (22.3 - 7 1 .0) 
-5. 1  (-35. 1 - 25.4) 
32.7 (5.6 - 76.2) 
39. 1 ( 12.6 - 6 1 .2) 
1 .2 (-37.1 - 20.6) 
1 .9 (0.0 - 25.7) 
5.9 (2.5 - 32.0)° 0 
2.7 (-2.3 - 13 .7) 
1 .9 (0.0 - 5.9) 
1.7 (0. 7 - 4.8) 
0.1 (-4.9 - 4.8) 
Squamous cells were not included in the number of total cells and in the percentages of all other cell types 
Values are medians (ranges). 
* p :'.S 0.05, ** p :'.S 0.01 versus current asthma total group. 
t p :'.S 0.05, H p  :'.S 0.o I ,  m p  :'.S 0.001 versus current asthma PC20 AMP positive. 
§ p :'.S 0.05, §§ p :'.S 0.01 versus current asthma PC20 AMP negative. 8 p :'.S 0.05, 8 8  p :'.S 0.0 1 ,  8 8 8 p = 0.001 versus at baseline. 
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disappeared in subjects with complete asthma rem1ss1on. T hus activation of the 
adenosine 2b receptor by AMP might not take place and neither the release of mast 
cell mediators. The loss of immunologically primed mast cells was not reflected by our 
data on histamine levels in sputum supernatant, histamine levels being similar in all 
groups. Bronchial biopsy studies are needed to further investigate the role of mast 
cells in complete asthma remission. 
This study does not completely prove that our subjects with complete asthma 
remission fully have outgrown their asthma, as we did not compare results with 
healthy controls. Several studies suggest that a cut off value of 1 % for sputum 
eosinophils can discriminate between current asthma and healthy controls( l 7-19). In 
our study, two subjects with complete asthma remission had > 1 % sputum eosinophils, 
possibly indicating that asthmatic inflammation may still be present in the airways. 
However, only one subject in the complete asthma remission group had a sputum 
eosinophil percentage > 1 % after AMP provocation. To our knowledge, no studies 
have investigated AMP induced sputum eosinophils in healthy controls, which clearly 
needs further study. Obviously, biopsy studies comparing subjects with complete 
asthma remission and healthy controls are needed to obtain a definite answer as 
to whether airway inflammation has disappeared entirely in subjects with complete 
asthma remission. Such studies might validate sputum induction after AMP provocation 
as a useful non-invasive tool to recognize patients who really have outgrown their 
asthma. Also longitudinal studies are needed to investigate if symptoms do not recur 
in patients suspected to be in complete asthma remission. 
To compare the effects of the high cumulative doses of AMP on the influx of sputum 
inflammatory cells, we divided patients with current asthma in groups with and 
without a bronchoconstrictive response to AMP. The PC20 AMP negative group, that 
still had a proven bronchoconstrictive response to histamine, received exactly the 
same cumulative dose of AMP as the complete asthma remission group (with negative 
PC20 histamine). In contrast to subjects with complete asthma remission, this group 
of current asthma patients with a negative PC20 AMP showed a modest but significant 
increase in sputum eosinophils after AMP provocation. T his result indicates that 
AMP has a differential effect on bronchoconstriction and bronchial inflammation in 
asthmatics with proven hyperresponsiveness to histamine. 
An intriguing finding is the discrepancy between the presence of a positive PC20 
histamine and absence of PC20 AMP in current asthmatics. We realize that the cut 
off values of 320 mg for PC20 AMP and 32 mg/ml for histamine are arbitrary and 
not objectively based on the presence or absence of asthmatic airway inflammation. 
Nevertheless, it may well be that current asthmatics with a positive PC20 AMP represent 
a different subset of asthma patients. Indeed, significant differences between the two 
groups are present in our study. Despite a lower cumulative dose of AMP, those with 
PC20 AMP had significantly more sputum eosinophilia than those without a PC20 
AMP and similar trends were observed with sputum ECP. In addition, reversibility to 
salbutamol and the presence of specific Ig E in serum were significantly higher in the 
asthma group with a positive PC20 AMP. A similar association between AMP sensitivity 
and atopic status has been described in an earlier study(20). It would be of interest 
to follow the asthmatics with a negative AMP test to assess whether they will develop 
clinical asthma remission. In other words it might represent an intermediate state 
between full blown asthmatic inflammation and absence of inflammation. 
CONCLUSIONS 
We conclude that our results suggest that the definition of complete asthma remission 
is valid, since sputum eosinophils do not increase after AMP provocation. T his is in 
contrast with the increase in sputum eosinophils in current asthma that occurs even 
in the absence of a bronchoconstrictive response to AMP. 
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CHAPTER 3 
ABSTRACT 
Rationale: Asthmatics may outgrow symptoms despite not using treatment, while 
others reach complete remission with absence of airway obstruction and bronchial 
hyperresponsiveness. It is uncertain whether this associates with remission of all 
inflammatory and remodeling asthma features. 
Objective: To compare the pathological phenotype of asthmatics with complete and 
clinical remission and active asthma, with and without the use of inhaled corticosteroids 
(!CS). 
Methods and Measurements : We investigated 165 individuals known with active 
asthma, upon re-examination having complete remission ( CoR, n=18), clinical remission 
(ClinR, n=44) and current asthma (CuA, n=103, 64 with, 39 without ICS). Inflammatory 
cells were measured in blood, induced sputum and bronchial biopsies, histamine and 
ECP in sputum, EPX immunopositivity and remodeling ( epithelial changes, E-cadherin 
expression, basement membrane (BM) thickening, collagen deposition) in bronchial 
biopsies. 
Main Results: Median (range) blood eosinophils from CoR were significantly lower 
than those from CuA (0.10(0 .04-0.24) vs. 0.18(0.02-1.16) x109/L). Bronchial EPX 
immunopositivity was lower in CoR than in both ClinR and CuA (67(0. 5-462) vs. 95(8-
5329) and 172(6-5313) pixels). Other inflammatory findings were comparable. BM 
thickness was lowest in CuA, caused by lower BM thickness in those using !CS (CoR: 
6.3(4.7-8.4), ClinR 6 .5( 3.8-11 .7), CuA 5.7(2.8-12.6) and res using CuA 5. 3(2.8-8.2) 
µm). 
Conclusion: CoR is still accompanied by airway abnormalities since BM thickness is 
similar in asthmatics with CoR, ClinR and CuA without ICS. Airway eosinophilic activation 
best differentiates these three groups, signifying their importance in the clinical expression 
and severity of bronchial hyperresponsiveness in asthma. 
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INTRODUCTION 
Some asthma patients outgrow their disease and reach clinical asthma remission (ClinR), 
i.e. their asthma symptoms have disappeared even without using asthma medication 
like inhaled corticosteroids (ICS) and B2-agonists. A recent prospective epidemiologic 
study reported an asthma remission rate of 2 per 100 person years, asthma remission 
being defined as no asthma symptoms in two consecutive years and no current asthma 
treatment(!). It is, however, still under debate whether subjects in ClinR have actually 
outgrown their disease since these subjects may still have (asymptomatic) bronchial 
hyperresponsiveness (BHR) and/or a low lung function. Indeed, Boulet et al have shown 
that individuals known with asthma yet without current asthma symptoms or asthma 
treatment for the past 2 years still had subclinical active disease, characterized by BHR, 
increased reversibility and low lung function(2). It is well possible that this subclinical 
active disease is reflecting ongoing airway inflammation and/or remodeling. In line with 
this, higher eosinophil numbers were reported in bronchoalveolar lavage fluid of atopic 
children in ClinR (no symptoms for 12 months and no current medication) compared to 
healthy controls(3). 
It has been speculated that the persistence of airway inflammation in ClinR will lead to 
progressive airway remodeling and consequently an increased risk of eventual asthma 
relapse(3;4). Indeed, a substantial proportion of subjects in ClinR have a rebound of 
asthma symptoms in later life(S), suggesting that information provided by the patient 
on asthma symptoms and medication use is likely insufficient to determine whether 
asthma is definitively in remission. Therefore, researchers have put forward the term 
"complete asthma remission (CoR)" signifying the absence of BHR and airway obstruction 
in addition to the absence of symptoms and asthma treatment(5;6). One might indeed 
anticipate that the absence of asthma symptoms, BHR and airway obstruction in former 
asthmatics who currently do not use asthma treatment is accompanied by normal airway 
wall pathology, i .e. no inflammation or remodeling. 
The aim of the present study was to characterize inflammatory phenotypes in a large 
group of individuals (n=165) with CoR (n=18), ClinR (n=44), and current asthma (CuA, 
n=103) in airway wall biopsies, induced sputum and blood. Since these phenotypes can 
be changed or masked by current ICS treatment, we investigated CuA with (n=64) and 
without (n=39) ICS use in case differences existed between asthma remission and CuA. 
Thus we investigated the airway pathology of 165 individuals known with active asthma 
in the past who after re-examination were divided into three groups : CoR, ClinR, and 
CuA (with and without ICS). 
METHODS 
SUBJECTS 
Subjects with complete asthma remission (CoR, n=18), clinical asthma remission (ClinR, 
n=44) and current asthma (CuA, n=103) were investigated (Table 1). All had a doctor's 
diagnosis of asthma, and documented reversibility and BHR to histamine in the past. 
Subjects were re-examined by lung function, BHR to histamine and/or adenosine 5'­
monophosphate (AMP), sputum induction and bronchoscopy with bronchial biopsies. 
CoR (n=18) was defined as no BHR to histamine (PC20histamine >32mg/ml) and AMP 
(PC20AMP >320mg/ml), normal lung function (FEV1 >90% predicted), absence of asthma 
medication (ICS or B-agonists) use and absence of asthma symptoms (no wheeze or 
asthma attacks during the last 3 years)(5;6). ClinR (n=44) was defined as absence of 
asthma medication (!CS or B-agonists) use and absence of asthma symptoms (no wheeze 
or asthma attacks during the last 3 years) in former asthmatics despite the presence 
of BHR to histamine (PC20histamine >32mg/ml) and/or AMP (PC20AMP >320mg/ml). 
CuA (n=147) was defined as presence of BHR to histamine (PC20histamine >32mg/ml) 
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and/or AMP (PC20AMP > 320mg/ml) and the presence of asthma symptoms (wheeze 
or asthma attacks during the last 3 years). The CuA group consisted of 64 patients 
using ICS a nd 39 not using ICS. The study protocol was approved by the local medical 
ethics committee. All subjects gave written informed consent. 
STU DY DESIGN 
All subjects were evaluated with blood sampling, sputum induction and lung function 
assessment, followed 1 to 2 weeks later by an AMP provocation test. At the third 
visit, again 1 to 2 weeks later, bronchoscopy with collection of bronchial biopsies was 
performed. Subjects with a negative AMP provocation test (PC20AMP >320 mg/ml) 
came for a fourth visit to undergo a histamine provocation test at least 3 weeks 
later. 
M EASUREMENTS 
Lung function, sputum induction a nd bronchoscopy with collection of bronchial 
biopsies were performed as published previously(7) and are described in detail in the 
online data supplement. In short, histamine (IBL, Ha mburg, Germany) and neutrophil 
elastase (Hycult, Uden, the Netherlands) in sputum supernatant were determined 
by ELISA and eosinophilic cationic protein (ECP) by a fluoroenzyme immunoassay 
(Im m unoCAP ECP, Phadia AB). 
Bronchial biopsies were fixed in 4% formalin, processed a nd embedded in paraffin 
and cut in 3µm thick sections. Immunohistochemical stainings (except for Ki67 and 
E-cadherin) were performed using DAKO autostainer (DAKO, Glostrup, Denmark). 
Immunohistochemistry was performed using antibodies directed against inflam matory 
cells (see the online data supplement), eosinophilic peroxidase (EPX8), mast cell 
tryptase (AAl, DAKO), proliferation (Ki67, DAKO), epithelial adhesion (E-cadherin, BD 
Biosciences, Breda, the Netherlands) and collagen 3 (Southern Biotech, Birmingham, 
AL, USA). Further details on the used immunohistochemistry and quantification 
procedures are presented in the online data supplement. 
STATISTICS 
Analyses were performed using SPSS (version 16.0; SPSS Inc, Chicago, IL, USA). 
Normality of distributions was assessed by Kolmogorov-Smirnov test. If necessary, 
normalization by transformation was attempted. Normally distributed data were 
analyzed with one-way ANOVA a nd independent sa mple t-tests, non-normally 
distributed data with Kruskal-Wallis and Man n-Whitney U tests. Chi-square tests 
were used to compare groups for dichotomous variables. Correlations were evaluated 
by Pearson tests or Spearman tests (normally and non-normally distributed data 
(rs), respectively). Normally distributed data, with or without transformation, were 
analysed by multiple linear regression analysis correcting for sex, age and current 
smoking. The p-values of the regression analyses are being presented in tables and 
graphs. Two tailed p-values of <0.05 were considered statistically significa nt. 
Further experimental information ca n be obtained from the online data supplement. 
RESULTS 
PATIENT CHARACTERISTICS 
In total, 165 former asthma patients were investigated: 18 subjects with complete 
asthma remission (CoR), 44 with clinical asthma remission (ClinR) a nd 103 current 
asthmatics (CuA). Table 1 presents their clinical characteristics. Subjects with CoR 
and subjects in ClinR had a significantly higher FEV1/VC (inspiratory Vital Capacity) 
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TABLE 1: PATIENT CHARACTERISTICS 
PC20AMP {mg/ml) 
FEY 1 (%pred) 
JCS use (n(%)) 
JCS dose (µg/day) 
Beta-agonist use (n(%)) 
Sex (m/t) 
Age (year) 
Reversibility FEY 1 (%) 
Atopy (n (%)) 
Phadiatop score (quotient) 
Smoking status (n (%)) current 
NO alveolar (ppb) 
NO bronchial (nL/s) 
Blood eosinophils (x 1 09/I) 
ex 
never 




1 1 7 (97- 137) 
7/1 1 
48 ( 1 7-67) 
82 (67-97) 
4.8 (- 1 .7- 14. 1 )  
1 0  (56) 
1 .5 (0.2-53.9) 
5 (28) 
2 ( 1 1 )  
1 1  (6 1 )  
4 .3  (0.9- 1 2.3) 
0.4 7 (0.09- 1 .26) 
0. 1 0  (0.04-0.24) 
262 (0.02->320i 
1 03 (60-1 23l 
22/22 
48 ( 1 9-70) 
79 (48-97) 
6.2 (-8.4- 1 9 . 1 )  
24  (55) 
3.9 (0. 1 -96.5) 
1 1  (25) 
12 (27) 
21 (48) 
4.6 (2. 1 - 1 2.4) 
0.57 (0.24-2.72) 




38.7 (0->320( # 
1 0 1  (42- 1 35)
° 
64 (62}*- H 
800 (28-2000) 
80 (78l 
5 1 /52 
50 (2 1 -7 1 )  
73  (39-98) • ,  # 










5 .6 ( 1 .5-5 1 .7) 
0.80 (0.06-1 0.38) 
0. 1 8  (0.02- 1 . 1 6) •, II 
Data are presented as median (range), unless stated otherwise. JCS dose is equivalent ofbeclomethasone. FEV 1 was determined after inhalation of 400 µg of Albuterol; reversibility FEV 1 = change in FEV 1, expressed as increase in percentage predicted normal value after 400 µg of Albuterol. PC20AMP = provocative concentration of adenosine 5'monophoshate causing a 20% fall 
in FEV1 • Atopy is defined as specific JgE's in patient serum/control serum > I .  Phadiatop score = quotient specific JgE in patient serum/control serum. JCS = inhaled corticosteroid, NO = nitric oxide. When applicable corrected for age, sex and smoking using 
multiple regression analysis. 
*: P<0.05, complete asthma remission versus current asthma 
#: P<0.05, clinical asthma remission versus current asthma 
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compared to CuA (Table 1, Figure 1A). 
Reversibility of FEV1 was significantly 
lower in both CoR and ClinR compared with 
CuA (Table 1, Figure 1B) .  The Phadiatop 
score, a measure for the severity of 
atopy, was significantly lower in subjects 
with both CoR and ClinR in comparison 
to CuA (Table 1 ,  Figure 1C). Alveolar and 
bronchial fractions of exhaled breath NO 
were not significantly different between 
the three groups (Table 1 ). Levels of 
alveolar and bronchial NO fractions 
correlated with blood eosinophil numbers 
in the complete population (CoR, ClinR 
and CuA combined, rs=0. 39, p<0. 00 1  
and rs=0. 37, p<0 .001,  respectively) . 
EOSINOPHILIC INFLAMMATION IN BLOOD, 
SPUTUM AND BIOPSIES 
The number of blood eosinophils was 
significantly lower in both CoR and ClinR 
than in CuA (Table 1, Figure 2A). 
T he percentage of sputum eosinophils 
and the ECP concentration in sputum 
supernatant were not significantly 
different between the three groups (Table 
2, Figure 2B,C). However, when the 
group with CuA was divided in non-JCS 
users and res users, sputum ECP was 
significantly higher in CuA patients with 
res use than in those with CoR and CuA 
without res use ( Figure 2C) . Sputum 
ECP correlated significantly with the 
percentage of sputum eosinophils in the 
complete population (CoR, ClinR and CuA 
combined, rs=0. 37, p<0. 001). 
EPX immunopositivity in the bronchial 
biopsy tissue was significantly lower in 
subjects with CoR than in subjects with 
ClinR and CuA (with and without res use, 
Table 3, Figure 2D). 
Figure 1 
Patient characteristics. (A) FEV1/VC (%), (BJ Revers­
ibility of FEV1 (% predicted), and (C) Phadiatop score 
in subjects with complete asthma remission, clinical 
asthma remission, no JCS using current asthmatics 
and JCS using current asthmatics. P-values of FEV1/ 
VC are after correction for age, sex and smoking us­
ing multiple regression analysis. Each circle repre­
sents one subject. Horizontal bars represent median 
values. 
PERSISTING REMODELING AND LESS AIRWAY WALL EosINOPHIL ACTIVATION IN COMPLETE REMISSION OF ASTHMA 
Eosinophilic inflammation in blood, sputum and biopsy correlated significantly 
with each other in the complete population (CoR, ClinR and CuA together), blood 
eosinophils versus sputum eosinophils (%) rs=0 .54, p<0 .001 ,  blood eosinophils 
versus EPX immunopositivity rs=0 .25, p=0 . 005 and sputum eosinophils (%) versus 
EPX immunopositivity rs= 0 . 39, p < 0 . 00 1 .  
OTH E R  I N FLAMMATORY C ELLS A N D  M EDIATORS I N  S PUTUM A N D  BIOPSIES 
The percentage of sputum lymphocytes was significantly higher in subjects with CoR 
than in CuA (Table 2). This was in particular found in CuA with ICS use ( 1 .4 (0-7. 3) % 
in CoR vs. 0 .5  (0-6.9) % in CuA without ICS and 0 . 3  (0-4. 1)  % in CuA with ICS). 
The level of histamine in sputum supernatant was significantly lower in subjects with 
ClinR compared to CuA (Table 2), and particularly lower than in CuA using ICS ( 18.5 
(0- 158.7) ng/ml in ClinR vs. 22. 7  (0- 1 39 .9) ng/ml in CuA without ICS and 41.7 (4. 7-
215.0) ng/ml in CuA with ICS). 
Besides group differences in eosinophils, we observed no significant differences in any 
of the other inflammatory cell types studied in bronchial biopsies (Table 3). 
TABLE 2: INFLAMMATORY CELLS AND MEDIATORS IN INDUCED SPUTUM 
Complete Clinical Current 
Asthma Asthma Asthma 
Remission Remission 
N=18  N=44 N=103 
Sputum not evaluable n (%) 5 (28) 20 (45) 22 (2 1 )  
No sputum n (%) 3 ( 1 6) 13 (29) 12 ( 1 1 )  
>80% squamous n (%) 1 (6) 4 (9) 7 (7) 
<600 cells n (%) 1 (6) 3 (7) 3 (3) 
Sputum evaluable n (%) 13 (72) 24 (55) 81 (79) 
Total cells (x1 06/l) 0.3 1 (0.05-2.90) 0.44 (0.06-2.27) 0.43 (0.03-3.86) 
Neutrophils (%) 62 ( 1 9-78) 58 (2 1 -94) 57 (1 6-94) 
Macrophages (%) 36 (20-78) 34 (5-77) 36 (5-83) 
Eosinophils (%) 0.2 (0-4.6) 0.9 (0- 16.8) 0.9 (0-67. 1 )  
Lymphocytes (%) 1 .4 (0-7.3) 0.7 (0-5.6) 0.4 (0-6.9) * 
Neutrophil elastase (µg/ml) 1 . 1  (0-5.0) 1 .6 (0.2-5.0) 1 .4 (0.2-5.0) 
Eosinophilic cationic protein (µg/1) 17 .9 (2.5-172) 24.3 (5.6-2467) 33.6 (4.2-1 363) 
Histamine (ng/ml) 22.7 (2.8-99.6) 1 8 .5 (0- 1 58.7) 35.4 (0-2 15 .0l 
Data are presented as median (percentage or range). When applicable corrected for age, sex and smoking using multiple 
regression analysis. 
*: P<0.05, complete asthma remission versus current asthma 
#: P<0.05, clinical asthma remission versus current asthma 
$: P<0.05, complete asthma remission versus clinical asthma remission 
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Figure 2 
Eosinophilic inflammation. (A) Absolute blood eosinophils (x1 09/L), (BJ Percentage of sputum eosinophils, (CJ 
Eosinophil cationic protein (ECP) in sputum supernatant (µg/L), and (DJ EPX immunopositivity (pixels) in bronchial 
biopsies in subjects with complete asthma remission, clinical asthma remission, no ICS using current asthmatics 
and ICS using current asthmatics. P-values of EPX immunopositivity are after correction for age, sex and smoking 
using multiple regression analysis. Each circle represents one subject. Horizontal bars represent median values. 
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TABLE 3: INFLAMMATORY CELLS IN BRONCHIAL BIOPSIES 
Complete Clinical Current 
Asthma Asthma Asthma 
Remission Remission 
N=15 N=32 N=82 
Submucosal 
CDf T-cells 52 (32-29 1 )  67  ( 1 3-294) 68 (4-2 19) 
CD4+ T-cells 12 (0-1 68) 21 (0-67) 1 7 (0-7 1) 
CDS+ T-cells 28 (7- 1 12) 18 (3- 103) 23 (0-205) 
CD20+ B-cells 2 (0-7 1 )  4 (0-98) 3 (0-56) 
NP5t neutrophils 7 (2-30) 8 (0-46) 6 (0-38) 
CD68+ macrophages 13 (2-86) 1 6  (0-37) 12 (0-57) 
EPX+ eosinophils 1 (0-1 0) 2 (0-40) 2 (0-32) 
AAi+ mast cells 7 (1 -26) 8 (0-20) 8 (0-26) 
(De)granulation 
EPX immunopositivity (pixels) 67 (0.5-462) 95 (8-5329l 172 (6-53 13). 
Degranulated AAl + mast cells (%) 71 (20- 1 00) 80 (22-1 00) 68 (0-100) 
Smooth Muscle 
AAl+ mast cells 1 (0-2) 1 �0- 1 5) 1 (0-6) Data are presented as median (range). The cell numbers are expressed per 0. 1 mm of tissue. When applicable corrected for 
age, sex and smoking using multiple regression analysis. 
*: P<0.05, complete asthma remission versus current asthma 
#: P<0.05, clinical asthma remission versus current asthma 
$: P<0.05, complete asthma remission versus clinical asthma remission 
AIRWAY WALL REMODELING 
Basement membrane ( BM) thickness was similar in CoR and ClinR. BM thickness was 
significantly increased in ClinR compared to CuA (Table 4, Figure 3). When JCS use 
was taken into account, BM thickness was significantly higher in both ClinR and CuA 
without ICS use than in CuA with ICS use ( Figure 3 ) .  
No significant differences were observed between the three groups in any o f  the other 
investigated remodeling parameters (Table 4). 
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TABLE 4: REMODELING IN BRONCHIAL BIOPSIES 
Bronchial epithelium 
Goblet cells (cells/mm BM) 
Normal Epithelium (%) 
Metaplasia (%) 
Ki67+ intact epithelium (%) 
Ki67+ basal epithelium (%) 











0 (0-2 1 .2) 
2.9 (0-43 . 1 )  
2 . 7  (0.2- 1 9.2) 
1 00 (0-1 00) 






8.9 (0-29 . I ) 
0 (0-26.2) 
2.8 (0- 1 3 .6) 
3 . 1  (0. 1 - 1 5 .5) 
1 00 (0- 1 00) 
6.5 (3 .8- 1 1 .7) 
Collagen 3 (% stained tissue) 38 .8  (14.5-54.9) 36.7 (8 .2-64.5) 
Data are presented as median (range). When applicable corrected for age, sex and smoking 
using multiple regression analysis. 
* :  P<0.05, complete asthma remission versus current asthma 
#: P<0.05, clinical asthma remission versus current asthma 
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36 (5- 1 1 9) 
9.0 (0-65.3) 
0 (0- 1 9.4) 
3.7 (0-24.2) 
3 . 1  (0-28 .9) 
86.4 (0- 1 00) 
5.7 (2.8-1 2.6/ 
41 .9 (13 .9-77.9) 
Airway remodeling. (A) Basement membrane thickness in subjects with complete asthma remission, clinical asth­
ma remission, no JCS using current asthmatics and JCS using current asthmatics. P-values are after correction 
for age, sex and smoking using multiple regression analysis. Each circle represents one subject. Horizontal bars 
represent median values. 
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DISCUSSION 
It has been long debated whether asthma can go in true remission. Our study shows 
that asthma can go in remission when considering the clinical characteristics of asthma, 
i.e. those in remission had no asthma symptoms, no bronchial hyperresponsiveness 
(BHR) and had normal lung function despite not using asthma treatment for at least 
three years. We demonstrate, however, that airway remodeling persists, as evidenced 
by a similar basement membrane thickness in those with complete asthma remission 
(CoR), clinical asthma remission (ClinR) and in current asthmatics (CuA) without res 
use. Of particular interest is the observation that eosinophilic inflammation was best 
differentiating CoR from CuA. Moreover eosinophilic activation in the airway wall, as 
indicated by increased degranulation in the EPX staining was significantly lower in 
subjects with CoR than those with ClinR and with CuA. 
It has been previously shown that subjects with elinR (no asthma symptoms and 
medication for 12 months) had ongoing airway inflammation and remodeling as 
reflected by increased numbers of eosinophils, T cel ls and mast cel ls in the airway 
mucosa and thickening of the reticular basement membrane when compared to control 
subjects without asthma(4). However, these individuals still had BHR and it is evident 
that persistence of BHR is abnormal. Also, asymptomatic BHR is a risk factor for future 
development of asthma symptoms in epidemiological studies(9). Thus, our study 
supports our previous findings(6; 10) that it is indeed possible that asthma patients 
who have expressed BHR accompanied by asthma signs and symptoms are capable 
to lose these clinical hal lmarks of asthma. We have previously published in a different 
group of asthmatics that basement membrane thickness was significantly larger in 
asthmatics than in age- and smoking matched healthy individuals(ll). Thus, the 
current study for the first time suggests that, even with complete asthma remission, 
some remodeling remains in the airways, likely as a sign of past disease or scarring. 
There are some limitations to our study. We investigated asthmatics at middle age 
and remission may have different underlying pathology in childhood remission. It was 
not possible to assess the duration of asthma in our study population, since at initial 
testing, when all participants had active asthma, it was not asked at which age asthma 
started. Therefore we cannot exclude that duration of asthma may have contributed 
to our findings as wel l. Nevertheless, we have investigated a considerable number of 
adult asthmatics with complete remission and our findings suggest that at this age 
remodeling may still be present. Finally, we found that the percentage of sputum 
lymphocytes was significantly higher in subjects with CoR than in CuA, particularly 
in euA with res use. Since we did not perform subset analysis of these lymphocytes 
further interpretation of this part of the results is not possible. 
Asthmatics with remission, be it CoR or ClinR, were less frequently atopic and had 
significantly lower Phadiatop scores, implying less severe atopy than those with CuA. 
This was paral leled by differences in eosinophilic activation in airway wall biopsies and 
may wel l  reflect that asthmatics in remission are less hampered by al lergic stimuli as 
present in the environment. It remains to be established whether the lower atopic 
prevalence in those with remission is due to loss of allergies during ageing, as has 
been shown previously(S). However, this will not likely affect results of our study 
since all groups had a comparable age of around 50 years when investigated. It 
is of interest that sputum eosinophil percentages were not significantly different in 
subjects with and without remission, suggesting that it is not merely the presence of 
eosinophils, but their activation state in the airway wall, as reflected by EPX staining, 
that drives their significant role in active disease. Sputum may thus constitute a waste 
basket of the presence of eosinophils in the airway wal l ,  where it is the activation of 
these eosinophils that contributes to active asthma. 
It was an unexpected finding that symptomatic CuA patients using res had more 
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severe eosinophilic inflammation than those not using ICS, as shown by higher blood 
eosinophil numbers and sputum ECP. T his may reflect that asthma was not under 
control in CuA patients using ICS, and higher doses may be necessary to reach 
control(12). As already mentioned, BM thickness was lower in CuA patients using 
ICS, showing that asthma symptoms are not driven by this remodeling feature. 
Functional abnormalities in asthma such as BH R are thought to be caused by 
airway inflammation and/or structural changes of the airways, like smooth muscle 
hyperplasia, airway wall thickening and edema. T hese structural changes, known as 
airway remodeling, are thought to appear early in the onset of the disease, sometimes 
even before symptoms appear(13). T he exact physiological consequences of airway 
wall remodeling are not understood. We here show that airway remodeling is also 
present in subjects in CoR. T his suggests that BM thickening per se is not responsible 
for the presence of BHR. In contrast, activation of eosinophils in the airway wall 
is almost absent in CoR and present in those with CuA, suggesting that this may 
contribute to the presence and/or severity of BHR. Nevertheless, other factors have 
to drive the presence and severity of BH R as well, since eosinophilia was absent in a 
proportion of our CuA patients. 
T he question arises if airway remodeling is an inherent feature of asthma, i.e. if it 
remains even though at extensive clinical examination asthma is in CoR. If this is 
true, then one might interpret the presence of increased BM thickening as a pending 
risk of asthma relapse. Alternatively, this merely reflects an end-stage disease with 
some "scarring" as a sign that an individual has had asthma. T here are indications 
that remodeling is a process that is amenable to treatment. Indeed two studies have 
shown that prolonged treatment with ICS can reduce BM thickness(14; 15). Moreover, 
collagen deposition(16) and airway vascularity(17) can improve with ICS use and are 
therefore also reversible. In the light of these observations it is of interest that CuA 
patients using ICS in our study had lower BM thickness than those without ICS. T his 
may thus simply result from ICS treatment for a prolonged time. However, despite 
this, patients still remain symptomatic. T herefore, we conclude that BM thickness itself 
does not associate with the clinical expression of asthma, but that other factors imprint 
on BM thickness that affect the severity of the disease and treatment requirements. 
Epithelial cells are the first barrier against inhaled allergens, hence these cells may be 
important for the induction, maintenance and severity of asthma. We have previously 
shown that smoking asthmatics have more respiratory symptoms and epithelial 
damage than non-smoking asthmatics(7). We had anticipated that CuA patients would 
have more epithelial changes than those with ClinR and CoR. However, the percentage 
intact epithelium and its expression of E-cadherin, an adhesion protein, were similar 
between the groups With respect to epithelial damage, we conclude that this is not 
differentiating remission from CuA. T his does, of course not preclude that the activation 
status of epithelial cells is different. It may well be that the production of chemo­
attractive cytokines by epithelium is increased in CuA compared to remission, which 
then adds to attracting eosinophils to the airway wall as observed in our study. 
In summary, we studied a group of 164 adult individuals known with active asthma 
in the past, including individuals with CoR, i.e. those being asymptomatic without 
airway obstruction, BHR and any respiratory treatment, individuals with ClinR (i.e .  
asymptomatic and without treatment) and with CuA. T he important message of this 
paper is that asthma can go in full remission according to all clinical phenotypes that 
characterize asthma, but that BM thickening, which accompanies asthma, persists. A 
second message of the paper is that airway wall eosinophilic activation differentiates 
CoR from ClinR and CuA. T his signifies the importance of eosinophil activation for the 
clinical expression of asthma and the severity of BH R. 
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Main exclusion criteria were: FEV1 < 1.2 L, bronchiectasis, upper respiratory tract 
infection (e.g. colds) and/or use of antibiotics or oral corticosteroids within the last 2 
months before inclusion. 
LUNG FUNCTION 
Lung function tests were performed with a daily calibrated spirometer according to 
standardized guidelines as described previously( !). FEV1 was measured with a calibrated 
water-sealed spirometer according to standardized guidelines( 1 ;2). Reversibility of 
FEV1 (% predicted) was measured after administration of 400µg Albuterol. B H R  to 
AMP was tested with a method adapted from Cockcroft and coworkers(3) using, after 
an initial nebulized 0.9% saline challenge, 2-min tidal breathing at 5-min intervals and 
doubling concentrations of AMP ranging from 0.04 to 320 mg/ml. BHR to histamine 
was tested as reported previously(4), using 30-second tidal breathing and doubling 
concentrations of histamine ranging from 0 . 1 3  to 32 mg/ml. 
ALVEOLAR AND BRONCHIAL NITRIC OXIDE 
Exhaled nitric oxide ( NO) was measured on the Aerocrine NO system ( Niox, Aerocrine 
AB, Stockholm, Sweden) in accordance with international g uidelinesES. Alveolar NO 
concentrations (ppb) and bronchial N O  fluxes (nL/s) were assessed according to 
Tsoukias and George(6) with some modifications(7). 
ATOPY 
Atopy was determined by the Phadiatop screening test(8) with the ImmunoCap system 
( Phadia AB, Uppsala, Sweden). T he Phadiatop score is expressed as quotient, i.e. 
fluorescence of the serum of interest divided by the fluorescence of a control serum. 
Positive Phadiatop, and thereby atopy, was defined as serum/control serum > 1. 
INDUCED SPUTUM 
Sputum was induced by 5% hypertonic saline aerosols over 3 consecutive periods of 5 
min. Cytospins of processed whole sputum samples were stained with May- Grunwald­
Giemsa and cell differentials were determined by a blinded observer by counting 
a total of 600 viable, non-squamous cells. Sputum was not used if percentage of 
squamous cells was greater than 80% or when the total number of non-squamous 
cells exceeded 600. Histamine (!BL, Hamburg, Germany) and neutrophil elastase 
(Hycult, Uden, the Netherlands) in sputum supernatant were determined by ELISA 
and eosinophilic cationic protein (ECP) by a fluoroenzyme immunoassay ( ImmunoCAP 
ECP, Phadia AB) . 
BRONCHIAL BIOPSIES 
After local anaesthesia, bronchial biopsies were obtained using a flexible bronchoscope 
(Olympus BF P20 or BF XT20) from segmental divisions of the main bronchi. Biopsies 
were fixed in 4% formalin, processed and embedded in paraffin and cut in 3µm thick 
sections. Morphological features were determined on sections stained with hematoxylin 
and eosin ( HE) and with periodic acid Schiff. Immunohistochemical stainings (except 
for Ki67 and E-cadherin) were performed using the DAKO autostainer ( DAKO, Glostrup, 
Denmark). The slides were included in a random fashion in each run to avoid groupwise 
staining. Immunohistochemistry was performed using antibodies directed against T­
cells : (CD3, DAKO; CD4, Novocastra, Newcastle, U K; and CDS, DAKO), B-cells ( CD20, 
DAKO), neutrophil elastase (N P57, DAKO), macrophages (CD68, DAKO), eosinophilic 
peroxidase (EPX(9)), mast cell tryptase (AA1, DAKO), proliferation ( Ki67, DAKO), 
epithelial adhesion (E-cadherin, BD Biosciences, Breda, the Netherlands) and collagen 
3 ( Southern Biotech, Birmingham, AL, USA). In short, sections were deparaffinized 
and after antigen retrieval, incubated with the primary antibodies. These antibodies 
were detected with Envision™ Detection Kit ( DAKO) and the chromogen NovaRED 
(Vector Labs, Burlingame, USA). EPX was detected via biotinylated anti-mouse IgG 1  
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(Southern Biotech), alkaline phosphatase-labeled conjugate (DAKO) and permanent 
Red (DAKO). Ki67, E-cadherin and collagen 3 were detected with two peroxidase­
labelled conjugates (both DAKO) and 3,3'-Diaminobenzidine tetrahydrochloride 
(Sigma-Aldrich, Zwijndrecht, the Netherlands). 
All stainings were quantified by a blinded observer using computer-assisted image 
analysis at a magnification of 200x (Qwin, Leica Microsystems Imaging Solutions, 
Cambridge, UK). Quantification was performed on the largest of three biopsy sections. 
Inflammatory cell numbers were quantified by counting the number of positively 
stained cells in the submucosal area 100µm under the basement membrane (BM), 
in a total area of 0.lmm2 per biopsy sample. Activation of eosinophils and mast 
cells was determined by their degree of degranulation. Degranulation of eosinophils 
was determined by computer-assisted quantification of EPX immunopositivity in the 
submucosa. The percentage of degranulated AAl+ cells was determined by counting 
intact (dense, compact AAl+ cells with unbroken boundaries) and degranulated mast 
cells (all other AAl+ cells), as described previously(l0). Goblet cell numbers were 
counted on PAS-stained biopsy sections and expressed per mm of BM. Epithelial layer 
integrity was assessed on HE-stained biopsy sections and expressed as the percentage 
of BM covered with 1) normal, intact epithelium (basal and ciliated columnar epithelial 
cells) and 2) metaplastic epithelium (multilayered epithelium covered by a flattened 
layer of squamous epithelial cells and absence of ciliated cells) .  Epithelial proliferation 
was determined by counting the number of Ki67+ cells in intact epithelium and basal 
epithelium. Epithelial adhesion was determined by assessment of the percentage of 
BM covered with E-cadherin+ intact epithelium. BM thickness was calculated based 
on computer-assisted measurements of BM surface area and BM length. Submucosal 
deposition of collagen 3 was determined by computer-assisted image analysis in an 
area of 200µm under the BM. 
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Rationale: Asthma is characterized by hyperresponsiveness, inflammation and 
remodeling. We have shown that responsiveness to adenosine S'monophoshate (AMP) 
constitutes an indirect determinant of airway inflammation ,  assessed in induced sputum. 
Not all asthmatics express an AM P-responsive phenotype. 
Objective: To assess whether an AMP-responsive phenotype in asthma associates with 
pathological changes, focussing on airway inflammation,  remodeling and adenosine 
receptor expression. 
Methods: 37 mild, steroid-na"ive, non-smoking asthma patients with (n =20) and without 
(n= 17) AMP hyperresponsiveness were investigated. 
Measurements: Inflammatory cell numbers, remodeling parameters and adenosine 
receptor expression were assessed in induced sputum and bronchial biopsies. 
Main Results : AMP-responsive asthmatics were more frequently atopic and had 
higher airway wall eosinophil n umbers and eosinophil degranulation. More severe AMP 
responsiveness associated with a thicker basement membrane which, in turn , correlated 
with higher eosinophil numbers. Adenosine receptor expression in bronchial biopsies 
and the number of mast cells expressing A2a or A2b receptors were comparable in 
asthmatics with and without an AMP-responsive phenotype. 
Conclusion: AMP-responsive asthma has a distinct pathological phenotype, characterized 
by increased eosinophilic inflammation and basement membrane thickness. As eosinophilic 
inflammation mostly responds well to corticosteroids, the AMP test might be of use to 
identify corticosteroid responsiveness in asthma. 
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INTRODUCTION 
Asthma is a chronic inflammatory disorder of the airways characterized by variable airway 
obstruction and bronchial hyperresponsiveness (BHR). The presence and severity of BHR 
is generally assessed by provocation with histamine or methacholine, both acting mainly 
by direct stimulation of airway smooth muscle cells. BHR is therefore dependent on smooth 
muscle contraction, and additionally on the presence and severity of airway inflammation 
and airway remodeling. BHR can also be assessed by inhaling stimuli that indirectly 
cause smooth muscle contraction, e.g. by inflammatory cell activation. Adenosine 5'­
monophosphate (AMP) is such a stimulus, which upon inhalation is rapidly converted to 
adenosine. Adenosine targets cells by interaction with specific receptors classified as the 
Al, A2a, A2b and A3 receptors(l). While these receptors are present on a wide variety 
of cell types, inhalation of adenosine is thought to lead to bronchoconstriction mainly 
after binding of A2b receptors on mast cells, resulting in mast cell degranulation(2;3). 
This suggests that AMP responsiveness is dependent on airway inflammation. This is 
supported by our previous observation that PC20AMP (provocative concentration of AMP 
causing a 20% fall in FEVl) is more closely associated with eosinophilic inflammation in 
sputum than PC20methacholine(4). Moreover, steroid treatment improves PC20AMP more 
rapidly than PC2omethacholine, an improvement solely related to a reduction in sputum 
inflammation(5). Based on these findings, one can anticipate that AMP provocation will 
constitute a good clinical test to monitor eosinophilic inflammation and treatment effects 
in asthma albeit that the above mentioned studies were performed in induced sputum, 
which is only a surrogate marker for airway inflammation. Until now, no data on AMP 
hyperresponsiveness and airway inflammation in lung tissue or biopsies are available. 
Not all asthma patients exhibit AMP hyperresponsiveness and the reported prevalence 
of a positive PC20AMP varies from 50 to 89%(4;6). This would be a d rawback to the 
clinical use of PC20AMP. Therefore, it is of interest to characterize the AMP-responsive 
phenotype by investigating the pathology of asthmatics with and without a positive or 
negative response to AMP provocation. 
Therefore, we investigated sputum as well as airway biopsies for pathological differences 
between AMP-responsive and unresponsive asthmatics with respect to inflammation and 
remodeling. Additionally, we studied adenosine receptor expression in the airway wall and 
on mast cells in these patients to unravel further mechanisms of AMP responsiveness. 
METHODS 
SUBJECTS 
Non-smoking asthma patients (n=37) aged between 35 and 70 years participated. 
All patients originated from cohorts investigated earlier by our research group and 
all had a doctor's diagnosis of asthma and a documented PC20histamine ::5 32 mg/ 
ml in the past(7). AMP responsiveness was assessed and two groups were identified: 
1) negative PC20AMP (PC20AMP >320 mg/ml and PC20histamine <32 mg/ml) and 2) 
positive PC20AMP (PC20AMP ::5320 mg/ml). Main exclusion criteria were: FEVl < 1.2 L, 
bronchiectases, upper respiratory tract infection (e.g. colds) and/or use of antibiotics 
the last 2 months before inclusion, the use of corticosteroids the last 5 years before 
inclusion or more than 5 years of cumulative corticosteroid use in the distant past. The 
study protocol was approved by the local medical ethics committee. All subjects gave 
their written informed consent. 
STUDY DESIGN 
Induced sputum samples, blood samples and lung function (flow-volume, CO diffusion) 
were obtained. An AMP provocation test was performed, followed 1-2 weeks later by a 
bronchoscopy with bronchial biopsies. Subjects with a negative AMP provocation test 
(PC20 AMP >320 mg/ml) were subjected to a histamine provocation test >3 weeks later 




FEV1 was measured with a calibrated water-sealed spirometer ( Lode Spirograph 
D53, Lode Instruments, Groningen, the Netherlands). Reversibility of FEV1 (% 
predicted) was measured after administration of 400 µg of Albuterol and expressed as 
percentage. Provocation tests were performed with a method adapted from Cockcroft 
and coworkers(8). After an initial nebulized 0.9% saline challenge, subjects inhaled 
doubling concentrations of AMP (0.04 to 320 mg/ml) by 2-min tidal breathing, at 
5-min intervals. BHR to histamine was tested as reported previously(9), using 30-
second tidal breathing and doubling concentrations ranging from 0 .13 to 32 mg/ml. 
To enable better estimation of the airway reactivity in asthmatics with a negative 
PC20AMP, we also analyzed the AMP challenges as the AMP dose-response slope, 
calculated by dividing the maximum fall in FEV1 (I) by the dose of AMP at reaching 
the threshold (mg)(10). 
ATOPY 
Total serum IgE (IU/L) was measured by a solid-phase immunoassay (VIDAS 
total IgE kit, BioMerieux, Marcy l'Etoile, France). Atopy was determined by the 
Phadiatop screening test with the ImmunoCap system ( Phadia AB, Sweden), results 
being presented as quotients (fluorescence of the serum of interest divided by the 
fluorescence of a control serum). Positive Phadiatop was defined as patient serum/ 
control serum >1. 
SPUTU M IN DUCTION, PROCESSING AND M EASUREMENTS 
Sputum was induced by inhalation of 5% hypertonic saline aerosols over 3 consecutive 
periods of 5 min. Processed whole sputum samples were stained with May-Grunwald­
Giemsa (MGG) to obtain cell differentials and counting 600 viable, non-squamous cells. 
Sputum was not used if the percentage squamous cells was >80% or the total number 
of non-squamous cells was < 600. Secreted mucin was measured by double-sandwich 
ELISA (Covance, Emeryville, USA), with the 17B1 protein-G purified antibody and 
17Q2 alkaline phosphatase-conjugated antibody specifically binding to the granules of 
the surface goblet cells and mucous gland cells, as previously described(11). 
Collection, processing and immunohistochemical staining of bronchial biopsies 
After local anaesthesia, bronchial biopsies were obtained using a flexible bronchoscope 
(type Olympus BF P20 or BF XT20) from segmental divisions of the main bronchi. T he 
biopsies were fixed in 4% buffered formalin, processed and embedded in paraffin. 
Bronchial biopsies were cut in 3 µm thick sections. 
All histochemical stainings (PAS and HE) were performed at one day. All 
immunohistochemical stainings (except for Ki67 and E-cadherin) were performed in 
an automated system using the DAKO autostainer in three consecutive runs per cell 
marker. The slides were included in random fashion in each run, to avoid groupwise 
staining .  
Immunohistochemistry was performed on biopsies using antibodies directed against 
T-cells (CD3, DAKO, Glostrup, Denmark, CD4, Novocastra, Newcastle, U K, CDS, 
DAKO), B-cells (CD20, DAKO), neutrophil elastase ( N P57, DAKO), macrophages 
(CD68, DAKO), eosinophilic peroxidase (EPX (12)), mast cell tryptase (AA1, DAKO), 
proliferation ( Ki67, DAKO), epithelial adhesion (E-cadherin, BD Biosciences, Breda, 
the Netherlands), collagen 3 (Southern Biotechnology, Birmingham, AL, USA), 
decorin (dermatan sulfate proteoglycan, Seikagaku, Tokyo, Japan), versican ( large 
proteoglycan (versican), Seikagaku) and adenosine receptors A2a, A2b (both from 
Alpha Diagnostics, San Antonio, TX, USA) and A3 (Santa Cruz Biotechnology, Santa 
Cruz, CA, USA). Stainings were performed as described previously(13) and details 
about the procedure can be obtained from the online supplement. 
QUANTIFICATION OF INFLAMMATORY CELL NUMBERS 
Quantification of inflammatory cell numbers and activation was performed by a 
blinded observer using computerized-assisted image analysis at a magnification of 
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200x (Qwin, Leica Microsystems). The number of positively stained inflammatory cells 
was counted in the submucosal area lO0µm under the basement membrane (BM), in a 
total area of 0.1mm2 per biopsy sample. Additionally, mast cells were quantified in the 
smooth muscle area, which could be readily identified by its morphologic appearance. 
A minimal area of 0.05 mm2 airway smooth muscle was considered sufficient for the 
assessment of mast cell infiltration. 
QUANTIFICATION OF ACTIVATED EOSINOPHILS AND MAST CELLS 
Activation of eosinophils and mast cells was determined by their degree of 
degranulation. EPX staining showed a widely spread distribution of eosinophilic 
granules, not necessarily in close proximity of EPX+ cells. Therefore, degranulation 
of eosinophils was determined by quantification of the EPX immunopositive area by 
computerized-assisted image analysis. AA1+ mast cell granules were only observed 
in close proximity of AA1 + cells and therefore, the percentage of degranulated AA1 + 
cells was determined by counting(14). In short, positively stained nucleated mast 
cells were classified as intact if they were dense, compact, had unbroken boundaries 
and did not have any surrounding positively stained granules. All other nucleated 
AA1+ cells were classified as degranulated. 
QUANTIFICATION OF REMODELING 
The number of goblet cells was counted on PAS-stained biopsy sections and expressed 
per mm of BM. Epithelial integrity was determined using HE-stained biopsy sections and 
was expressed as the percentage of BM that was covered with either intact epithelium 
(a layer of basal and ciliated columnar epithelial cells without detachment from the 
BM), only basal epithelial cells, metaplastic epithelium (multilayered epithelium 
covered by a flattened layer of squamous epithelial cells and absence of ciliated cells) 
or the percentage of BM that was denuded from epithelial cells. Epithelial proliferation 
was determined by counting the number of Ki67-positive epithelial nuclei in intact and 
basal epithelium. Epithelial adhesion was determined by expression of the adhesion 
marker E-cadherin. In intact epithelium and basal epithelium the percentage of the 
BM that was covered with either E-cadherin-positive or negative epithelium was 
determined. BM thickness was calculated by dividing the BM surface area by the 
BM length(15). Expression of collagen 3, versican, and decorin was measured in the 
submucosal area 200µm under the BM by computerized-assisted image analysis, and 
was expressed as the percentage of positive tissue per biopsy section. 
QUANTIFICATION OF ADENOSINE RECEPTOR EXPRESSION 
A2a, A2b and A3 receptor expression was determined quantitatively using three 
categories as described previously(16). In the epithelium and smooth muscle, 
expression was categorized as 0 (negative), 1 (positive) or 2 (strongly positive) 
and expression in submucosal inflammatory cells and vascular endothelium was 
categorized as O (no positive cells/vessels), 1 (few positive cells/vessels) or 2 (many 
positive cells/vessels). In the submucosal area (excluding the epithelial layer) and 
in the smooth muscle we counted the number of AA1+/A2a receptor and AA1+/A2b 
receptor double-positive cells and expressed them as the percentage of the total 
number of AA1+ mast cells. 
STATISTICS 
All analyses were performed using SPSS (version 16.0; SPSS Inc, Chicago, IL, USA). 
Normality of distributions was assessed using the Kolmogorov-Smirnov test. When 
necessary, normalization by transformation was attempted. To test for differences 
between the negative PC20AMP and positive PC20AMP groups independent samples 
T-tests were used for normally distributed data and Mann-Whitney U tests for 
non-normally distributed data. Chi-square tests were used to compare groups 
for dichotomous variables. Correlations were evaluated by Pearson (for normally 
distributed data; expressed as r) or Spearman (for non-normally distributed data; 






Thirty-seven asthmatic patients were included, 20 patients with and 17 patients without 
a positive PC2QAMP (Table 1). T he latter group did demonstrate responsiveness to 
histamine. Lung function parameters, i.e. FEV1 (%pred), FEV1/VC and reversibility 
were all comparable between asthmatics with a positive and negative PC2QAMP. 
Asthmatics with a positive PC2QAMP were more often atopic and had a significantly 
higher Phadiatop score than asthmatics with a negative PC2QAMP. The Phadiatop 
score positively correlated with the severity of AMP responsiveness (expressed as the 
AMP dose-response slope, Spearman correlation rs=0 .50, p=0.002). Blood eosinophil 
numbers were not significantly different in asthmatics with a positive and a negative 
PC20AMP, but they correlated significantly with AMP dose-response slope in the whole 
group of 37 asthmatics (rs=0. 39, p=0.017, Figure 1A-B). 
EOSINOPHILS AND MAST CELLS IN BRONCHIAL BIOPSIES 
Bronchial biopsies were successfully obtained from 29 of the 37 asthma patients. 
Asthmatics with a positive PC20AMP had higher eosinophilic inflammation as shown 
by a higher number of submucosal EPX+ eosinophils and higher EPX immunopositivity 
(measure of eosinophilic degranulation products) than those with a negative PC20AMP 
( Figure 1C, E-F, Table 2). Bronchial eosinophils, both EPX+ eosinophils and EPX 
immunopositivity, correlated positively with AMP dose-response slope (rs=0. 59, 
p=0.001 and rs=0.64, p<0.001, respectively ( Figure 1 D)). 




PC20AMP (mg/ml) >320 1 8 .2 (0.02- 1 74.3) 
AMP dose-response slope 0.4 (-0.3- 1 .8) 27.5 ( 1 .9-30 1 50.0)* 
Sex (M/F) 9/8 14/6 
Age (years) 48 (35-70) 53 (38-62) 
FEV 1 (% predicted) 100 (76.9- 1 25 .0) 99 (84.8- 1 30.9) 
FEV1NC (%) 78.2 (58.0-90.7) 72.0 (56.4-83.8) 
Reversibility FEV 1 (%) 6.5 (- 1 .4- 1 5 .0) 8.5 (-8.4-28. 7) 
Atopic (n (%)) 9 (53%) 17 (85%)* 
Phadiatop score ( quotient) 2.6 (0. 1 -29 .5) 20.0 (0.3-92. 1  )* 
IgE (IU/L) 55 ( 1 3-246) 8 1  ( 1 1 -558) 
Data are presented as median (range), unless stated otherwise. PC20AMP = provocative 
concentration of adenosine S 'monophoshate causing a 20% fall in FEY 1 • The AMP dose­
response slope was calculated by dividing the maximum fall in FEY 1 (I) by the dose of AMP 
at reaching the threshold (mg). FEY 1 (% predicted) was detennined after inhalation of 400 µg 
of Albuterol; reversibility FEY1 = change in FEY 1 , expressed as increase in percentage 
predicted normal value after 400 µg of Albuterol; Atopy is defined as specific IgE's in patient 
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Eosinophilic inflammation and AMP responsiveness. (A) Blood eosinophils in asthmatics with a negative or a posi­
tive PC20AMP. (BJ Correlation between blood eosinophils (log10 transformed) and AMP dose-response slope (In 
transformed). (CJ Degranulation of eosinophils, measured by EPX immunopositivity, in bronchial biopsies of asth­
matics with a negative or a positive PC20AMP. (DJ Correlation between EPX immunopositivity (log10 transformed) 
and AMP dose-response slope (In transformed). (E-F) Representative pictures of EPX staining (pink) in asthmatic 
patients, assessing both a negative (E) and positive (F) PC20AMP patient. Notice the extracellular EPX+ granules 
observed in the PC20AMP patient in addition to the intracellular EPX + granules, quantified as EPX immunopositiv­
ity. Original magnification 400x. (G) Sputum eosinophil percentages in asthmatics with a negative or a positive 
PC20AMP. (HJ Correlation between sputum eosinophil percentages (In transformed) and AMP dose-response slope 
(In transformed). Each closed circle represents one subject, open circles are asthmatics with a negative PC20AMP 
and closed circles are asthmatics with a positive PC20AMP. Horizontal bars represent median values. 
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CHAPTER 4 
In the submucosa, both the number of mast cells and the percentage of degranulated 
mast cells were comparable between asthmatics with a positive and negative PC20AMP 
(Table 2) . In the airway smooth muscle, the number of mast cells did not differ 
sig nificantly between the two groups (Table 2). The number of airway wall T-cells, 
B-cells, neutrophils and macrophages was not significantly different between the two 
groups (Table 2) . 
REMODELING IN BRONCHIAL BIOPSIES 
Basement membrane thickness derived from H&E stained 1tng biopsy sections ( Figure 
2A) was significantly higher in bronchial biopsies of asthmatics with than without a 
positive PC2QAMP ( Figure 2B) . Basement membrane thickness correlated strongly with 
the AMP dose-response slope ( Figure 2C). Moreover, basement membrane thickness 
correlated significantly with eosinophilic inflammation, i.e. the percentage of sputum 
eosinophi ls (rs=0.67, p=0. 001) and the number of EPX+ eosinophi ls (rs= 0. 51, 
p=0.006) and EPX immunopositivity (rs=0. 54, p=0. 003) in the airway wall. 
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3 (0- 1 9) 
56 (2 1 - 1 268) 




85 (2 1 - 1 36) 
26 (2-57) 
1 9 ( 1 -84) 
3 (0-22) 
5 ( 1 -46) 
16 (4-30) 
6 (2-40)* 
6 (0- 1 3) 
343 (60-5329)* 
75 (50-1 00) 
AAl+ mast cells 0.5 (0.2- 1 5 .3) 1 .2 (0-6.0) 
Data are presented as median (range). The cell numbers are expressed per 0 . 1  mm2 of tissue. 
* :  P<0.05 
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Basement membrane thickness and AMP responsiveness. (A) Representative photomicrograph of an H&E stained 
section typical of the photographs used to measure basement membrane (BM) thickness. The black line indicates 
the measured area. Original magnification 40Dx. (B) BM thickness in asthmatics with a negative (open circles) or 
a positive (closed circles) PC2DAMP. (C) Correlation between BM thickness and the AMP dose-response slope (In 
transformed). Each circle represents one subject. Horizontal bars represent median values. 
Sputum of asthmatics with a positive PC20AMP contained more mucin protein than in 
those with a negative PC20AMP (Table 3). The airway epithelium of asthmatics with 
a positive PC20AMP contained a higher percentage of metaplastic epithelium than 
asthmatics with a negative PC20AMP (Table 3). Sputum mucin protein and metaplastic 
epithelium did not significantly correlate with the AMP dose-response slope. Other 
features of epithelial integrity including the presence of intact, basal or denuded 
epithelium, the number of goblet cells, epithelial proliferation (Ki67 expression), and 
the epithelial adhesion (E-cadherin expression) were all comparable in both groups 
(Table 3). Moreover, no significant differences were observed in the submucosal 
expression of extracellular matrix components (i.e. collagen 3, versican and decorin) 
between the asthmatics with a positive and a negative PC20AMP (Table 3). 
TABLE 3: REMODELING IN SPUTUM AND BIOPSIES 
S utum 
Mucin in sputum (units) 
Bronchial epithelium 
Goblet cells (cells/mm BM) 
Intact Epithelium (%) 
Basal Epithelium (%) 
Denuded Basement Membrane (%) 
Metaplasia (%) 
Ki67+ intact epithelium (%) 
Ki67+ basal epithelium (%) 
E-cadherin+ intact epithelium (%) 
E-cadherin+ basal epithelium (%) 
Submucosa 
Collagen 3 (% stained tissue) 
Versican (% stained tissue) 
Decorin (% stained tissue) 




0.4 (0.0 1 - 1 .6) 
29 (4-78) 
8.9 (0-34.2) 
57.8 ( 13 .5- 1 00) 
14.4 (0-58.8) 
0 (0-5.6) 
1 .5 (0-6.3) 
1 . 8  (0.3-9.0) 
65 .7 (0- 1 00) 
94 (67- 1 00) 
36.3 (8.6-64.5) 








58. 7 (20.6-92.9) 
9.2 (0-34.3) 
0 (0-26.2)* 
1 .4 (0-24.2) 
1 .3 (0-5.5) 
58.3 (0- 1 00) 
96.6 ( 1 0- 1 00) 
37.4 ( 1 8.3-63 .0) 
35.4 (2 1 .8-64.4) 
39.0 ( 14.7-55.4) 
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INFLAMMATORY CELLS IN INDUCED SPUTUM 
Induced sputum samples were successfully obtained in 24 of our 37 asthmatic 
patients. Apart from eosinophils, total or differential cell counts were comparable 
(Table 4). Sputum eosinophil percentages were significantly higher in asthmatics with 
a positive PC20AMP than with a negative PC20AMP (Table 4, Figure 1G). Moreover, 
the percentage of sputum eosinophils correlated strongly with the AMP dose-response 
slope ( Figure 1H). 




Sputum not evaluable (n (%)) 5 (29) 8 (40) 
No sputum (n (%)) 3 ( 1 8) 3 ( 1 5) 
>80% squamous (n (%)) 2 ( 1 1 )  3 ( 1 5) 
<600 cells (n (%)) 2 ( 1 0) 
Sputum evaluable (n (%)) 12 (7 1 )  12  (60) 
Total cells (x1 06/l) 0.3 (0. 1-2.3) 0.3 (0.0-2.0) 
Neutrophils (%) 56.8 (20.7-94.5) 56.5 ( 19.8-93 .6) 
Macrophages (%) 40.0 (5.3-76.4) 32.2 (5.6-76.2) 
Eosinophils (%) 0.2 (0- 1 .8) 2.3 (0-25 .7)* 
Lymphocytes (%) 2.0 (0.2-6.9) 1 .6 (0-5 .9) 
Data are presented as median (percentage or range). * :  P<0.05 
lMMUNOHISTOCHEMICAL LOCALIZATION OF A2A, A 2B AND A3 RECEPTORS IN BRONCHIAL 
BIOPSIES 
To further unravel the mechanism of AMP responsiveness, we investigated the 
expression patterns of A2a, A2b and A3 receptors. Of these receptors, the A2a receptor 
showed the most abundant expression pattern, localized in the complete bronchial 
epithelial layer, the vascular endothelium, bronchial smooth muscle, and in infiltrating 
cells in the submucosal area ( Figure 3A). The A2b receptor was present mainly in 
basal cells of the bronchial epithelium, the bronchial smooth muscle, and in infiltrating 
cells in the submucosal area, many of which had an elongated shape suggestive of 
mast cel ls ( Figure 3B) . The A3 receptor showed the least abundant expression pattern 
of the 3 receptors, with expression in the basal cells of the bronchial epithelium 
and bronchial smooth muscle ( Figure 3C). The pattern of expression of these three 
adenosine receptors was not significantly different between the asthmatics with a 
positive and negative PC2QAMP (Table 5). We did not quantify the Al receptor since 
this receptor was nominal in bronchial biopsies . 
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A B 
Figure 3 
Adenosine receptor expression in bronchial biopsies. Representative pictures of A2a (A), A2b (B) and A3 receptor 
expression (C) in consecutive slides of the same biopsy sample. A2a receptor expression in mast cells was shown 
by fluorescent double-staining for AA1 (D) and A2a receptor (E). The overlap of signal is shown in the overlay (F). 
A2b receptor expression in mast cells was shown by fluorescent double-staining for AA1 (G) and A2b receptor 




EXPRESSION OF A2A AND A2e RECEPTORS ON MAST CELLS 
Since A2a and A2b receptors on mast cells are thought to contribute to mast cell 
degranulation and AMP responsiveness, we studied mast cell expression of A2a and 
A2b receptors in a subset of patients by immunofluorescence and specific antibodies. 
Both A2a ( Figure 3D-F) and A2b receptor ( Figure 3G-I) expression was shown on a 
hig h percentage of AAl + mast cells with medians ranging from 65 to 100% (Table 6). 
Double-staining for tryptase elucidated that the A2b receptor positive spindle-shaped 
cells were mast cells ( Figure 3G-I). T he percentages of A2a and A2b receptor positive 
mast cells in the submucosal area and smooth muscle were not significantly different 
between asthmatics with and without a positive PC20AMP (Table 6). 
















1 .25  
1 .5 













Expression was scored in a semi-quantitative way ranging from O to 2 (see methods section). 
Data are presented as median. No significant differences between the groups. 
TABLE 6: ADENOSINE RECEPTOR EXPRESSION IN MAST CELLS 
Negative Positive 
PC20 AMP PC20 AMP 
Sub mucosa! 
A2a + mast cells (%) 73 (56-84) 67 (58-90) 
A2b + mast cells (%) 70 (42-87) 75 (70-78)  
Smooth Muscle 
A2a + mast cells (%) 1 00 (0- 1 00) 83 ( 1 9- 1 00) 
A2b + mast cells (%) 80 (67- 1 00) 65 (50-74) 
Data are presented as median (range). The cell numbers are expressed per 0.1 mm- of tissue. 
No significant differences between the groups. 
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DISCUSSION 
This is the first study describing the pathological phenotype of AMP-responsive asthma 
patients, which appears to be characterized by airway wall eosinophilic inflammation 
and basement membrane thickening. Our data indicate that an AMP provocation test 
can be used to identify specific asthma phenotypes. 
To our knowledge, we are the first to show that AMP responsiveness in asthma is 
associated with increased eosinophilic inflammation in the bronchial airway wall. 
Mechanistically, AMP is thought to exert its action via adenosine receptors. Since 
activation of the A3 receptor on eosinophils has been described to inhibit their 
migration(17), it also would have been of interest to study the expression pattern 
of this receptor on eosinophils. The number of A3-positive eosinophils in bronchial 
biopsy tissue were, however, too low for reliable quantification. 
T he increase in eosinophils in bronchial biopsies was paralleled by increased 
sputum eosinophil numbers in AMP-responsive asthmatics, compatible with results 
from previous studies(4;5;18;19) and indicating that sputum eosinophilia reflects 
airway wall inflammation in this group of patients. Migration of eosinophils to the 
sputum in asthma patients is a characteristic feature of AMP provocation(18;19), 
and does not occur after methacholine provocation. We have shown previously that 
an AMP-induced increase in sputum eosinophils is less pronounced in asthmatics 
using inhaled corticosteroids ( ICS)(19), a drug specifically suppressing eosinophilic 
inflammation(20). Furthermore, we showed that both AMP responsiveness and sputum 
eosinophil numbers decrease after therapy with ICS(5;21). T hese findings support 
a causal relationship between AMP responsiveness and eosinophilic inflammation. 
Moreover, in a randomized, double-blind, crossover study on the changes in B H R  
with AMP and sputum cell counts in asthma patients after budesonide treatment, it 
was indeed shown that AMP-responsiveness reflects the anti-inflammatory effects of 
corticosteroids(22). A positive AMP provocation test may thus identify asthmatics that 
are responsive to !CS, thereby signifying the importance of identification of an AMP­
responsive phenotype. 
The second characteristic of the AMP-responsive phenotype in asthma was an 
increased BM thickness. Moreover, a thicker BM strongly correlated with more severe 
AMP responsiveness. This finding is in line with previous studies indicating not only 
a relationship between BM thickness and BHR assessed with AMP(23) provocation 
but also with methacholine(24-26) and histamine(27), suggesting an overall role for 
BM thickening in BHR. Although it is possible that airway structural changes, like BM 
thickening, contribute to airflow limitation or BHR, a direct causal relationship has not 
been shown so far. 
BM thickness additionally strongly correlated with eosinophilic inflammation in 
bronchial biopsies and sputum, a finding consistent with the literature(24-26;28;29) 
and supporting a role for airway eosinophils in the process leading to BM thickening . 
Indeed, airway eosinophils have been shown to produce T G F-13( 30), a well-established 
inducer of extracellular matrix ( ECM) production by stimulating proliferation and 
differentiation of ECM producing cells, i .e .  (myo)fibroblasts( 31). This has been 
hypothesized to lead to excessive ECM deposition at the lamina reticularis, thereby 
thickening the airway subepithelial BM. Moreover, reduction of airway eosinophils 
after 12-months ICS treatment reverses BM thickening(25), also supporting the 
observed relation of airway eosinophils with BM thickening. A thickened BM is, 
however, not specific to asthma since this is also observed in other diseases with 
increased eosinophil numbers, like rhinitis and eosinophilic bronchitis without asthma 
symptoms(28). Therefore, we assume that BM thickening is an epiphenomenon of 
eosinophilic inflammation in asthmatics with AMP responsiveness rather than the 
underlying cause of AMP responsiveness itself. 
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Although several studies have shown that AMP-induced bronchoconstriction exerts 
its main action via the release of mast cell mediators, asthmatics with a positive 
PC2QAMP in our study did not show higher submucosal mast cell numbers than those 
with a negative PC2QAMP. It is conceivable that the smooth muscle rather than the 
bronchial submucosa is of relevance for AMP-induced bronchoconstriction, since mast 
cell degranulation products cause smooth muscle constriction. Nevertheless, we also 
did not find an association between AMP responsiveness and mast cell numbers in 
the smooth muscle. Our data are in agreement with two earlier studies in asthma 
that were not able to demonstrate an association between AMP responsiveness and 
mast cell numbers in both bronchial mucosa and smooth muscle (32;33). This lack of 
association may be due to the fact that the mast cells involved in bronchoconstriction 
reside in more peripheral parts of the lung rather than the central airways, which we 
studied. Indeed, the peripheral airways contain more mast cells in the airway wall 
and smooth muscle than central airways(14). Another option is that while there is 
not an increase in mast cell numbers between AMP-responsive and non-responsive 
asthmatics, the relevant issue is that induced changes in mast cell functionality are 
responsible for mast cell-mediated AMP responsiveness. 
We investigated the functionality of mast cells by adenosine receptor expression, 
i.e. A2a and A2b receptors on mast cells, since Al and A3 receptors are not 
expressed(2;34). Studies from human cultured mast cells showed that A2a receptor 
activation inhibits their histamine and tryptase release(35), while A2b receptor 
activation has an opposite effect, i.e. mast cell degranulation(36). Based on these 
findings we hypothesized that an unbalance in A2a/ A2b receptor expression may 
accompany AMP responsiveness. Our data did, however, not confirm this hypothesis. 
We were unable to distinguish AMP-responsive and non-responsive asthmatics based 
on mast cell A2a and A2b receptor expression. We also did not find evidence for an 
association between AMP responsiveness and overall expression pattern of A2a, A2b 
and A3 receptors in asthmatic bronchial biopsies. We think this does not rule out a role 
for adenosine receptors in asthma, since differences are found in adenosine receptor 
expression on blood and sputum inflammatory cells between asthmatics and healthy 
controls and between samples before and after allergen challenge(37). Our data 
suggest that AMP responsiveness in asthma is not directly mediated by adenosine 
receptor expression. Clearly, functional studies using selective adenosine receptor 
agonists or antagonists are needed to prove or refute the contribution of adenosine 
receptors in AMP responsiveness in asthma. 
In conclusion, we show that AMP responsiveness in asthma identifies asthmatics with a 
distinct pathological phenotype characterized by eosinophilic airway inflammation and 
BM thickening. As eosinophilic inflammation mostly responds well to corticosteroids, an 
AMP provocation test might be used to identify corticosteroid responsive asthmatics. 
This is an interesting option that has to be proven in future studies. 
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IMMUNOHISTOCHEMICAL STAINING PROCEDURES 
In short, sections were deparaffinized and after antigen retrieval, incubated with the 
primary antibodies. CD3, CD4, CD20, N P57, CD68, AAl , decorin and versican were 
detected with Envision™ Detection Kit (DAKO). Ki67, E-cadherin and collagen 3 were 
detected with two peroxidase-labelled conjugates (both DAKO). CDS and EPX were 
detected with biotinylated anti-mouse IgGl (Southern Biotechnology, Birmingham 
AL, USA) and streptavidine-peroxidase conjugate (CDS) or streptavadine-alkaline 
phosphatase conjugate (EPX, both DAKO). Adenosine receptors were detected with 
biotinylated anti-rabbit conjugate (Southern Biotechnology) and strepABComplex/ 
PO ( DAKO). We chose the chromogen for each antigen based on its suitability for 
quantification, i.e. NovaRED for CD3, CD4, CDS, CD20, NP57, CD68 and AAl (Vector 
Labs, Burlingame, USA), 3,3'-Diaminobenzidine tetrahydrochloride for decorin, 
versican, collagen 3, Ki67 and E-cadherin ( DAB, Sigma-Aldrich, Zwijndrecht, the 
Netherlands), Permanent Red for EPX (DAKO) or 3-amino-9-ethylcarbazole for 
Adenosine Receptors (AEC, Sigma-Aldrich). 
Immunofluorescence double staining was performed to show adenosine A2a and A2b 
receptor expression on mast cells, using donkey anti-rabbit ALEXA 488 ( Invitrogen, 
Breda, the Netherlands) for the receptors and donkey anti-mouse ALEXA 555 
(Invitrogen) for mast cells. Counterstaining was performed with 4', 6-diamidino-2-
phenylindole ( DAPI, Sigma-Aldrich). Fluorescence microscopy was performed using a 
Leica DM LB microscope ( Leica Microsystems, Rijswijk, the Netherlands), Leica DC300F 
camera and Leica QWin 2.8 software . 
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Background: As it is unknown whether complete asthma remIssIon or progression 
of asthma is associated with airway inflammation and remodeling, we assessed these 
characteristics in bronchial biopsies of relevant subsets of asthma patients. 
Methods: Sputum and bronchial biopsies were obtained from asthma patients in 
remission ( PC20 histamine > 32 mg/ml, PC20 AMP > 320 mg/ml) and from those with 
either a slow FEV1 decline ( < 30 ml/year) or fast decline ( > 30 ml/year). Inflammatory 
cells and mediators were determined in sputum, inflammatory cells and aspects of airway 
remodeling in bronchial biopsies. 
Results : Asthmatics in remission and asthma patients with a slow FEV1 decline had a 
similar extent of airway inflammation and remodeling in sputum and bronchial biopsies. 
Asthma patients with a fast FEV1 decline had high sputum eosinophil numbers. Moreover, 
FEV1 decline (ml/year) correlated with sputum eosinophil numbers ( Rs=0.51, P=0.003) 
and ECP levels ( Rs=0.57, P=0.001). Airway remodeling, i.e. basement membrane 
thickness, correlated with sputum eosinophils ( Rs=0.69, p<0.001), sputum ECP 
( Rs=0. 46, p=0.018) and airway wall eosinophil numbers ( Rs=0.49, p=0.002). 
Conclusions: Asthma, even when in remission, is accompanied by airway inflammation 
and remodeling. Data suggest that eosinophils are important in a subset of asthma 
patients by association to accelerated FEV1 decline and change of basement membrane 
thickness. 
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INTRODUCTION 
Asthma is a chronic inflammatory disorder of the airways associated with airway obstruction 
that is often reversible, either spontaneously or with treatment. Nevertheless, asthma 
patients have on average a lower lung function than healthy controls ( 1). Furthermore, 
some patients have an even accelerated decline in forced expiratory volume in 1 second 
( FEV1) over time (2), probably caused by ongoing airway inflammation and the resulting 
airway remodeling ( 3). Not all asthmatics are predestined for this scenario since some 
subjects show stable lung function and others even outgrow their disease. As yet, it 
is unknown whether these differences in the natural course of clinical asthma reflect 
differences in the underlying inflammatory processes and structural changes in the 
airways. 
Some patients fully outgrow their asthma, so-called asthma remission, which is 
characterized by normal lung function, absence of bronchial hyperresponsiveness ( BH R) 
and respiratory symptoms while not using asthma medication ( 4). Others are in "clinical" 
asthma remission, i .e.  they are asymptomatic but still show BHR. T he latter type of 
remission is associated with ongoing airway inflammation and remodeling as reflected 
by increased numbers of eosinophils, T cells and mast cells in the airway mucosa and 
thickening of the reticular basement membrane ( BM) when compared to control subjects 
without asthma ( 5). However, it is unknown whether complete remission with the absence 
of BHR is associated with less airway inflammation and remodeling when compared 
to persistent asthma. T herefore, we investigated airway inflammation and remodeling 
in patients with complete asthma remission, defined by the absence of BHR, asthma 
symptoms and treatment. 
Previous studies have revealed multiple risk factors for an accelerated FEV1 decline 
( 15-50 ml/year) in asthma : low baseline lung function ( FEV1 % predicted) (6), less 
reversibility to 132-agonists (6), more severe BHR (7),  smoking (8), increased mucus 
production (2), male gender (9) and frequent exacerbations ( 10). T he pathological 
processes underlying the accelerated FEV1 decline in asthma are unknown. Several 
suggestions for the underlying pathological process come from cross-sectional studies 
demonstrating an association between the above described risk factors and markers of 
airway inflammation and remodeling. For example, low baseline lung function has been 
associated with increased airway wall thickness ( 1 1), more severe BH R with thickening of 
the subepithelial BM ( 12), smoking with epithelial metaplasia ( 13), goblet cell hyperplasia 
( 14) and increased subepithelial collagen deposition ( 15), and increased mucus production 
has been associated with hyperplasia and hypertrophy of epithelial goblet cells ( 16) 
and increased presence of submucosal mucous glands ( 16). Moreover, U lrik et al. ( 1 7) 
showed an association between higher blood eosinophil numbers and accelerated FEV1 
decline in adult asthma patients, thereby postulating a role of eosinophils. Based on 
these findings it is tempting to speculate that an accelerated FEV1 decline in asthma 
indeed results from progressive airway inflammation and remodeling . 
Aim of this study was to characterize the pathological background of asthma remission 
and progression. T herefore, we recruited 47 steroid-na"ive, non-smoking subjects with a 
documented asthma diagnosis in the past, we assessed their annual FEV1 decline over 
a minimum period of at least 5 years and categorized them into 3 groups : subjects with 
asthma remission, current asthma patients with a slow FEV1 decline ( < 30 ml/year) and a 
fast FEV1 decline ( > 30 ml/year). Airway inflammation and remodeling were investigated 
in sputum samples and bronchial biopsies. 
METHODS 
SUBJECTS 
Non-smoking subjects (n=47) aged between 32 and 70 years, without oral or inhaled 
corticosteroids were recruited. All subjects originated from research cohorts investigated 
earlier by our research group and all had a doctor's diagnosis of asthma and a documented 
PC20 histamine (using 30-seconds tidal breathing) ::5 32 mg/ml in the past (4). T hese 
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subjects were extensively characterized according to a standard protocol (including 
FEV1 ) at least five years prior to our study. Subjects were re-assessed in the present 
study with lung function, hyperresponsiveness to adenosine 5'-monophosphate 
(AMP) , sputum induction and bronchial biopsies. T hree groups were identified: 1 )  
asthma remission (FEV1 >90% predicted, PC20 AMP > 320 mg/ml, PC20 histamine 
> 32 mg/ml), 2) slow FEV1 decline ( < 30 ml/year over at least 5 years and PC20 AMP 
� 320 mg/ml or PC20 histamine � 32 mg/ml) , 3) fast FEV1 decline ( > 30 ml/year over 
at least 5 years and PC20 AMP � 320 mg/ml or PC20 histamine �32 mg/ml) . Main 
exclusion criteria were : the use of corticosteroids during the period over which the 
FEV1 decline was being calculated or more than 5 years of cumulative corticosteroid 
use in the distant past. Furthermore, FEV1 < 1 .2 L, bronchiectases, upper respiratory 
tract infection (e.g. colds) and/or use of antibiotics the last 2 months before inclusion 
were exclusion criteria. The study protocol was approved by the local medical ethics 
committee. All subjects gave their written informed consent. 
STU DY DESIG N 
Peripheral blood eosinophil counts and IgE, induced sputum samples and lung 
function (flow-volume, CO diffusion) were obtained. An AMP provocation test was 
performed followed 1-2 weeks later by a bronchoscopy. Subjects with a negative AMP 
provocation test (PC20 AMP >320 mg/ml) were subjected to a histamine provocation 
test > 3  weeks later to determine BHR. 
LUNG FUNCTION 
FEV1 was measured with a calibrated water-sealed spirometer at the current and 
past visit (Lode Spirograph D53, Lode Instruments, Groningen, the Netherlands). 
Reversibility of FEV1 (% predicted) was measured after administration of 800 µg 
of Albuterol. Annual FEV1 decline (ml/year) was calculated by subtracting FEV1 
(post-bronchodilator) at the first and second measurement, divided by the number of 
years between the two measurements (minimum of 5 years) . Provocation tests were 
performed with a method adapted from Cockcroft and coworkers ( 18) . After an initial 
nebulized 0.9% saline challenge, subjects inhaled doubling concentrations AMP (0.04 
to 320 mg/ml) by 2-min tidal breathing,  at 5-min intervals. BHR to histamine was 
tested as reported previously ( 19),  using 30-seconds tidal breathing and doubling 
concentrations ranging from 0. 13  to 32 mg/ml . 
ATOPY M EASU REMENTS 
Atopy was determined by the Phadiatop screening test with the ImmunoCap system 
(Phadia AB, Sweden) and results are presented as quotients (fluorescence of the 
serum of interest divided by the fluorescence of a control serum). Positive Phadiatop 
was defined as patient serum/control serum > 1.  
SPUTUM INDUCTION AND PROCESSING 
Sputum was induced by inhalation of 5% hypertonic saline aerosols as over 3 
consecutive periods of 5 min. Processed whole sputum samples were stained with 
May Grunwald Giemsa ( MGG) to obtain cell differentials by counting total 600 viable, 
non-squamous cells. Sputum was not scored if the percentage squamous cells was 
>80% or the total number of non-squamous cells was <600. 
SPUTUM SUPERNATANT MEASUREMENTS 
Histamine was measured by ELISA ( IBL, Hamburg, Germany). Adenosine was 
measured by H PLC as described previously (20). T he concentration of eosinophilic 
cationic protein (ECP) was measured using a fluoroenzyme immunoassay (ImmunoCAP 
ECP, Pharmacia, Uppsala , Sweden) . 
Secreted mucin was measured by double-sandwich ELISA (Covance, Emeryville, USA), 
with the 1 7B1 protein-G purified antibody and 1 7Q2 alkaline phosphatase-conjugated 
antibody specifically binding to the granules of the surface goblet cells and mucous 
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gland cells, as previously described (21). 
Collection, processing and immunohistochemical staining of bronchial biopsies 
After local anaesthesia, bronchial biopsies were obtained using a flexible bronchoscope 
(type Olympus BF P20 or BF XT20) from segmental divisions of the main bronchi. 
The biopsies were fixed in 4% formalin, processed and embedded in paraffin. 
Bronchial biopsies were cut in 3 µm thick sections. All stainings were performed in 
an automated system using the DAKO autostainer and were manually counterstained 
with methylgreen. 
The inflammatory profile was assessed with specific antibodies against eosinophilic 
peroxidase (EPX, the laboratories of Drs. NA Lee and JJ Lee), mast cell tryptase 
(AAl, DAKO, Glostrup, Denmark), macrophages (CD6S, DAKO), neutrophil elastase 
(NP57, DAKO) and T-lymphocytes (CD3 (DAKO), CD4 (Novocastra, Newcastle upon 
Tyne, UK) and CDS (DAKO)). In short, sections were deparaffinized and after antigen 
retrieval, incubated with the primary antibodies. These antibodies were detected 
with Envision ™ Detection Kit (DAKO) except for EPX and CDS, which were detected 
using biotinylated anti-mouse IgGl (Southern Biotechnology, Birmingham AL, USA) 
and alkaline phosphatase- (DAKO) or peroxidase-labelled streptavidine conjugates 
(DAKO). Permanent Red (DAKO) or NovaRED (Vector Labs, Burlingame, USA) was 
used as chromogen. 
Periodic acid-Schiff (PAS) staining was used to determine the presence of goblet cells 
in the bronchial epithelium. Haematoxylin eosin (HE) staining was used for evaluation 
of epithelial integrity and basement membrane (BM) thickness. 
Deposition of extracellular matrix (ECM) components in the sub-epithelial compartment 
was assessed by specific antibodies against collagen 3 (Southern Biotechnology), 
decorin (dermatan sulfate proteoglycan, Seikagaku, Tokyo, Japan) and versican 
(large proteoglycan (versican), Seikagaku). In short, sections were deparaffinized 
and after antigen retrieval, incubated with the primary antibodies. These antibodies 
were detected with Envision ™ Detection Kit (DAKO) except for collagen 3, which was 
detected using peroxidase labelled rabbit anti-goat and goat anti-rabbit conjugates 
(both DAKO). 3.3'-Diaminobenzidine tetrachloride (DAKO) was used as chromogen. 
QUANTIFICATION OF THE HISTOLOGICAL STAININGS 
Quantification of inflammatory cells was performed using computerized-assisted image 
analysis at a magnification of 200x (Qwin, Leica Microsystems Imaging Solutions, 
Cambridge, UK). A blinded investigator counted the number of positively stained 
inflammatory cells in the submucosal area. This submucosal area was restricted to 
l00µm under the basement membrane (BM) and a total area of 0.1mm2. For each 
subject three sections of one biopsy sample were counted and average numbers were 
used for further analysis. 
The number of goblet cells was counted on PAS-stained biopsy sections and expressed 
per mm of BM. Epithelial integrity was determined using HE-stained biopsy sections and 
was expressed as the percentage of BM that was covered with either intact epithelium 
(a layer of basal and ciliated columnar epithelial cells without detachment from the 
BM), only basal epithelial cells, metaplastic epithelium (multilayered epithelium 
covered by a flattened layer of squamous epithelial cells and absence of ciliated cells) 
or the percentage of BM that was denuded from epithelial cells. BM thickness was 
determined by the measurement of the total BM length and surface on HE-stained 
biopsy sections. Subsequently, the mean thickness could be calculated by dividing the 
BM surface area by its length. 
Expression of ECM components was measured by computerized-assisted image 
analysis in the submucosal area 200 µm under the BM, and was expressed as the 
percentage of positive tissue per biopsy section .  For each subject two different biopsy 
sections were quantified and average percentages were used for further analysis. 
STATISTICS 
All analyses were performed using SPSS (version 14.0; SPSS Inc, Chicago, IL, USA). 
Normality of distributions was assessed using the Kolmogorov-Smirnov test. When 
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necessary, normal ization by transformation was attempted . Norma l ly distributed data 
was analysed with one-way ANOVA and independent samples t-tests . Non-normal ly 
distributed data was ana lysed with Kruska l-Wal l is and Mann-Whitney U tests . Chi­
square tests were used to compare groups for d ichotomous variables. Correlations 
were evaluated by Pearson (for normal ly d istributed data) or Spearman (for non­
norma l ly distributed data) tests. Two tai led p-va l ues of <0 . 05 were considered 
statistica l ly s ignificant. 
RESULTS 
SUBJECT CHARACTERISTICS 
Forty-seven subjects were incl uded : 10 subjects with complete asthma remission, 20 
asthma patients with a s low FEV1 decl ine over at least 5 years ( <30 ml/year) a nd 17 
with a fast FEVl decl ine over at least 5 years ( >30 ml/year) . As expected, FEVl was 
lowest in asthmatics with a fast FEV1 decl ine, intermediate with a slow decl i ne and 
highest in  asthma remission ;  reversibi l ity was not significantly different between the 
three groups. Asthma patients with a fast FEV1 decl ine had sign ificantly higher blood 
eosinophi l counts than those with a slow FEV1 decl ine (Table 1 ) .  
TABLE 1 :  PATIENT CHARACTERISTICS 
Remission Slow FEY 1 Decline Fast FEY 1 Decline 
(n=lO) (n=20) (n=l7) 
Sex (M/F) 3/7 1 1 /9 1 2/5 
Age (yr) 53 (32-67) 48 (35-70) 53 (38-64) 
FEY 1 decline (ml/year) 8.0 (-35-35) 1 8.6 (-27-29) 50.3 (34- 1 o5t·$ 
Interval between FEY 1 8.7 (6- 1 4) 8.9 (5- 1 3) 9.3 (5- 1 3) 
measurements (years) 
FEY 1 (% predicted) 1 1 1  ( 1 02- 1 46) 1 00 (78- 1 3 1 )* 98 (77- 1 27/ 
FEY1NC (%) 79 (67-93) 75 (65-9 1 )  7 3  (56-84/ 
MEFso (% predicted) 1 05 (60- 1 47) 69 (46- 1 47)* 68 (36-98/ 
Reversibility FEY1 (%) 3 .9 (0.4- 1 1 .5) 8 (-0.4-28.7) 8.3 (-8.4- 1 7.2) 
PC20AMP (mg/ml) >320 >320 (0.02->320)* 46.2 (0.02->320/ 
KCO (% predicted) 95 (84- 1 3 1 )  9 9  (78- 1 27) 1 1 0 (82- 1 4 1 )  
lgE (IU/L) 60 (7-23 1 )  6 6  ( 1 4-552) 70 ( 1 1 -558) 
Positive Phadiatop (n (%)) 5 (50%) 13 (65%) 13 (76%) 
Phadiatop score (ratio) 0.96 (0.33-54) 9 . 1 (0.22-92) 1 5  (0.06-92) 
Blood eosinophils (x 1 09/L) 0. 1 2  (0.06-0.24) 0. 1 2  (0.02-0.3 5) 0. 1 9  (0.07-0.5 1 l  
Values are presented as median values (ranges), unless stated otherwise. All spirometric data were determined 
after inhalation of 800 µg of Albuterol; reversibil ity FEV 1 - change in FEV 1 , expressed as increase in percentage 
predicted value after 800 µg of Albuterol; PC20 AMP = provocative concentration of adenosine S 'monophoshate 
causing a 20% fall in FEV 1 ; Positive Phadiatop = specific IgE's in patient serum/control serum > l ;  n = number. 
* p<0.05 remission vs. slow FEV 1 decline 
N p<0.05 remission vs. fast FEV 1 decline 5 p<0.05 slow vs. fast FEV 1 decline. 
74 
AIRWAY EosINOPHILIA IN REMISSION AND PROGRESSION OF ASTHMA: ACCUMULATION WITH A FAST DECLINE OF FEV1 
INFLAM MATORY CELLS AND IN FLAM MATORY MEDIATORS IN SPUTUM 
The absolute number of sputum eosinophils was higher in patients with a fast FEVl 
decline than with a slow FEVl decline (Table 2, Figure lA). Annual FEVl decline 
correlated significantly with the absolute number of sputum eosinophils (Figure 
1B). Sputum neutrophils, macrophages and lymphocytes did not significantly differ 
between the three study groups (Table 2). 
The levels of inflammatory mediators in the supernatant of induced sputum, i.e. 
histamine, adenosine and mucin were similar for subjects with asthma remission and 
asthma patients with a slow or a fast FEVl decline (Table 2). Moreover, the levels of 
inflammatory cytokines and growth factors (IFN-y, IL-4, 5, 8, 13, 17, EGF, Eotaxin, 
FGFb, GM-CSF, MCPl, RANTES, VEGF) were similar for all groups (See additional 
file 1). Sputum ECP values were highest in asthma patients with a fast FEVl decline 
(59. 8  (12-2467) µg/I), values being significantly higher than in subjects with asthma 
remission (16.0 (3-172) µg/I) and slightly, but not significantly, higher than in asthma 
patients with a slow FEVl decline (27.0  (6-447) µg/I, p=0.056) (Table 2, Figure lC). 
Moreover, a higher annual FEVl decline correlated significantly with higher sputum 
ECP levels (Figure 10). 
TABLE 2: INFLAMMATORY CELLS AND MEDIATORS IN SPUTUM 
Remission Slow FEV1 Decline Fast FEV I Decline 
(n=lO) (n=20) (n=l7) 
No sputum 2 (20%) 3 ( 1 5%) 3 ( 1 8%) 
Sputum not evaluable 
>80% squamous n (%) I ( 1 0%) 2 ( 1 0%) 3 ( 1 8%) 
<600 cells n (%) 2 ( 1 1 %) 
Total cells (x 1 06/ml) 0.46 (0.06-2.90) 0.3 1 (0. 1 2-2.27) 0.4 1 (0.03-2.05) 
Neutrophils (%) 62 ( 1 9-78) 60 (20-94) 55 (35-85) 
(x I 06/ml) 0.40 (0.03- 1 . 1 9) 0.2 1 (0.03- 1 .58) 0.28 (0. 1 1 - 1 .44) 
Macrophages (%) 36 (20-78) 32 (5-76) 33 ( 1 3-62) 
(x I 06/ml) 0. 1 6  (0.02-2 . 14) 0. 1 0  (0.0 1 - 1 .07) 0. 1 8  (0.08-0.6 1 )  
Eosinophils (%) 0.2 (0-4.6) 0.2 (0-4.8) 1 .8 (0-26.0) 
(x 1 06/ml) 0.002 (0-0.03) 0.00 1 (0-0.02) 0.0 I (0-0.34)* 
Lymphocytes (%) 2.2 ( 1 .4-7.3) 2.6 (0.2-6.9) 1 .3 (0-5.6) (x 1 06/ml) 0.02 (0.001 -0.04) 0.0 I (0.00 1 -0.07) 0.004 (0-0. 1 I )  
Histamine (ng/ml) 1 3 .4 (2.8-29.8) 9. 1 (0.2-28.8) 1 3 .8 (4.8-38.0) 
Adenosine (ng/ml) 56.5 (8.0- 1 1 0) 34.6 (6.2- 1 78) 23 .0 (0.9-20 1 )  
ECP (µg/1) 1 6.0 (2.5- 1 72) 27.0 (6.0-447) 59.8 ( 1 1 .9-2467)*'# 
Mucin (units) 0.25 (0.04-3.9) 0.78 (0.08- 1 0.3) 1 .0 (0. 1 8-2.7) 
Values are presented as median values (percentages or ranges). Eosinophils: * p<0.05 vs. slow FEV 1 decline. 
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Figure 1 
Eosinophilic inflammation in sputum. (A) Absolute number of sputum eosinophils (log transformed) in subjects 
with asthma remission and asthmatic subjects with a slow or a fast FEVl decline. (B) Correlation between the 
annual FEVl decline and the absolute number of sputum eosinophils (log transformed). (CJ Sputum ECP (log 
transformed) in subjects with asthma remission and asthmatic subjects with a slow or a fast FEVl decline. (DJ 
Correlation between the annual FEVl decline and sputum ECP (log transformed). Each closed circle represents one 
subject. Horizontal bars represent median values. 
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I N FLAM MATORY C ELLS IN B RO NC HIAL BIOPSIES 
No significant differences were observed in  numbers of eosinophils, mast cells, 
macrophages, neutrophils and T lymphocytes in bronchial biopsies of subjects with 
asthma remission, asthma patients with a slow or fast FEV1 decline (Table 3, Figure 
2A-C). 
TABLE 3: INFLAMMATORY CELLS IN BRONCHIAL BIOPSIES 
Remission Slow FEV 1 Decline Fast FEV 1 Decline 
(n=9) (n=l8) (n=ll) 
EPX+ eosinophils 4 (0- 1 0) 3 (0- 1 8) 3 (0-40) 
AA 1 + mast cells 5 ( 1 -20) 3 (0- 1 3) 7 ( 1 - 1 9) 
CD68+ macrophages 1 7  ( 1 2-86) 16 (4-37) 17 (3-30) 
NP57+ neutrophils 9 (2-30) 9 ( 1 -46) 9 (2-38) 
CD3+ lymphocytes 75 (35-29 1 )  7 7  (2 1 - 1 77) 62 (33-246) 
CD4+ lymphocytes 1 9  (9- 1 68) 21 (2-67) 24 (9-65) 
CD8+ lymphocytes 28 (7- 1 1 2) 2 1  ( 1 - 1 1 2) 1 7  (3- 1 03) 
Number of cells expressed per 0. 1 mm2. Values are presented as median values (ranges). No significant 
differences between the 3 groups. 
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AIRWAY REMODELING DETERMINED IN BRONCHIAL BIOPSIES 
No differences were observed in remodeling parameters in bronchial epithelium 
(goblet cells and epithelial integrity), BM (thickness) and submucosal tissue (presence 
of ECM components) between subjects with asthma remission and asthma patients 
with a slow or fast FEVl decline (Table 4). 
BM thickness correlated significantly with all investigated parameters in sputum and 
bronchial biopsies that are associated with eosinophilic inflammation, i.e. sputum 
eosinophils ( Figure 3A), sputum ECP ( Fig ure 3 B) and EPX+ cells in biopsies ( Figure 
3C). T he correlation scatters showed two outliers for BM thickness ( Figure 3). However, 
without these two subjects, significant correlations were still present between BM 
thickness and all investigated eosinophil markers (not shown). 
TABLE 4: REMODELING IN BRONCHIAL BIOPSIES 
Remission 




Epithelium Goblet cells (N) 28 (0-42) 36 (7-78) 22 (4-220) 
Intact epithelium (%) 6.8 (0-32) 6.8 (0-30) 6.7 (0-34) 
Basal epithelium (%) 63 (30-82) 59 (2 1 - 1 00) 50 ( 1 3-86) 
Denuded BM (%) 22 (0-48) 8 (0-52) 13 (0-59) 
Metaplasia (%) 0 (0-2 1)  0 (0-26) 0 (0- 1 9) 
Basement BM thickness (µm) 6.3 (4.9-8.4) 6.6 (3 .8-8 .6) 7 (4.4- 1 2.6) 
Membrane 
Submucosa Versican (%) 45 (20-67) 38 ( 1 9-70) 44 (29-69) 
Collagen 3 (%) 39 ( 1 5-48) 36 (1 7-63) 40 (9-65) 
Decorin (%) 43 ( 1 6-76) 36 (1 5-85) 44 (27-55) 
Values are presented as median values (ranges). Intact and basal epithelium, denuded basement 
membrane (BM) and metaplasia are presented as the percentage of BM covered with this type of 
epithelium. Versican, collagen 3 and decorin are presented as the percentage of positive tissue. No 
significant differences between the 3 groups. 
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Eosinophilic inflammation and basement membrane thickness. (A) Correlation between basement membrane (BM) 
thickness and the absolute number of sputum eosinophils (log transformed). (B) Correlation between BM thick­
ness and sputum ECP (log transformed). (C) Correlation between BM thickness and the number of EPX+ cells in 




T he present study describes the pathological background of asthma remission and 
progression in a well-characterized group of asthma patients. We investigated patients 
with complete asthma remission, i .e .  individuals with established asthma in the past 
who at the present time of investigation lacked asthma symptoms, airway obstruction 
and bronchial hyperresponsiveness ( BH R) while not using any asthma treatment. 
T his remission was associated with a similar extent of inflammation and remodeling 
as present in individuals with current asthma and an FEVl decline in the range of the 
normal population. In contrast, patients with current asthma and a fast FEVl decline 
had more pronounced eosinophilic inflammation in blood and sputum . In line with 
this observation, the annual FEVl decline correlated significantly with eosinophilia in 
sputum. Basement membrane ( BM) thickness, which is considered as an important 
hallmark of airway remodeling, was positively correlated with eosinophilic inflam mation 
in both sputum and the airway wall .  
An important finding of our study is that these patients with complete asthma remission 
have signs of airway wall inflam mation and remodeling . To our surprise, the extent 
of airway inflammation and remodeling is compatible with that of asthma patients 
with a slow FEVl decline. The question remains how to explain the similar findings in 
these two different groups of asthma patients. One possible explanation is that the 
clinical disease activity is not determined by the number but rather the activation 
state of inflammatory cells, and that complete asthma remission does not excludes 
the presence of quiescent inflammatory cells. However, our data shows that sputum 
levels of inflam matory cytokines and growth factors were similar in subjects with 
remission and current asthma, suggesting that the activation status and functionality 
of the inflammatory cells is not different .  Another explanation may be that clinical 
disease activity is determined by inflammation and/or remodeling in other regions of 
the lung not accessible by induced sputum or bronchial biopsies. T he type of clinical 
expression may for example be caused by the volume of smooth muscle in more distal 
parts of the central or peripheral airways, or the presence or absence of activated 
mast cells between smooth muscle bundles. 
Our findings extend observations in other studies since ongoing airway inflammation 
and remodeling were also reported in subjects with less strict criteria for asthma 
remission (5;22), i .e .  with BHR still present. It is still possible that these types of 
asthma patients need anti-inflammatory treatment. T his is an intriguing yet unresolved 
question since no study has prospectively followed these patients to older age.  
Our second interesting observation is that an accelerated FEVl decline is associated 
with increased sputum eosinophil numbers and ECP concentrations. This finding 
extends results of several cross-sectional studies demonstrating the relationship 
between eosinophilic inflammation and airway obstruction in asthma (23;24) and 
a longitudinal study showing a positive association between blood eosinophils and 
FEVl decline in asthma ( 17) . However, FEVl decline in our asthma patients was 
not associated with the number of airway wall eosinophils, just as van Rensen et al . 
(25) found . There are two possible explanations for this discrepancy. First, bronchial 
biopsies give only a snap-shot of the cellular composition of the airway wall which is 
not identical to the traffic of inflammatory cells through the airway wall. Second, an 
accelerated FEVl decline may be associated with increased recruitment of eosinophils 
from the bone marrow to the blood . Possibly, these eosinophils move straight from 
the blood to the luminal space of the lung and are not retained in the airway wall e .g .  
due to  epithelial damage. 
Although not demonstrated by our study, it can be anticipated that additional aspects 
of inflammation, besides eosinophils, contribute to the FEVl decline in asthma as well. 
Previous studies already have shown an association between lower FEVl levels and 
neutrophilic inflam mation in sputum (26) and between accelerated FEVl decline and 
CDS-positive T-cells in bronchial biopsies (25). However, these studies did, in contrast 
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to the "clean population" in our study, include asthma patients who smoked and/or 
used ICS, and it is known that smoking and ICS use change the inflammatory profile 
(19;27). 
Our study did not find significant associations between FEV1 decline and different 
remodeling parameters like mucus secretion in sputum and goblet cells in bronchial 
epithelium. Lange et al . reported an association between self-reported mucus production 
and FEV1 decline (2) .  The fact that the latter study was a large epidemiological study 
over many years including a heterogeneous group of smoking and non-smoking 
asthmatics may explain the difference with our study. 
Thickening of the subepithelial BM as a result of ECM deposition is one of the hallmarks 
of airway remodeling (28) and was previously shown to be negatively correlated with 
the level of FEV1 in asthma (29). We did not observe an association between BM 
thickness and the annual FEV1 decline, which i s  in  line with observations by  van 
Rensen et al (25) .  It has to be realized that BM thickening in asthma is considered to 
constitute an early airway wall change, already observed in childhood asthma ( 30).  
This may possibly explain why we did not observe an association with FEV1 decline 
over the last years. 
Importantly, BM thickness correlated significantly with sputum eosinophils, ECP 
concentrations in sputum and eosinophils in bronchial biopsies, but not with FEV1. 
Indeed airway eosinophils have been shown to produce TGF-13 ( 31) whereas ECP 
stimulates secretion ofT GF-13 by human lung fibroblasts ( 32). T GF-13 is a well-established 
inducer of ECM production by stimulating the proliferation and differentiation of ECM 
producing cells, i .e. (myo)fibroblasts ( 33). This can lead to excessive ECM deposition 
at the lamina reticularis and thus thickening of the airway subepithelial BM. So far it 
is unclear whether thickening of the BM is an epiphenomenon or really contributes to 
the accelerated FEV1 decline. 
We realize that our study has both strengths and weaknesses. A strength is that 
we defined asthma remission by the additional criterion of the absence of B H R  for 
both AMP and histamine. Thus our definition of asthma remission is more strict than 
the classical description of asthma remission (5;22), and it is better distinguishable 
from current asthma. Another strength is that we carefully excluded subjects with 
a history of smoking and use of (oral or) inhaled corticosteroids since ICS are 
known to reduce (27) and smoking to accelerate FEV1 decline in asthma (19). The 
consequence of this exclusion may be that we included less severe asthma patients, 
thereby underestimating the differences in inflammation and remodeling. However, 
the obvious advantage of this exclusion is that our population enabled us to study 
the natural course of cl inical asthma without these important confounding factors. 
A relative weakness of our study is that, although we studied FEV1 longitudinally in 
our patients, we only sampled sputum and bronchial biopsies at the end of follow­
up. Therefore, we can not exclude the possibility that eosinophilic inflammation in 
sputum is not the cause but rather the consequence of accelerated FEV1 decline. 
Second, it can be argued that for an accurate estimation of longitudinal decline in lung 
function, two measurements, with an average interval of 8.9 years, are not sufficient 
( 34). However, we would like to emphasize that the two spirometric measurements 
in our study were performed according to a standardized protocol using the same 
equipment. 
The present study is of clinical relevance since it suggests the need for specific 
adaptations in therapy in subsets of asthma patients. First, we showed that subjects 
with complete asthma remission have airway inflammation. This observation does 
not support but also not refutes the recommendation to stop the use of ICS in these 
subjects. Long-term studies may g ive a definite answer on the question whether 
airway inflammation ultimately disappears completely. Second, we showed that 
asthma patients with a fast FEV1 decline are characterized by increased eosinophilic 
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inflammation in blood and sputum. Therefore, intensive ICS treatment, known to 
reduce the accelerated FEV1 decline (27), might be especially beneficial for asthmatics 
with increased eosinophilic inflammation. 
In conclusion, complete clinical and functional asthma remission is accompanied by 
airway inflammation and remodeling. This indicates that there is no strong relationship 
between airway inflammation and BHR and, more importantly, that asthma remission 
never is really "complete". Furthermore, eosinophilic inflammation may be important 
in a subset of asthma patients as eosinophils are associated with accelerated FEV1 
decline and increased BM thickness. 
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LEVELS OF INFLAMMATORY CYTOKINES AND GROWTH FACTORS IN 
SPUTUM SUPERNATANT 
Remission Slow FEY1 Decline Fast FEY 1 Decline 
(n=7) (n=lS) (n=9) 
IFN-y (pg/ml) 1 1 .4 1 1 .4 1 3.2 
(0- 1 3 .2) (0- 1 5.9) (0-34. 1 )  
IL-4 (pg/ml) 25.9 25.9 23.0 
(0-4 1 .4) (0-72.3) (0-40.4) 
IL-5 (pg/ml) 4.0 4.0 5.0 
(0-6.3) (0-20.9) (0-7.7) 
IL-8 (pg/ml) 868.3 486.4 2384.5 
(78.0-3608) (I 1 5-5 5 1 67) ( 1 87-23666) 
IL- 1 3  (pg/ml) 0 0 0 
(0-122) (0-206) (0-65. 1 )  
IL- 17  (pg/ml) 0 0 0 
(0-65.9) (0-106) (0-94.0) 
EGF (pg/ml) 46.3 64.0 92.6 
( 1 2.2- 1 30) ( 1 5.2-1 32) (2 1 .9- 149) 
Eotaxin (pg/ml) 0.3 2 . 1  0 
(0-3.3) (0- 1 5.0) (0- 1 .9) 
FGFb (pg/ml) 0 0 0 
(0- 1 3.3) (0-7. 1 )  (0-4.9) 
GM-CSF (pg/ml) 94.3 94.3 94.3 
(0-1 04) (0- 1 52) (0-98.5) 
MCP- 1 (pg/ml) 3 1 9  347 391 
(0-375) (50.9-8620) ( 1 95-922) 
RANTES (pg/ml) 7.9 9.5 4.2 
(0- 1 3 . 1 )  (0-2 1 .0) (0- 1 6.9) 
VEGF (pg/ml) J O I  1 04 1 3 1  
(46.0- 1 56) (53.0-252) (5 1 .8-249) 
Values are presented as median values (ranges). No significant differences between the groups. 
A human custom multiplex antibody bead kit (Biosource, Invitrogen Ltd, Paisley, U K) 
was used to measure IFN-y, IL-4, 5, 8, 13, 17, EGF, Eotaxin, FGFb, G M-CSF, MCP1, 
RANT ES, VEGF by Luminex, according to the manufacturers' instructions. Data was 
analysed using Starstation software. For each cytokine or growth factor undetectable 
values, those below the detection limit, were set at 0 (detection limits : IFN-y :  5, IL-4: 
5, IL-5: 3, IL-8: 3, IL-13: 10, IL-17: 10, EGF: 25, Eotaxin : 5, FGFb : 20, G M-CSF: 15, 
MCP1 : 10, RANTES : 15, VEGF: 15 pg/ml). 
We detected no significant differences in the level of the inflammatory cytokines and 
growth factors IFN-y, IL-4, 5, 8, 13, 17, EGF, Eotaxin, FGFb, GM-CSF, MCP1, RANTES 
and VEGF between subjects with asthma remission and asthma patients with a slow 
or a fast FEV1 decline. 
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Rationale: Smoking has detrimental effects on asthma outcome, such as increased 
cough,  wheezing, sputum production, and frequency of asthma attacks. T his results in 
accelerated lung function decline. T he underlying pathological process of smoke-induced 
deterioration of asthma is unknown. 
Objectives: To compare bronchial inflammation and remodeling in never-smokers, ex­
smokers, and current smokers with asthma. 
Methods: A total of 147 patients with asthma (66 never-smokers, 46 ex-smokers, and 
35 current smokers) were investigated. 
Measurements and Main Results: Lung function, exhaled nitric oxide levels, and 
symptom questionnaires were assessed, and induced sputum and bronchial biopsies 
were obtained for determination of airway inflammation and remodeling. Smokers with 
asthma had lower FEV1 and alveolar and bronchial nitric oxide levels than never-smokers. 
Smokers also had more goblet cells and mucus-positive epithelium, increased epithelial 
thickness, and a higher proliferation rate of intact and basal epithelium than ex-smokers 
and never-smokers. Smokers had hig her numbers of mast cells and lower numbers 
of eosinophils than never-smokers. Ex-smokers had similar goblet cell numbers and 
mucus-positive epithelium, epithelial thickness, epithelial proliferation rate, and mast cell 
numbers as never-smokers. 
Conclusions: Smokers with asthma have epithelial changes that are associated with 
increased asthma symptoms, such as shortness of breath and phlegm production. T he 
fact that epithelial characteristics in ex-smokers are similar to those in never-smokers 
suggests that the smoke-induced changes can be reversed by smoking cessation. 
AT A GLANCE COMMENTARY 
SCIENTIFIC KNOWLEDGE ON THE SUBJECT 
Smoking has detrimental effects on asthma outcome, such as increased cough,  
wheezing, sputum production, and frequency of  asthma attacks. T his ultimately results in 
accelerated lung function decline. T he underlying pathological process of smoke-induced 
deterioration of asthma is unknown. 
WHAT THIS STUDY ADDS TO THE FIELD 
T his study shows that smoking in asthma induces epithelial changes, thereby possibly 
increasing asthma symptoms such as shortness of breath and phlegm production. T he fact 
that epithelial characteristics were similar in ex-smokers and never-smokers with asthma 
suggests that the smoke-induced changes can be reversed by smoking cessation. 
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INTRODUCTION 
Asthma is a chronic inflammatory disorder of the airways characterized by variable airway 
obstruction and hyperresponsiveness. T he clinical outcome of asthma is negatively 
affected by cigarette smoking, yet smoking is equally common in patients with asthma 
and the general population. Smokers with asthma have more severe asthma symptoms 
than nonsmokers with asthma (1), a higher frequency of asthma attacks (2), and 
accelerated lung function decline ( 3) .  T he underlying pathological processes of smoke­
induced deterioration of asthma are largely unknown. 
Cigarette smoking has negative effects on the lung in subjects without asthma, associated 
with increased airway inflammation (e .g . ,  increased neutrophil, macrophage, and CD8+ 
lymphocyte numbers in bronchoalveolar lavage fluid) (4-7) and increased inflammatory 
cell numbers in the bronchial wall, such as neutrophils, eosinophils, macrophages, and 
mast cells (5, 6, 8) . Moreover, cigarette smoking has been associated with features of 
increased remodeling in subjects without asthma, such as increased tenascin and laminin 
deposition under the basement membrane (8). 
Because smokers are often excluded in asthma studies to prevent coexistence of chronic 
obstructive pulmonary disease (COPD), only a few studies have been performed to 
investigate the effects of smoking on inflammation in asthma. T hese few studies were 
of small size and showed that cigarette smoking has an impact on asthmatic airway 
inflammation by increasing white blood cell numbers, sputum neutrophils (9, 10), and IL-
8 levels (10) and by increasing the presence of bronchial metaplasia, neutrophil elastase 
and IFN- , and intraepithelial IL-8 (11) in the airway wall. 
In the present study, we investigated the underlying pathological process of smoke­
induced deterioration of asthma in a large asthma population. We hypothesized that 
smoking affects the outcome of asthma by increased bronchial inflammation and 
remodeling . To test this hypothesis, we included 147 patients with asthma (66 never­
smokers, 46 ex-smokers, and 35 current smokers). Airway inflammation and remodeling 
were investigated in sputum samples and bronchial biopsies. 
Some of the results of these studies have been previously reported in the form of an 
abstract (12) . 
METHODS 
SUBJECTS 
Smokers and nonsmokers with asthma (n = 147) were recruited (Table 1) . All patients 
originated from cohorts investigated earlier by our research group, and all had a doctor's 
diagnosis of asthma and documented reversibility and bronchial hyperresponsiveness 
(BHR) to histamine in the past. Subjects were reexamined by lung function, BHR 
to  histamine and/or adenosine 5'-monophosphate (AMP), sputum induction, and 
bronchoscopy with bronchial biopsies. T hree groups were identified: (1) never-smokers 
(lifelong never-smokers; n = 66), (2) ex-smokers ( had to have stopped smoking for at 
least 1 year and smoked at least 20 packs of cigarettes or 12 oz ( 360 g) of tobacco in a 
lifetime or at least one cigarette per day for 1 year or at least one cigar per week for 1 
year [13] ; n = 46), and ( 3) smokers (currently smoking ; n = 35). Main exclusion criteria 
were FEVl <1 .2  L, bronchiectases, upper respiratory tract infection (e.g., colds), and/or 
use of antibiotics or oral corticosteroids within the last 2 months. T he study protocol was 
approved by the local medical ethics committee. All subjects gave their written informed 
consent. 
STUDY DESIGN 
One or two weeks after blood eosinophil count, sputum induction and lung function 
assessments an AMP provocation test was performed, followed 1 to 2 weeks later 
by bronchoscopy. Subjects with a negative AMP provocation test (i.e., those with a 
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provocative concentration of AMP resulting in a 20% decline in FEVl,  AMP PC20 >320 
mg/ml) underwent a histamine provocation test more than 3 weeks later to determine 
BHR. 
QUESTIONNAIRES 
To determine cigarette smoke-induced symptoms, all patients were asked to fill out 
the clinical COPD questionnaire (CCQ) (14). Shortness of breath was determined by 
question 2: "On average, during the past week, how often did you feel short of breath 
doing physical activities?" (0 = never, 6 = almost all the time.) Sputum or phlegm 
production was determined by question 6: "In general, during the past week, how 
much of the time : did you produce phlegm?" ( 0  = never, 6 = almost all the time.)  
LUNG FUNCTION 
Lung function tests were performed with a daily calibrated spirometer according 
to standardized guidelines as described previously (15). FEV1 was measured with 
a calibrated water-sealed spirometer according to standardized guidelines (15, 16). 
Reversibility of FEVl (% predicted) was measured after administration of 400 µg 
albuterol. Provocation tests were performed with a method adapted from Cockcroft 
and coworkers (17). After an initial nebulized 0.9% saline challenge, subjects inhaled 
doubling concentrations of AMP (0.04-320 mg/ml) by 2-minute tidal breathing at 5-
minute intervals. BHR to histamine was tested as reported previously (18) using 30-
second tidal breathing and doubling concentrations ranging from 0.13 to 32 mg/ml. 
ALVEOLAR AND B RONCHIAL N ITRIC OXIDE 
Exhaled nitric oxide ( NO) was measured on the Aerocrine NO system ( Niox; Aerocrine 
AB, Stockholm,  Sweden) in accordance with international guidelines (19). Alveolar 
NO concentrations (ppb) and bronchial NO fluxes (nl/s) were assessed according to 
Tsoukias and George (20) with some modifications (21). 
ATOPY M EASUREMENTS 
Atopy was determined by the Phadiatop screening test with the ImmunoCap system 
( Phadia AB, Uppsala, Sweden), and results are presented as quotients (fluorescence 
of the serum of interest divided by the fluorescence of a control serum) .  Positive 
Phadiatop was defined as serum/control serum greater than 1. 
SPUTUM INDUCTION AND PROCESSING 
Sputum was induced by inhalation of 5% hypertonic saline aerosols over three 
consecutive periods of 5 minutes. Processed whole sputum samples were stained 
with May Grunwald Giemsa to obtain cell differentials by counting total 600 viable, 
nonsquamous cells. Sputum was not used if the percentage of squamous cells was 
greater than 80% or if the total number of nonsquamous cells was less than 600. 
Sputum Supernatant Measurements 
Histamine ( IBL, Hamburg, Germany) and neutrophil elastase ( Hycult, Uden, The 
Netherlands) were determined by ELISA. Eosinophilic cationic protein was measured 
using a fluoroenzyme immunoassay ( lmmunoCAP ECP; Phadia AB). 
COLLECTION, PROCESSING, IMMUNOHISTOCHEMICAL STAINING, AND CELLULAR 
QUANTIFICATION OF BRONCHIAL BIOPSIES 
After local anesthesia, bronchial biopsies were obtained using a flexible bronchoscope 
(type Olympus BF P20 or BF XT 20; Olympus, Center Valley, PA) from segmental 
divisions of the main bronchi. The biopsies were fixed in 4% formaldehyde solution, 
processed, and embedded in paraffin. Bronchial biopsies were cut into 3-µ m-thick 
sections. 
All histochemical stainings (periodic acid-shift [PAS] and H&E) were performed in 1 
day using staining machines at the Pathology department. All immunohistochemical 
stainings (except for Ki67 and E-cadherin) were performed in an automated system 
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using the DAKO autostainer in three consecutive runs per cell marker. The slides were 
included in random fashion in each run to avoid groupwise staining. The inflammatory 
profile was assessed with specific antibodies against eosinophilic peroxidase (EPX) 
(laboratories of NA Lee and JJ Lee, Mayo Clinic, Scottsdale, AZ), mast cell tryptase 
(AAl ; DAKO, Glostrup, Denmark), macrophages (CD68; DAKO), neutrophil elastase 
( N P57; DAKO), and T lymphocytes (CD3; DAKO). Sections were deparaffinized and, 
after antigen retrieval, incubated with the primary antibodies. T hese antibodies were 
detected with Envision Detection Kit ( DAKO) followed by the chromogen N ovaRED 
(Vector Labs, Burlingame, CA). EPX was detected using biotinylated antimouse IgGl 
(Southern Biotech, Birmingham, AL) and alkaline phosphatase-labeled conjugate 
( DAKO) followed by permanent Red ( DAKO). Sections were manually counterstained 
with methylgreen. Epithelial proliferation was assessed by Ki67 expression, epithelial 
adhesion by E-cadherin expression, and submucosal deposition of extracellular matrix 
by collagen 3 expression. Sections were deparaffinized and, after antigen retrieval, 
incubated with antibodies against Ki67 ( DAKO), E-cadherin ( BD Biosciences, Breda, 
the Netherlands), and collagen 3 (Southern Biotech). These antibodies were detected 
with two peroxidase-labeled conjugates (both DAKO). 3,3'-Diaminobenzidine 
tetrahydrochloride (Sigma-Aldrich, Zwijndrecht, the Netherlands) was used as 
chromogen, and hematoxylin ( Ki67 and E-cadherin) or methylgreen (collagen 3) were 
used for counterstaining. 
All stainings were quantified by a blinded observer using computer-assisted image 
analysis at a magnification of 200x (Qwin; Leica Microsystems Imaging Solutions, 
Cambridge, UK). T he largest of three biopsy sections was chosen for quantification. 
The number of positively stained inflammatory cells was counted in the submucosal 
area 100 µm under the basement membrane ( BM) in a total area of 0.1 mm2 per 
biopsy sample.  T he number of goblet cells was counted on PAS-stained biopsy sections 
and expressed per mm of BM. The number of PAS-positive pixels was determined 
in the epithelium and expressed as the percentage of mucus-positive epithelium 
per biopsy section. Epithelial integrity was determined using H&E-stained biopsy 
sections and expressed as (1) percentage of BM covered with normal epithelium (a 
layer of basal and ciliated columnar epithelial cells without detachment from the BM) 
or (2) metaplastic epithelium (multilayered epithelium covered by a flattened layer 
of squamous epithelial cells and absence of ciliated cells). The percentage of BM 
covered with E-cadherin-positive or E-cadherin-negative stained intact epithelium 
was determined. Epithelial thickness was determined by dividing the epithelial surface 
area by the BM length. Epithelial proliferation was determined by counting the number 
of Ki67-positive epithelial nuclei in intact and basal epithelium. Similarly to epithelial 
thickness, BM thickness was calculated by dividing the BM surface area by the BM 
length. Expression of collagen 3 was measured by computer-assisted image analysis 
in the submucosal area 200 µm under the BM and was expressed as the percentage 
of positive tissue per biopsy section. 
STATISTICS 
All analyses were performed using SPSS (version 16.0;  SPSS Inc. ,  Chicago, IL). 
Normality of distributions was assessed using the Kolmogorov-Smirnov test. If 
necessary, normalization by transformation was attempted. Normally distributed data 
were analyzed with one-way analysis of variance and independent sample t tests. 
Nonnormally distributed data were analyzed with Kruskal-Wallis and Mann-Whitney 
U tests. Chi-square tests were used to compare groups for dichotomous variables. 
Correlations were evaluated by Pearson (for normally distributed data) or Spearman 
(for nonnormally distributed data : rs) tests. Multiple linear regression analysis was 
used to assess the influence of the independent variables inhaled corticosteroid ( !CS) or 
long-acting �-agonist ( LABA) use (yes/no) and smoking (smoking vs. never-smoking, 
smoking vs. ex-smoking, ex-smoking vs. never-smoking) on our different outcome 
variables (dependent variable) (see Tables E4 and ES in the online supplement). Two­





A total of 147 patients with asthma were incl uded (66 never-smokers, 46 ex-smokers, 
and 35 current smokers) .  The n umber of pack-years was sign ifi cantly lower in ex­
smokers compared with smokers (Table 1 ) .  FEV1 %pred icted (%pred) was sign ificantly 
lower in ex-smokers and current smokers compared with never-smokers (Table 1 ) .  
A h igher FEV1 (% pred) correlated sign ificantly with a h igher number o f  pack-years 
smoking in ex-smokers and current smokers (Spearman r [rs]  = 0 .22;  P = 0 . 046) . 
!CS use and dose were s imi lar between never-smokers, ex-smokers, and current 
smokers (Table 1 ) .  The use of long-acting 13-agonists ( LABA) was sign ificantly higher 
in  ex-smokers compared with never-smokers and current smokers (Table 1 ) .  Alveolar 
and bronch ia l  NO was significantly lower in smokers than in never-smokers and ex­
smokers (Table 1 ) .  A lower a lveola r  and bronchial NO correlated with a higher number 
of pack-years in ex-smokers and current smokers (rs = -0 .38 ;  P = 0 . 004 and rs = -
0 .33 ;  P = 0 . 0 14, respectively) . A lower bronchia l NO correlated with a h igher number 
of cigarettes smoked da i ly in current smokers (rs = -0 . 58 ;  P = 0 . 002) . 
Self-reported symptoms, determined using the CCQ, were s imi lar  between the groups 
(Table El ) .  
SMOKE EXPOSURE A N D  M EDICATION Use 
Because of the difference in pack-years between ex-smokers and cu rrent smokers, 
we tested within the ex-smoking group whether the number of pack-years affected 
our outcome variables . None of our outcome variab les correlated signifi cantly with 
the number of pack-years in the ex-smoking group (Ta ble E3) .  Fu rthermore, we 
investigated the influence of !CS use and smoking on our  data . Except for basement 
membrane (BM)  thickness being lower with !CS use, none of the outcome variables 
was sign ificantly influenced by !CS use (Table E4) . The contribution of !CS use is 
visual ized by indicating which patients are !CS users (open circles) and which are non­
ICS users (sol id circles) in the g raphs in Figures 1 through 4.  !CS and non-ICS users 
were randomly d istributed . The i nfluence of LABA use and smoking on our outcome 
variables was tested, and we found  that LABA use did not s ign ificantly influence our 
data (Table ES) . 
BRONCHIAL EPITHELIAL REMODELING 
A total of 114 patients with asthma underwent bronchoscopy successfu l ly ( 49 never­
smokers, 40 ex-smokers, and 25 cu rrent smokers) . Smokers had higher numbers of 
goblet cel ls (Table 2) and a h igher percentage of mucus-positive epithe l ium (Figures 
1A and 1B;  Table 2) compared with ex-smokers and never-smokers .  They a lso had 
a thicker epithel ia l  layer (Figu res 1C and 1D; Table 2) and more prol iferation of 
intact epithe l ium (Ki67+ intact ep ithel ial cel ls ;  Figures 1E and 1F; Table 2). A s imi lar 
increase in prol iferation was observed in  the basal  epithe l ium of smokers compared 
with ex-smokers and never-smokers (Table 2 ) .  There were no s ignificant differences 
in percentages of normal epithe l ium (Table 2) and metaplasia between the three 
groups or in the percentage of E-cadherin-positive i ntact epithel ium, a marker of 
epithel ia l  integrity (data not shown) .  In ex-smokers and current smokers, prol iferation 
of intact and basa l epithel ia l  cel ls was sign ificantly h igher with an i ncreasing number 
of pack-years (rs = 0 . 28 ;  P = 0 .026 and rs = 0 . 33 ;  P = 0 . 007,  respectively) . Epithel ia l  
thickness correlated with the percentage of mucus-positive epithel ium (Figure 2A) 
and the percentage of Ki67+ intact (Figure 2B) and basal epithel ia l  cel ls ( rs = 0 .29 ;  
P = 0 .009) . There were no sign ificant correlations between lung function pa rameters 
(e .g ., FEV1) and a l l  epithel ia l  parameters . 
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Cigarettes I day (n) 
ICS use (yes/no) 
ICS dose (µg/day) 
beclomethasone equivalent 
Long-Acting Pragonist use n (%) 
Atopy n (%) 
FEV1 (L) 
FEV1 (% pred) 
FEV1NC (%) 
Reversibility (% pred) 
MEF50 (% pred) 
PC20AMP (mg/ml) 
NO alveolar (ppb) 
NO bronchial (nUs) 




47 (1 9-71 ) 
27/39 




1 04 (58-135) 
77 (55-98) 
8.8 (-1 .4-38.4) 
74 (24-1 52) 
62.5 (0-640) 
6.3 (3. 1 -51 .7) 
1 .02 (0.1 2-1 0.4) 










3.2 (1 .5-5.8) 
94 (43-123)$ 
72 (39-91l 
7 .7  (-8.4-28.4) 
65 (1 7-147)$ 
1 1 5.5 (0.08-640) 
5.6 (1 .5-14.9) 
0.93 (0.22-4 . 1 )  












3 . 1  ( 1 . 8-5. 1 )  





4.3 (2. 1 - 1 0.4)*'# 
0.38 (0.06-1 .4 )*,# 
0.23 (0-0.49) 
Values are medians (ranges). Packyears = smoking history, cigarettes per day = current smoking. ICS (inhaled 
corticosteroid) dose only in subjects using ICS and expressed as the dose of beclomethasone, all other ICS 
doses were converted to their equivalent doses of beclomethasone. Atopy was based on a positive Phadiatop 
test; specific lgE's in patient serum/control serum >1 . FEV1 = forced expiratory volume in 1 s, FEV1 was 
measured after inhalation of BOO µg Albuterol. VC= vital capacity. Reversibility FEV1 = change in FEV1 ,  
expressed as  increase in  percentage predicted normal value after 400 µg of  Albuterol; MEF50= maximum 
expiratory flow rate at 50% of vital capacity. PC20 AMP = provocative concentration of adenosine 
5'monophoshate causing a 20% fall in FEV1 n= number. 
* = smokers vs. ex-smokers p<0.05 
# = smokers vs. never-smokers p<0.05 
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Epithelial morphology. (A) Percentage of mucus-positive epithelium in asthmatic never-, ex- and current smokers. 
(BJ Pictures of PAS stained goblet cells in never- (upper picture) and current smokers (lower picture). (CJ Epithe­
lial thickness in asthmatic never-, ex- and current smokers. (DJ Pictures of epithelial thickness in never- (upper 
picture) and current smokers (lower picture). (E) Percentage of Ki67+ intact epithelial cells in asthmatic never-, 
ex- and current smokers. (F} Pictures of Ki67 expression in intact epithelium in never- (upper picture) and current 
smokers (lower picture). Lens magnification 400x. Each circle represents one subject; closed circles are non-ICS 
users and open circles are the ICS users. Horizontal bars represent median values. 
94 
AIRWAY EPITHELIAL CHANGES IN SMOKERS euT NoT IN Ex-SMOKERS WITH ASTHMA 
TABLE 2: REMODELING IN BRONCHIAL BIOPSIES 
Never-smokers Ex-smokers Smokers 
N=49 N=40 N=25 
Epithelium Goblet cells (N) 31 (4-220) 36 (2-69) 65 (21 -1 1 9)*,# 
Mucus (%) 6.2 (0.2-37.0) 9.4 (0.8-33.9) 1 6.9 (2.5-46. 1 )*'# 
Thickness (µm) 1 7.0 (7.9-91 .4) 1 7.8 (7.5-48. 1 )  24.6 (1 1 .8-64.4)*'# 
Ki67+ (%intact) 2.6 (0-24.2) 2.8 (0.2-20. 1 )  6.6 ( 1 .3-1 5.5)*'# 
Ki67+ (%basal) 2.6 (0-1 0.7) 2.7 (0-28.9) 5.6 (1 .2-25.5)*'# 
Normal epithelium (%) 7.6 (0-65.3) 9.7 (0-50.7) 9.5 (0-32.8) 
Basement Thickness (µm) 6.1 (3. 1 -1 1 .7) 5. 7 (2.8-1 2.6) 6.4 (3.7-9) Membrane 
Values are medians (ranges). Number of goblet cells is expressed per mm basement membrane. Mucus is 
expressed as the percentage of mucus-positive epithelium. Ki67 expression is presented as the percentage of 
Ki67-positive nuclei of all epithelial cell nuclei in either intact or basal epithelium. Normal epithelium is the 
percentage of the BM covered with normal epithelium. 
* = smokers vs. ex-smokers p<0.05 
# = smokers vs. never-smokers p<0.05 
s = ex-smokers vs. never-smokers p<0.05 
A B 
- 2. 0 - 2. 0 r 5
= 0.35 
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Figure 2 
Correlations with epithelial thickness. (A) Correlation between the percentage of mucus-positive epithelium (sqrt 
transformed) and epithelial thickness (log transformed) in asthmatic never, ex- and current smokers. (B) Correla­
tion between the percentage of Ki67+ intact epithelial cells and epithelial thickness (log transformed) in asthmatic 
never, ex- and current smokers. Each circle represents one subject; closed circles are non-JCS users and open 
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Figure 3 
Eosinophils and mast cells in bronchial biopsies. (A) The number of EPX+ eosinophils in 0. 1 mm2 bronchial biopsy 
tissue. (B) The number of AA1 +  mast cells in 0. 1 mm2 bronchial biopsy tissue. Representative pictures of (C) 
EPX+ eosinophils in biopsies of asthmatic never-smokers (upper picture) and current smokers (lower picture) and 
(D) AA1 + mast cells in biopsies of asthmatic never-smokers (upper picture) and current smokers (lower picture). 
Lens magnification 400x. Each circle represents one subject; closed circles are non-JCS users and open circles are 
the ICS users. Horizontal bars represent median values. 
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CORRELATIONS BETWEEN BRONCHIAL EPITHELIAL REMODELING AND SELF-REPORTED 
SYM PTOMS 
Analysis of the complete study population revealed that the severity of self-reported 
phlegm production (CCQ, question 6) correlated significantly with the number of 
goblet cells (rs = 0. 26; P = 0.034), presence of mucus-positive epithelium ( rs = 
0. 23; P = 0.045), and epithelial thickness (rs = 0. 29; P = 0.011). T he severity of self­
reported shortness of breath (CCQ, question 2) correlated significantly with epithelial 
thickness (rs = 0. 26; P = 0.018). 
OTH ER PARAMETERS OF AIRWAY REMODELING 
BM thickness (Table 2) and collagen 3 deposition (not shown) were similar between 
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Figure 4. Neutrophilic and eosinophilic inflammation in sputum. (A) The absolute number of sputum neutrophils 
(log transformed) in asthmatic never-, ex- and current smokers. (BJ Sputum concentration of neutrophil elastase 
in asthmatic never, ex- and current smokers. (C) Correlation between the absolute number of sputum neutrophils 
(log transformed) and the sputum concentration of neutrophil elastase. (D) The absolute number of sputum eosin­
ophils (log transformed) in asthmatic never-, ex- and current smokers. (E) Sputum concentration of eosinophilic 
cationic protein (ECP, log transformed) in asthmatic never-, ex- and current smokers. (F) Correlation between the 
absolute number of sputum eosinophils (log transformed) and the sputum concentration of eosinophilic cationic 
protein (ECP, log transformed). Each circle represents one subject; closed circles are non-JCS users and open 
circles are the JCS users. Horizontal bars represent median values. 
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I NFLAMMATORY CELLS IN BRONCHIAL BIOPSIES 
Smokers and ex-smokers had lower numbers of EPX+ eosinophils than never­
smokers ( Figures 3A and 3C). T he number of EPX+ eosinophils in biopsies increased 
with increasing duration of smoking cessation in ex-smokers (rs = 0 . 32; P = 0 . 044). 
Smokers had a higher number of bronchial AA1+ mast cells than ex-smokers and 
never-smokers ( Figures 3B and 3D). Bronchial EPX+ eosinophils or AA1+ mast cells 
did not significantly correlate with lung function, symptoms, or epithelial remodeling .  
T he number of airway wall neutrophils, macrophages, and CD3-positive lymphocytes 
did not differ significantly between the three groups (Table 3) . 
INFLAM MATORY CELLS AND M EDIATORS IN SPUTUM 
A total of 105 patients with asthma underwent sputum induction successfully (47 
never-smokers, 33 ex-smokers, and 25 current smokers). T h e  percentage and absolute 
number of sputum macrophages was highest in never-smokers. T he absolute number 
of sput um neutrophi ls was slightly but significantly increased in never-smokers and 
ex-smokers compared with current smokers ( Figure 4A; Table E2). Similar to the 
percentage and absolute number of neutrophils, the level of neutrophil elastase in 
sputum was highest in ex-smokers ( Figure 4B; Table E2). T he level of neutrophil 
elastase correlated significantly with the number of sputum neutrophils ( Figure 
4C). N ine patients had neutrophil elastase levels that were above the measurement 
threshold, and the level of these patients was set at a maximum value of 5. When 
these patients were excluded, a significant correlation was still present between 
neutrophil elastase and the number of sputum neutrophils. 
Sputum eosinophils did not differ significantly between the three groups ( Figure 4D; 
Table E2) . However, the level of eosinophilic cationic protein was significantly lower in 
smokers compared with ex-smokers and never-smokers ( Figure 4E) and correlated 
significantly with the number of sputum eosinophils ( Figure 4F). T he percentage and 
absolute numbers of sputum lymphocytes were lower in ex-smokers and current 
smokers compared with never-smokers. T he level of histamine in sputum supernatant 
was similar between the three groups (Table E2). 
TABLE 3: INFLAMMATORY CELLS IN BRONCHIAL BIOPSIES 
Never-smokers Ex-smokers Smokers 
Cells/0.1 mm2 N=49 N=40 N=25 
EPX+ eosinophils 3 (0-40) 1 (0-26)$ 1 (0-9)# 
AA 1 + mast cells 6 (0-1 9) 7 (0-22) 1 2  (0-26)*'# 
CD68+ macrophages 1 5  (3-36) 1 1  (0-57) 1 0  (0-37) 
NP57+ neutrophils 6 (0-46) 9 (0-34) 6 (0-20) 
CD3+ lymphocytes 77 (21 -294) 67 (4-21 9) 62 ( 1 3-2 1 6) 
Values are medians (ranges). 
* = smokers vs. ex-smokers p<0.05 
# = smokers vs. never-smokers p<0.05 
s = ex-smokers vs. never-smokers p<0.05. 
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DISCUSSION 
T his is the first study in a large population of patients with asthma to compare current, 
ex-smokers, and never-smokers. T he results show that cigarette smoking increases 
bronchial epithelial remodeling and thereby possibly asthma symptoms, such as 
shortness of breath and phlegm production. Concerning inflammation, smoking in 
asthma was characterized by lower bronchial eosinophil and hig her mast cell numbers. 
Because the smoking-related changes in epithelium and mast cell numbers were 
not observed in ex-smokers, this suggests that these smoking-related changes are 
reversible by smoking cessation. 
Smoking associated with increased epithelial cell proliferation in our asthma 
population, and this increase correlated with a higher number of pack-years. It has 
been reported that cigarette smoke induces epithelial regeneration to restore the 
bronchial epithelium after smoke-induced damage (22)  by epithelial cell migration, 
proliferation, and differentiation ( 23) . Chronic exposure to cigarette smoke can disturb 
adequate epithelial regeneration, leading to excessive epithelial proliferation ( 24, 25) 
and squamous or mucous cell metaplasia ( 22) .  T his excessive epithelial proliferation 
can lead to thickening of the epithelial layer, as we observed in our smokers with 
asthma and as was previously shown in smokers without asthma ( 26). T he epithelial 
thickening was associated with increased proliferation of intact and basal epithelial 
cells and by goblet cell hyperplasia. Goblet cell hyperplasia and increased mucus 
production may be caused directly by cigarette smoke exposure ( 27) or indirectly via 
the activation of mucin gene transcription by inflammatory cell mediators ( 22) . 
Our data suggest that the increased epithelial thickness may underlie increased 
respiratory symptoms. T his is supported by the correlation between epithelial 
thickness and self-reported shortness of breath and the correlations between epithelial 
thickness, goblet cell numbers, and mucus-positive epithelium with self-reported 
phlegm production. T herefore, it can be envisaged that cigarette smoking causes an 
increase in bronchial epithelial thickness in the asthmatic lung by epithelial hyperplasia, 
contributing to narrowing of the airway and resulting in increased shortness of 
breath and, indirectly via goblet cell hyperplasia, increased phlegm production. Over 
the longer term, this might contribute to the decreased lung function as shown by 
significantly lower FEV1 %predicted values in smokers with asthma compared with 
never-smokers. 
In asthma, exhaled NO has been put forward as a reliable indicator of disease activity 
(28). We show, in line with a previous report ( 29), that exhaled nitric oxide ( NO)  is 
lower in smokers than in nonsmokers with asthma. Moreover, in ex-smokers and 
current smokers with asthma, a lower level of alveolar and bronchial NO was associated 
with a hig her number of pack-years. Several mechanisms for a reduction in NO by 
cigarette smoke have been suggested, such as smoke-induced down-regulation of 
NO synthase by high concentrations of NO in cigarette smoke ( 30) and inactivation of 
NO by oxidants present in cigarette smoke or by smoke-induced toxic damage to N O­
producing cells (31 ). T he observed suppressive effect of cigarette smoke on exhaled 
NO negatively affects its value as a reliable marker to monitor disease activity in 
smokers with asthma. 
T he inflammatory profile appeared to be different in smokers compared with ex­
smokers and never-smokers with asthma, as shown by higher numbers of mast 
cells and lower numbers of eosinophils in the bronchial airway wall. T hus, cigarette 
smoking in asthma suppressed eosinophilic inflammation, a characteristic of asthma, 
whereas it did not change the inflammatory pattern toward a COPD-like profile, which 
characteristically would be dominated by macrophages and neutrophils in sputum 
and bronchoalveolar lavage fluid, and T lymphocytes and macrophages in bronchial 
biopsies ( 32). 
T he increase in mast cell numbers as observed in smokers with asthma was in line 
with reports showing increased mast cell numbers in lungs and skin of asymptomatic 
smokers ( 33). Mast cells are thoug ht to promote smoke-induced airway remodeling 
( 34) and mucus hypersecretion (35) and were shown in an experimental mouse model 
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to contribute to the initiation and maintenance of airway epithelial proliferation after 
chronic exposure to ozone (36). In our study, we did not find a correlation between 
mast cell numbers and epithelial changes (i.e., epithelial layer thickness, goblet cells, 
and proliferation). Therefore, our data do not support a mast cell-driven mechanism 
to explain bronchial epithelial changes and deteriorating asthma symptoms in smokers 
with asthma. 
Eosinophil numbers were higher in never-smokers than in smokers and ex-smokers in 
our study. Numbers of EPX+ eosinophils increased with increasing duration of smoking 
cessation in ex-smokers, suggesting that smoking cessation reverses the down­
regulatory effect of smoking on the number of eosinophils. These data indicate that 
smoking inhibits asthma-related eosinophilia not only acutely but also as a sustained 
effect that only gradually decreases after smoking cessation. Smoke-related decreases 
in eosinophilic inflammation in asthma have also been reported by others in blood 
(37) and sputum (10). In addition, we and others showed a down-regulatory effect 
of smoking on ovalbumin-induced airway eosinophilia in a mouse model of asthma 
(38, 39). Mechanisms involved in the reduction of eosinophilic airway inflammation 
by smoking in asthma may include reduced eosinophil recruitment from the bone 
marrow or increased apoptosis of activated eosinophils by the actions of exogenous 
NO (40) or carbon monoxide (4 1) in cigarette smoke. 
With respect to neutrophils, ex-smokers with asthma had higher neutrophil numbers 
and neutrophil elastase levels in sputum than their smoking counterparts. An increase 
in sputum neutrophil numbers has also been reported in ex-smokers with COPD ( 42) 
and is possibly caused by the reduction of antiinflammatory factors after smoking 
cessation (e.g., CO) that are present in cigarette smoke. Although neutrophil infiltration 
may contribute to goblet cell degranulation (43) and lung tissue destruction (44), we 
did not observe these changes in airways of ex-smokers with asthma. Neutrophils also 
play a role in normal tissue repair and thus in restoration of tissue homeostasis after 
taking away the smoking-induced tissue-damage effect ( 42). 
Tsoumakidou and colleagues recently found that cigarette smoking in subjects with 
asthma caused a reduction in mucosa! CD83+ mature dendritic cells and CD20+ B 
cells compared with never-smokers with asthma and healthy control subjects (45). 
With respect to our results, it can be envisaged that such a loss of dendritic cells might 
contribute to an alteration in the balance of inflammatory cell phenotypes, concurrent 
with lower bronchial eosinophil and higher mast cell numbers as was observed in 
the smokers with asthma in our study. This is compatible with the suggestion that 
a change in airway immunity may be responsible for the increases in exacerbation 
frequency and the accelerated lung function decline observed in smokers with asthma 
(46). 
We studied a population of subjects with asthma that was heterogeneous not only in 
smoking habits and history but also in medication use. Therefore, res or LABA use 
together with smoking might have influenced our results. Because medication use did 
not significantly influence our outcome variables, we can rule out the possibility that 
this caused the differences in airway remodeling and inflammation between the never­
smokers, ex-smokers, and current smokers. However, one of our outcome variables, 
BM thickness, was reduced by ICS use rather than by smoking. A thickened BM is a 
specific characteristic of airway remodeling in asthma, and, although still controversial, 
ICS treatment has been shown in several studies to reduce BM thickness ( 47-50), 
which is supported by our data. 
The inclusion of ex-smokers with asthma in our study enabled us to investigate the 
possible reversibility of smoke-related changes upon smoking cessation. Our ex­
smoking group had a significantly lower number of pack-years compared with the 
smoking group, suggesting that differences between these two groups might be due 
to lower cumulative smoke exposure in ex-smokers. This was not the case because the 
number of pack-years was not significantly correlated to any of our outcome variables in 
the ex-smoking group. It is possible that current rather than past exposure to cigarette 
smoke is important for the bronchial changes we observed. With respect to bronchial 
remodeling and inflammation, ex-smokers with asthma differed from smokers with 
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asthma with significantly less epithelial layer thickness, mucus-producing epithelium, 
epithelial cell proliferation, a nd airway wall mast cell numbers. Although epithelial 
changes were associated with higher self-reported asthma symptoms in smokers, 
lung function and self-reported asthma symptoms were not significantly different 
between ex-smokers and current smokers. This indicates that epithelial thickness 
does not solely cause the symptomatology a nd severity of airway obstruction in  
smokers with asthma but may be an  important contributor. Another important aspect 
when interpreting our study is its cross-sectional design, necessitating confirmation 
in  a longitudinal study on smoking cessation in asthma. Nevertheless, based on our 
observations, we speculate that the smoke-related epithelial changes a nd increase i n  
mast cell numbers are reversible by smoking cessation. 
In conclusion, we show in a large population of patients with asthma that cigarette 
smoking induces epithelial changes in association with increases in asthma symptoms, 
such as shortness of breath and phlegm production. Cigarette smoking in asthma was 
associated with lower bronchial eosinophil and higher mast cell numbers. The fact that 
epithelial changes and higher mast cell numbers were not observed in ex-smokers 
with asthma suggests that these smoke-induced changes can be reversed by smoking 
cessation. 
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A human custom multiplex antibody bead kit (Biosource, Invitrogen Ltd, Paisley, UK) 
was used to measure IFN-y, IL-4, 5, 8, 13, 17, EGF, Eotaxin, FGFb, GM-CSF, MCP1,  
RANTES, VEGF by Luminex, according to the manufacturers' instructions. Data was 
analysed using Starstation software. For each cytokine or growth factor undetectable 
values, those below the detection limit, were set at 0 (detection limits: IFN-y : 5, IL-4: 
5, IL-5: 3, IL-8: 3, IL-13: 10, IL- 17: 10, EGF: 25, Eotaxin: 5, FGFb: 20, GM-CSF : 15, 
MCP1:  10, RANTES: 15, VEGF: 15 pg/ml). 
We detected no significant differences in the level of the inflammatory cytokines and 
growth factors IFN-y, IL-4, 5, 8, 13, 17, EGF, Eotaxin, FGFb, GM-CSF, MCP1, RANTES 
and VEGF between subjects with asthma remission and asthma patients with a slow 
or a fast FEV1 decline. 
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TABLE E1 : Clinical COPD questionnaire (CCQ) data 
Never-smokers Ex-smokers Current smokers 
N=47 N=33 N=31 
On average during the past week, how often did you feel: 
q.1 Short of breath at rest? 0 (0-3) 0 (0-3) 0 (0-2) 
q.2 Short of breath doing physical activities? 2 (0-4) 1 (0-6) 1 (0-5) 
q.3 Concerned about getting a cold or your breathing 
0 (0- 1 )  0 (0-3) 0 (0-2) 
getting worse? 
q.4 Depressed (down) because of your breathing 
0 (0-2) 0 (0-3) 0 (0-2) 
problems? 
In general, during the past week, how much of the time: 
q.5 Did you cough? 1 (0-6) 2 (0-4) 2 (0-4) 
q.6 Did you produce phlegm? 1 (0-4) 2 (0-6) 2 (0-4) 
On average, during the past week, how limited were you in these activities because of your breathing 
problems: 
q.7 Strenuous physical activities (such as climbing 
stairs, hurrying, doing sports)? 
q.8 Moderate physical activities (such as walking, 
housework, carrying things)? 
q.9 Daily activities at home (such as dressing, washing 
yourself)? 
q . 10  Social activities (such as talking, being with 





1 (0-6) 1 (0-4) 
0 (0-5) 0 (0-3) 
0 (0-3) 0 (0-2) 
0 (0-2) 0 (0-3) 
CCQ Total score 8 (0-1 8) 7 (0-30) 6.5 (0-24) 
Total domain score symptoms 5 (0-1 1 )  5.5 (0-1 6) 5.5 (0-1 1 )  
Total domain score functional 2 (0-1 0) 1 (0-1 2) 1 (0-1 1 )  
Total domain score mental 0 (0-3) 0 (0-6)* 0 (0-3) 
Values are medians (ranges). Patients were asked to check the number of the response that best described 
how they have been feeling during the past week. For questions 1 -6 patients could chose from the answers: 
0=never, 1 =hardly ever, 2=a few times, 3=several times, 4=many times, 5=a great many times, 6=almost all 
the time. For questions 7-1 0 patients could chose from the answers: 0=not limited at all, 1 =very slightly 
limited, 2=slightly l imited, 3=moderately limited, 4=very limited, 5=extremely limited, 6=totally l imited/or 
unable to do. 
* P<0.05 vs. never-smokers. 
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TABLE E2: INFLAMMATORY CELLS AND MEDIATORS IN SPUTUM 
Never-smokers Ex-smokers Smokers 
N=47 N=33 N=25 
Total cells 
(x1 06/ml) 0.50 (0.03-3.00) 0.50 (0.06-3.86) 0.32 (0.05-1 .05)*' # 
Macrophages 
$ (%) 42.0 (4.9-82.5) 26.9 (5.3-74.7) 38. 1  (7. 1 -76.5)* 
(x1 06/ml) 0. 1 5  (0.03-1 .07) 0. 1 5  (0.01 -0 .61 )  0. 1 0  (0.02-0.61 )*' # 
Neutrophi ls 
$ (%) 47.4 ( 15.6-94) 67.6 (22.5-94.5) 55.8 (21 .6-92.7)* 
(x1 06/ml) 0.22 (0.05-2.70) 0 .32 (0.03-3.23) 0. 1 2  (0.01 -0.48)*' # 
Eosinophi ls 
(%) 0.8 (0-67. 1 )  0.5 (0-38.6) 1 .4 (0.2-5.9) 
(x1 06/ml) 0.005 (0-0.34) 0 .004 (0-0 .61 ) 0.003 (0-0.02) 
Lymphocytes 
$ # (%) 0.9 (0-6.9) 0.3 (0-3 .3) 0.2 (0-1 . 1 )  
(x1 06/ml) 0.004 (0-0 . 1 1 )  0 .002 (0-0 .07)$ 0.0006 (0-0.008l 
Neutrophil Elastase (µg/ml) 1 .4 (0.2-5) 2.4 (0.3-5) 0.8 (0.2-3.3)*' # 
Eosinophil ic Cationic 35.0 (4-2467) 42.7 (4-1 363) 1 7 .4 (6-88)*' # 
Protein (ECP) (µg/I) 
H istamine (ng/ml)  27.8 (0.2-1 29.5) 28.8 (5.6-1 34. 1 ) 25.6 (0-21 5) 
Values are medians (ranges). 
* = smokers vs. ex-smokers p<0.05 
# = smokers vs. never-smokers p<0.05 
s = ex-smokers vs. never smokers p<0.05. 
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TABLE E3: CORRELATION WITH SMOKE EXPOSURE-RELATED VARIABLES IN EX-SMOKERS 
Packyears Duration of smoking cessation 
p value p value 
FEV1 {o/opred) -0.096 0.53 -0. 1 84 0.23 
NO alveolar (ppb) -0.223 0.24 0.332 0.07 
NO bronchial (nUs) -0. 1 05 0.58 0.212 0.26 
Goblet cells {N) -0.283 0. 12  0 . 182 0.32 
Mucus-positive epithelium {%) -0.028 0.88 0.040 0.83 
Epithelial thickness {µm) 0.202 0.26 0 . 126 0.49 
Ki6t intact epithelium {%) -0.033 0.84 -0.076 0.64 
Ki6t basal epithelium {%) 0.176 0.29 0 . 131 0.43 
Eosinophils (per 0.1mm2 tissue) 0 . 161 0.32 -0.023 0.89 
Mast cells (per 0.1 mm2 tissue) -0.232 0.1 5  0.320 0.04* 
*P<0.05, the table only shows those variables that were significantly different in smoking asthmatics compared to 
ex- and never-smokers 
109 
CHAPTER 6 
TABLE E4: Multiple linear regression analyses - ICS use and smoking 
Dependent Variable R square ICS use ICS use S vs. NS S vs. NS 
(y/n) (y/n) 
Beta evalue Beta evalue 
FEV1 (%pred) 0.077 -0. 1 47 0. 1 36 -0.244 0.014* 
NO alveolar (ppb) 0. 1 87 0.1 1 9  0.295 -0.408 0.001 * 
NO bronchial (nUs) 0.230 0.1 38 0.212 -0.450 <0.001 *  
Goblet cells (N) 0. 1 38 0.089 0.495 0.366 0.007* 
Mucus-positive epithelium (%) 0 . 199 -0.0 19 0.884 0.444 0.001 * 
Epithelial thickness (µm) 0 . 108 -0.081 0.555 0.3 14 0.026* 
Mast cells (per 0 . 1mm2 tissue) 0.086 -0.057 0 .620 0.283 0.0 15* 
Basement membrane thickness (µm) 0. 1 30 -0.357 0.002* 0.038 0.737 
R square ICS use ICS use S vs. EX S vs. EX 
(y/n) (y/n) 
Beta e value Beta e value 
FEV1 (%pred) 0.018 -0. 1 25 0.280 0.028 0.806 
NO alveolar (ppb) 0 . 100 0.088 0.509 -0.287 0.035* 
NO bronchial (nUs) 0.264 0.069 0.570 -0.496 <0.001 * 
Goblet cells (N) 0.306 0. 1 78 0. 1 73 0.560 <0.001 *  
Mucus-positive epithelium (%) 0 . 133 0.026 0.842 0.369 0.006* 
Epithelial thickness (µm) 0.1 1 1  -0.037 0.779 0.324 0.01 6* 
Mast cells (per 0.1 mm2 tissue) 0. 1 06 -0.01 1 0.931 0.323 0.01 1 *  
Basement membrane thickness (µm) 0 . 145 -0.333 0.007* 0 . 130 0.282 
R square ICS use ICS use EX vs. NS EX vs. NS 
(y/n) (y/n) 
Beta e value Beta e value 
FEV1 (%pred) 0.080 -0.098 0.299 -0.253 0.008* 
NO alveolar (ppb) 0.047 0. 1 67 0. 1 66 -0. 1 64 0 . 175 
NO bronchial (nUs) 0.030 0 . 173 0. 1 56 -0.039 0.746 
Goblet cells (N) 0.013 0.079 0.520 -0.097 0.430 
Mucus-positive epithelium (%) 0.024 -0.068 0.61 1 0 . 149 0.265 
Epithelial thickness (µm) 0.01 1 -0. 1 04 0.435 0.021 0.872 
Mast cells (per 0. 1mm2 tissue) 0.009 -0.068 0.534 -0.056 0.608 
Basement membrane thickness (µm) 0. 136 -0.348 0.00 1 *  -0.086 0.401 
* p<0.05, the table only shows those variables that were significantly different in smoking asthmatics 
compared to ex- and never-smokers (except for basement membrane thickness) and were normally 
distributed (if necessary after transformation). ICS = inhaled corticosteroids, S = smoking, NS = never 
smoking, EX = ex-smoking. 
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TABLE ES: Multiple linear regression analyses - LABA use and smoking 
Dependent Variable R square LABA use LABA use S vs. NS S vs. NS 
(y/n) (y/n) 
Beta e value Beta e value 
FEV1 (%pred) 0.076 -0. 145 0 . 141 -0.240 0.016* 
NO alveolar (ppb) 0. 1 76 0.055 0.632 -0.414 0.001*  
NO bronchial (nUs) 0.2 14  0.056 0.6 16  -0.458 <0.001* 
Goblet cells (N) 0. 1 30 -0.020 0.877 0.360 0.008* 
Mucus-positive epithelium (%) 0.205 -0.083 0.524 0.443 0.001*  
Epithelial thickness (µm) 0. 1 02 -0.017 0.904 0.31 8 0.024* 
Mast cells (per 0 .1  mm2 tissue) 0.087 -0.068 0.549 0.285 0.014* 
R square LABA use LABA use S vs. EX S vs. EX 
(y/n) (y/n) 
Beta e value Beta e value 
FEV1 (%pred) 0.0 1 9  -0. 1 32 0.259 0.022 0.848 
NO alveolar (ppb) 0.093 -0.004 0.975 -0.306 0.027* 
NO bronchial (nUs) 0.262 -0.052 0.668 -0.522 <0.001*  
Goblet cells (N) 0.284 0.097 0.463 0.548 <0.001*  
Mucus-positive epithelium (%) 0. 1 33 -0.01 2 0.929 0.361 0.008* 
Epithelial thickness (µm) 0 .1 1 3  0.054 0.682 0.344 0.012* 
Mast cells (per 0 .1  mm2 tissue) 0. 1 05 0.000 0.994 0.324 0.01 1 *  
R square LABA use LABA use EX vs. NS EX vs. NS 
(y/n) (y/n) 
Beta e value Beta e value 
FEV1 (%pred) 0.078 -0.086 0.366 -0.248 0.01 0* 
NO alveolar (ppb) 0.030 0 .1 01 0.409 -0. 1 62 0 .1 88 
NO bronchial (nl/s) 0 .006 0.077 0.534 -0.032 0.795 
Goblet cells (N) 0.008 -0.01 5  0.906 -0.083 0 .503 
Mucus-positive epithelium (%) 0 .036 -0. 1 31 0.328 0. 1 67 0.21 4 
Epithelial thickness (µm) 0.001 -0.030 0.827 0.01 4 0.920 
Mast cells (per 0 .1  mm2 tissue) 0.008 -0.067 0.544 -0.051 0.644 
* p<0.05, the table only shows those variables that were significantly different in smoking asthmatics compared to 
ex- and never-smokers and were normally distributed (if necessary after transformation). LABA = long-acting beta-
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CHAPTER 7 
ABSTRACT 
Background: Control of asthma is the goal of asthma management worldwide. The 
Global Initiative for Asthma (GINA, 2006) defined control by a composite measure of 
clinical findings but without using markers of airway inflammation, the hallmark of 
asthma. We investigated whether such markers and quality of life are associated with 
the level of asthma control. 
Methods : Control of asthma was assessed over a period of four weeks in 1 1 1  asthmatics: 
22 totally controlled, 47 well controlled, and 42 uncontrolled. Lung function, quality of 
life, airway hyperresponsiveness to adenosine-5'-monophosphate, sputum and blood 
eosinophils, exhaled nitric oxide and bronchial biopsies were obtained. 
Findings: The 69 subjects with controlled asthma (totally and well controlled combined) 
had lower median blood eosinophil numbers, slope of hyperresponsiveness to adenosine-
5'-monophosphate, and alveolar nitric oxide levels than the 42 subjects with uncontrolled 
asthma: 0. 18 (range 0 .01-0. 54) versus 0.22 (0.06-1. 16) x 1 09/L (p<0.05),  3.8 (-0.4-
1 7750) versus 39. 7 (0.4-28000) mg/ml (p< 0.05),  and 5 . 3  ( 1 . 5-14.9) versus 6. 7 
(2.6-51. 7) ppb (p< 0. 05)  respectively. Biopsies from subjects with controlled asthma 
contained fewer eosinophilic granules ( 1 1 3  (6- 1787) versus 219 ( 19-5313) (p< 0.05) and 
more intact epithelium ( 1 1.8 (0-65. 3) versus 5.6 (0-47.6)% (p<0.05) than uncontrolled 
subjects. Controlled asthmatics had better Asthma Quality of Life Questionnaire scores 
than uncontrolled patients: 6. 7 (5.0-7.0) versus 5.9 (3.7-7.0)  (p<0.001). 
Interpretation: The level of control of asthma, based on a composite measure of 
clinical findings, is associated with both direct and indirect markers of inflammation and 
is related to patients' quality of life. 
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INTRODUCTION 
Aiming for total control of asthma by applying strict rules for treatment was the focus 
of the Gaining Optimal Asthma control (GOAL) study in 2004(1). In this landmark 
study, totally controlled and well controlled asthma were composite measures based on 
respiratory symptoms during the day and night, use of rescue medication, peak expiratory 
flow rate, exacerbations, emergency visits to the doctor or hospital, and adverse side­
effects of treatment(!). Indeed, many patients with uncontrolled asthma improved 
to a well controlled or totally controlled level after stepwise increase of fluticasone or 
fluticasone combined with salmeterol. In line with GOAL, the Global Initiative for Asthma 
(GINA) in 2006 emphasized the importance of asthma control, and also defined asthma 
control on the basis of a composite measure of clinical indices. Surprisingly, a marker 
of inflammation was not included in the definition of asthma control, whereas chronic 
airway inflammation is the hallmark of asthma. 
Airway inflammation does not correlate well with the level of lung function or with the 
symptoms of asthma(2). The question therefore arises as to whether well- or totally 
controlled asthma based on clinical criteria alone sufficiently reflects an adequate control 
of the underlying airway inflammation. One can further argue that, for an individual 
patient, it is not only important to have reduced airway inflammation, but also to have 
an optimal quality of life(3). In our opinion, a more thorough insight is needed into the 
complex interplay between clinical control of asthma, quality of life and the underlying 
airway inflammation. In this observational study we investigated airway inflammation 
and quality of life in subjects with totally controlled, well controlled, and uncontrolled 
asthma, defined according to the strict GOAL criteria. 
METHODS 
SUBJECTS 
Smoking and non-smoking asthma patients, aged 19 to 71 years, some of whom using 
inhaled corticosteroids, were recruited from research cohorts investigated earlier by 
our group. All subjects had a doctor's diagnosis of asthma and documented bronchial 
hyperresponsiveness to histamine (Provocative concentration of histamine causing 
a 10% fall in forced expiratory volume in one second (FEV1) from baseline (PC10 
histamine) :516 mg/ml, using 30-second tidal breathing). Patients were included if they 
had a provocative concentation of adenosine-5'-monophosphate causing a 20% fall in 
FEV1 from baseline (PC20AMP) :5 320 mg/ml. If PC20AMP was higher, an additional 
histamine provocation challenge was performed within 2 weeks and subjects had to 
demonstrate a PC10 histamine :5 16 mg/ml. The main exclusion criteria were: FEV1 < 1.2 
L,  bronchiectasis, upper respiratory tract infection (e.g. colds) and/or use of antibiotics 
or oral corticosteroids within 2 months prior to inclusion in the study. The local medical 
ethics committee approved the study protocol and all subjects gave their written informed 
consent. 
STUDY D ESIGN 
This prospective cross-sectional study involved the subjects paying four visits to the 
clinic. At visit 1, written informed consent was obtained and patients were enrolled in 
the study if they fulfilled the inclusion criteria. Patients were instructed how to keep a 
diary and how to measure peak expiratory flow (PEF) at home for the next four weeks. 
At visit 2 (four weeks later), clinical control of asthma was assessed according to the 
GOAL criteria (table 1 in supplement for Web-only publication) and the quality of life was 
determined using the Asthma Quality of Life Questionnaire (AQLQ). Blood was drawn for 
measurements of eosinophils and atopy. Then reversibility of FEV1 was carried out with 
800 µg of inhaled albuterol (Ventolin) followed by sputum induction. Within two weeks, 
at visit 3, hyperresponsiveness to AM P was assessed. One to two weeks later this was 





T he Phadiatop screening test was used to determine atopic status; it was performed 
on the ImmunoCap system, according to the manufacturer's instructions ( Phadia AB, 
Sweden) . T he results are presented as q uotients (fluorescence of the serum of interest 
divided by the fluorescence of a control serum). A positive Phadiatop was defined as 
patient serum/control serum > 1.  
ASTHMA QUALITY OF LIFE 
T he Dutch version of the Asthma Quality of Life Questionnaire (AQLQ) was used for 
this study(4). The AQLQ is scored on a 7-point scale, with 32 questions on four 
domains : symptoms, responses to environmental stimuli and the need to avoid them, 
limitation of activities, and emotional dysfunction. 
LUNG FUNCTION 
FEV1 was measured with a calibrated water-sealed spirometer according to 
standardized guidelines( S). Reversibility of FEVl %-predicted was measured before 
and after administration of 800 µg of albuterol. Provocation tests were performed 
using a method adapted from Cockcroft and co-workers(6). After an initial nebulized 
saline challenge, subjects inhaled doubling concentrations of AMP (0.04 to 320 mg/ 
ml) by 2-min tidal breathing and at 5-min intervals. T he slope of the AMP curve 
was calculated as the ratio between the change in FEVl (difference between the 
values at baseline and at final dose of AMP) and the final dose of AMP. Bronchial 
hyperresponsiveness to histamine was tested as reported previously(7) ,  using 30-
second tidal breathing and doubling concentrations ranging from 0.13 to 32 mg/ml. 
SPUTUM INDUCTION AND SPUTUM PROCESSING 
Sputum was induced by inhalation of hypertonic saline aerosols as previously 
described(8). Hypertonic saline (5%) was nebulized over three consecutive periods of 
5 minutes. Whole sputum samples were processed according to a method modified 
from that of Fahy and colleagues(9,8). May Grunwald Giemsa ( MGG) staining was 
used to obtain cell differentials from a total of 600 viable, non-squamous cells. T he 
sputum was not evaluated if the percentage of squamous cells was >80% or if the 
total number of non-squamous cells was <600. 
ALVEOLAR AND BRONCHIAL NITRIC OXIDE 
Exhaled NO measurement was performed at multiple flow rates ( 30 mL/s, 50 mL/s, 
100 mL/s and 200 mL/s) on a NIOX (Aerocrine, Stockholm, Sweden). The mean 
eNO value (ppb) of three technically acceptable attempts per flow rate was used for 
analysis. T he alveolar NO fraction (ppb) as well as the bronchial NO flux (nL/s) were 
calculated with a modification of the two-compartment model of NO exchange by 
Tsoukias and George( l0,11). 
COLLECTION, PROCESSING, IMMUNOHISTOCH EMICAL STAINING AND QUANTIFICATION OF 
BRONCHIAL BIOPSIES 
After local anesthesia, bronchial biopsies were obtained using a flexible bronchoscope 
(Olympus BF P20 or BF XT 20) from segmental divisions of the main bronchi. T he 
biopsies were fixed in 4% formalin, processed and embedded in paraffin. Bronchial 
biopsies were cut into 3 µm thick sections. T he inflammatory profile was assessed with 
specific antibodies against a large panel of inflammatory markers. The inflammatory 
cells were quantified using computer-assisted image analysis (See Methods section in 
the supplement for Web-only publication for more details). 
STATISTICS 
All analyses were performed using SPSS (version 14 . 0.1; SPSS Inc, Chicago, IL, 
USA) . T he differences in the continuous variables between groups were tested with 
the Mann-Whitney U-test for non-normally distributed data and with the independent 
116 
CLINICAL CONTROL OF ASTHMA ASSOCIATES WITH MEASURES OF AIRWAY INFLAMMATION 
sample t-test for normally distributed data. PC20AMP, slope of AMP, blood, sputum 
and bronchial eosinophils, and eNO were transformed logarithmically to normalize 
their distribution. We compared the groups' dichotomous variables using the chi­
squared test and performed multiple logistic regression analysis to investigate which 
variables were significant determinants for asthma control (see Results section in 
the supplement for Web-only publication). We used principal component analysis to 
determine the inter-relationships between different variables that might determine 
asthma control (see Methods section in the supplement for Web-only publication). 
RESULTS 
PATIENT CHARACTERISTICS 
One hundred and eleven asthmatic patients with a median age of 50 (range 19-71) 
years were included. The reasons for not having totally controlled or well controlled 
asthma are given in the online supplement (Table El). Twenty-two subjects (20%) 
were totally controlled, 47 ( 42%) well controlled, and 42 (38%) uncontrolled. 
TABLE 1 :  BASELINE CHARACTERISTICS 
Sex (Male/Female) 
Age (years) 
Atopy (Phadiatop ratio) 
Current smokers n (%) 
Ex-smokers n (%) 
Pack years in all subjects 




Totally controlled Well controlled 
(n=22) (n=47) 
1 0/12 2 1 /26 
48 (1 9-64) 52 (22-7 1 )  
4.93 (0. 1 3-96.5) 5.56 (0.06-1 06) 
7 (32) 12 (26) 
13 (59) 27 (57) 
0.9 (0-3 1 )  2 . 0  (0-64) 
5 (23) 26 (55) 
0 (0-1000)" 200 (0-1200) 







27.3 (0. 15-128)* # 
1 0  (24) 
25 (60) 
0.2 (0-45) 
30 (7 1 )** 
450 (0-1000)*### 
800 ( 1 00-2000) 
Patients using LABA, n (%) 3 (14) 1 5  (32) 16 (38) 
FEV 1 (% predicted) 1 07 (78- 122)" 96 (42 - 132) 98 (56- 135l 
FEV 1/FVC (%) 80 (58-97)" 74 (39-88) 73 (40-97l 
Reversibility FEV 1 (%) 8.7 (0.7-23.9) 9.0 ( 1 .5-23.3) 1 0.7 (-2.2 - 38.4) 
PC20 AMP (mg/mL) 640 (8. 1 -640) 1 00 (0. 1 -640) 7.7 (0-640)*** ttt### 
Values are medians (ranges), unless stated otherwise. 1dose equivalent of beclomethasone. ICS denotes inhaled 
corticosteroids, LABA long-acting �2-agonist, PC20AMP the provocative concentration of adenosine-5 ' -
monophosphate causing a 20% fall in FEY,. reversibility FEV 1 (%) change in FEV1 expressed as increase in 
percentage predicted after 800 µg of Albuterol. 
* p<0.05 or ** p<0.01 or *** p<0.001 versus controlled 
ttt p<0.001 versus well controlled 
# p<0.05 or ### p<0.001 versus totally controlled 
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Figure 1. Biological parameters assessed in asthmat­
ics. 
Peripheral blood eosinophils (upper panel), slope of 
AMP (middle panel), and alveolar nitric oxide concen­
trations (lower panel) in totally controlled, well con­
trolled and uncontrolled asthmatics. Each dot repre­
sents one subject. Horizontal bars represent median 
values. AMP denotes adenosine-5'-monophosphate, 
NO nitric oxide. 
118 
M ARKERS OF INFLAM MATION 
T he 69 subjects with controlled asthma 
(totally and well controlled combined) had 
lower median blood eosinophil numbers 
than uncontrolled subjects: 0.18 (range 
0.01-0.54) versus 0.22 (0.06-1.16) x109/ 
L (p<0. 05) ( Fig. 1). The slope of PC20AMP 
was lower in asthmatics who were totally 
controlled or well controlled than in 
subjects with uncontrolled asthma: 3.8 
(-0.4-17750) versus 39. 7 (0.4-28000) 
mg/ml (p< 0.05). The slope of PC20AMP 
tended to be higher in totally controlled 
subjects than in well controlled subjects 
(p=0. 08) ( Fig. 1). Alveolar NO levels were 
lower in subjects with controlled asthma 
than in uncontrolled subjects: 5. 3 (1.5-
14.9) versus 6. 7 (2.6-51.7) ppb, p<0.05 
( Fig . 1). 
In sputum, both the total number and 
proportion ( %) of inflammatory cell 
types did not differ significantly between 
controlled and uncontrolled subjects 
(Table E2 in the on line supplement). Post­
hoc analysis in subgroups of asthmatics 
divided according to current smoking 
status and current corticosteroid use did 
not affect these results. 
Subjects with controlled asthma had a 
lower level of eosinophil activation, as 
determined byEPX( eosinophil peroxidase)­
immunopositivity in bronchial biopsies, 
than uncontrolled subjects (Table 2, Fig. 
2). Controlled asthma was accompanied 
by an increase in intact epithelium 
compared to uncontrolled asthma (Table 
2, Fig. 2) . All the other inflammatory and 
remodeling variables we investigated 
were comparable in controlled and 
uncontrolled subjects (Tables 2 and E3 in 
the online supplement). 
M U LTIPLE LOGISTIC REGRESSION ANALYSIS 
ON ASTHMA CONTROL 
Multivariate logistic regression analysis 
was used to reveal which variables 
determine the control of asthma. Due to 
multi-co-linearity all the variables related 
to eosinophilic inflammation could not be 
entered simultaneously into the model. 
We therefore created a model including 
sex, age, Phadiatop ratio, inhaled 
corticosteroid (ICS) use and FEV1/VC, 
with the other variables (alveolar NO, 
blood eosinophils, AMP slope, EPX­
positive pixels or the percentage intact 
epithelium) being entered separately. 
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TABLE 2: INFLAMMATION AND REMODELING IN BIOPSIES 
Controlled asthma Uncontrolled asthma 
Totally controlled Well controlled Uncontrolled 
n=1 9  N=33 n=37 
Inflammatory cells 
Eosinophils 2 (0-26) 1 (0-2 1 )  2 (0-32) 
Mast cells 12 (3-24) 8 (0-26) 9 (0- 1 7) 
Macrophages 15 (0-30) 12 (0-47) 1 1  (0-57) 
Neutrophils 9 (0-46) 5 (0-34) 6 (0-20) 
T lymphocytes (CD3l 68 (23-294) 55 ( 1 3- 1 77) 66 (4-2 1 9) 
T lymphocytes (CD4+) 24 (4-70) 16 (0-67) 1 7  (0-7 1 )  
T lymphocytes (CD8l 25 (4- 1 39) 1 7 (0- 1 36) 23 ( 1 -205) 
Inflammatory cell activation 
EPX immunopositivity 157  ( 16- 1268) 101 (6- 1 787) 2 1 9  ( 1 9-53 12)*' tt 
Mast cell degranulation (%) 80 (22- 100) 69 (25- 100) 75 (0-100) 
Remodeling 
BM thickness (µm) 6.3 ( 4.3-9) 5.2 (3.6-8 .  7) 5 .9 (2. 8- 12.6) 
Intact epithelium (%) 1 3  (0-32.8) 10.5 (0-65.3) 5 .6 (0-47.6)* 
Inflammatory cells are expressed as the number per 0. 1 mm2. Values are medians (ranges). * p<0.05 versus 
controlled, tt p<0.0 I versus well controlled. 
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EPX (eosinophil peroxidase) immunopositivity (left panel) and the percentage of intact epithelium (right panel) in 
bronchial biopsies totally controlled, well controlled and uncontrolled asthmatics. Each dot represents one subject. 
Horizontal bars represent median values. 
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T his showed that a higher Phadiatop ratio and res use were significant determinants 
of worse asthma control in most of the models. It was noteworthy that a higher AMP 
slope (OR: 0. 39; 95%CI: 0.24-0.63) and higher EPX-positive pixel numbers (OR: 
0. 32; 95%CI : 0.13-0. 79) were significant determinants for worse asthma control (see 
Results section in the supplement for Web-only publication) . 
COMPARISON WITH ASTHMA QUALITY OF LIFE (AQ LQ) 
Subjects with controlled asthma demonstrated higher median scores in the total AQLQ 
than uncontrolled subjects: 6. 7 (range 5.0-7.0) versus 5. 9 ( 3. 7-7.0) (p<0.001) ( Fig. 
3). They also had significantly higher scores in all domains of the AQLQ: symptoms 6. 7 
(4 .9-7.0) versus 5.5 (3 .7-7.0), activity 6.8 (4.5-7.0) versus 6. 3 ( 3.9-7.0), emotion 
7.0 (5.0-7.0) versus 6.6 ( 3.8-7.0) and environment 6.5 ( 3.8-7. 0) versus 5.5 ( 3. 0-
7 . 0). AQLQ scores did not differ significantly between the totally and well controlled 
subjects. 
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Figure 3. Asthma quality of life as assessed with the Asthma Quality of Life Questionnaire. 
The AQLQ (Juniper et al4) was given to totally controlled, well controlled and uncontrolled asthmatics. It is divided 
into four domains: symptoms, activities, emotions, environmental. Each dot represents one subject. Horizontal 
bars represent median values. 
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DISCUSSION 
The Global Initiative for Asthma ( GINA, 2006) defined control of asthma by a composite 
measure of clinical findings but without including markers of airway inflammation, 
the hallmark of asthma(12). Our study is the first to have investigated whether the 
level of asthma control according to GINA is associated with both direct and indirect 
markers of airway inflammation including airway wall biopsies in a large group of 
asthmatics with a wide spectrum of disease severity. Patients with totally controlled 
and well controlled asthma demonstrated less hyperresponsiveness to AMP, lower NO 
levels in  exhaled air, lower eosinophil numbers in  peripheral blood, lower activated 
eosinophil numbers in the bronchial wall, a higher degree of epithelial intactness in 
the bronchial wall, and higher quality of life scores than uncontrolled subjects. 
Our data show that control of asthma is associated with a lower degree of airway 
inflammation as assessed by indirect markers like PC20AMP, exhaled NO, and 
peripheral blood eosinophils. Even more importantly, we found that control of asthma 
was associated with a lower degree of airway inflammation as assessed by the 
pathological gold standard of asthma, namely the mucosa! infiltration of activated 
eosinophils and loss of epithelial integrity. Thus, the concept of a composite measure 
for clinical asthma control, combining different variables like night- and daytime 
symptoms, PEF, and use of rescue medication, appears to be valid, or at least to have 
an underlying pathobiological substrate. 
We have further demonstrated that different aspects of inflammation (nitric oxide, 
eosinophils, epithelial cells, PC20AMP) stemming from different parts of the lung 
(exhaled air, blood, bronchial biopsies) are associated with control of asthma. T his is 
not particularly surprising since all these inflammatory factors interact and contribute 
to the overall, general inflam mation that is present in asthma. On the other hand, 
the heterogeneity of asthma with different inflammatory subtypes is increasingly 
acknowledged(13,14). Our study also lends support to this concept, as we found 
that less severe hyperresponsiveness to AMP, lower eosinophil numbers, and better 
epithelial integrity are all independent factors contributing to higher asthma control. 
Regardless of the exact relationship, our results suggest that aiming for clinical control 
of asthma does suppress the underlying inflammation. Randomized intervention 
studies with a longitudinal study design are needed to further demonstrate a m ore 
causal and specific relationship. 
We had three unexpected findings in this study. First, smoking history did not contribute 
significantly to the level of asthma control, despite smoking being associated with 
poorer asthma control in two other studies(15,16). This could be explained by a 
"healthy smoker" effect, i.e. those with relatively healthy airways are able to tolerate 
smoke inhalation, to persist in their smoking habit, and to show good control of their 
asthma. 
Secondly, ICS use contributed to the variation in asthma control, but in an opposite 
direction to that expected, with a significantly higher percentage of ICS users and 
dose of ICS used in the uncontrolled group. Indeed, an "unhealthy ICS" effect may 
well have been present in our study, since it is well-known that some asthmatics do 
not respond well to corticosteroids(17,18) . This was also found in the GOAL study, 
which showed that 20-30% of the participants did not improve their baseline level of 
uncontrolled asthma despite long-term administration of increasing doses of ICS. 
Thirdly, control of asthma did not significantly associate with lower sputum eosinophils, 
opposite to two other studies(19,20). Apart from a different asthma population the 
two studies also used different tools to assess asthma control. Quaedvlieg et al(19) 
used the shortened Asthma Control Questionnaire that does not take lung function 
into account(21), whereas Romagnoli et al(20) included variation of PEF in stead of 
PEF itself(22). Both studies measured asthma control during one week only, and not 
as a strict composite measure during 4 weeks as we did. Our study shows that other 
inflammatory measures relate to the strictly used definition of asthma control, and 
particularly eosinophilic makers in peripheral blood and airway wall biopsies. It is an 
intriguing finding that control of asthma significantly associates with lower peripheral 
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blood eosinophils and lower activated eosinophil numbers in the bronchial wall, yet 
not with sputum eosinophils. We do not have an explanation for this discrepancy, but 
if true, it is questionable whether sputum eosinophils can be used to monitor control 
of asthma. 
The health-related quality of life in our patients with controlled asthma was significantly 
better than in those with uncontrolled asthma. As the difference between the two 
groups was higher than the minimal, clinically important difference of 0.5 point, it is 
also more attractive from the patients' perspective to aim for a better level of control 
in those without adequate control(23). In addition, we observed a ceiling in the 
quality of life measures between the totally controlled and well controlled subjects, 
suggesting that aiming for the best level of asthma control does not further improve 
an individual's quality of life. 
The participants in this study are not fully comparable to those in the larger GOAL 
study(24), which included only subjects with uncontrolled asthma, whereas we also 
included subjects with totally controlled and well controlled asthma. The GOAL study 
also included younger subjects (including children) and had a lower prevalence of 
ex-smokers, lower lung function, and higher bronchodilator reversibility. When we 
compared the reasons why patients failed to achieve asthma control in the GOAL study 
and in our study, there were a few striking differences. T he percentages of patients 
failing to achieve control due to the GOAL criteria were 63% due to awakening in 
GOAL vs our study 50%, daytime symptoms (95% vs 29%), rescue medication (92% 
vs 48%), and PEF >80% predicted (72% vs 76%).  Thus, the prevalence of daytime 
symptoms and rescue medication in the GOAL study were considerably higher than in 
our study. It is possible that the patients in the GOAL study had more severe disease, 
having a lower baseline lung function and more symptoms than our patients .  Larger, 
explorative studies will be needed to determine why some patients do not achieve 
total control of their asthma and this may well have important consequences for the 
therapies prescribed. 
In conclusion, our observational study demonstrates that clinical control of asthma is 
associated with both direct and indirect markers of airway inflammation. Moreover, 
better asthma control associates with a higher quality of life for the patients .  Thus, 
aiming for good clinical control of asthma, as recommended by the GINA guidelines, 
is important from the patients' point of view and suppresses the underlying airway 
inflammation as well. 
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CLINICAL CONTROL OF ASTHMA ASSOCIATES WITH MEASURES OF AIRWAY INFLAMMATION 
ONLINE SUPPLEMENT: METHODS 
COLLECTION, PROCESSING AND IMMUNOHISTOCHEMICAL STAINING OF BRONCHIAL 
BIOPSIES 
The inflammatory profile of 11 asthmatic subjects was assessed with specific antibodies 
against eosinophilic peroxidase (EPX, laboratories of NA Lee and JJ Lee, Mayo Clinic, 
Scottsdale, Arizona, USA), mast cell tryptase (AA1, DAKO, Glostrup, Denmark), 
macrophages (CD68, DAKO), neutrophil elastase (NP57, DAKO) and T-lymphocytes 
(CD3 (DAKO), CD4 (Novocastra, Newcastle upon Tyne, UK) and CDS (DAKO). In short, 
sections were deparaffinized, antigens were retrieved, and the sections then incubated 
with the primary antibodies. These antibodies were detected with Envision™ Detection 
Kit (DAKO) followed by the chromogen NovaRED (Vector Labs, Burlingame, California, 
USA). EPX and CDS were detected using biotinylated anti-mouse IgGl (Southern 
Biotechnology, Birmingham, Alabama, USA) and alkaline phosphatase- (DAKO) or 
peroxidase-labeled streptavidine conjugates (DAKO), followed by permanent Red 
(DAKO) and NovaRed chromogens, respectively. Epithelial proliferation was assessed 
by Ki67 expression and submucosal deposition of extracellular matrix (ECM) by 
collagen 3 expression. In short, sections were deparaffinized, antigens were retrieved, 
and the sections incubated with antibodies against Ki67 (DAKO) and collagen 3 
(Southern Biotechnology). These antibodies were detected with two peroxidase­
labeled conjugates (both DAKO). 3,3'-diaminobenzidine tetrahydrochloride (Sigma­
Aldrich, Zwijndrecht, the Netherlands) was used since chromogen and hematoxylin 
(Ki67) or methylgreen (collagen 3) were used for counterstaining. All stainings (except 
for Ki67) were performed in an automated system using the DAKO autostainer in 
three consecutive runs per cell marker. Sections were manually counterstained with 
methyl green. 
QUANTIFICATION 
Quantification of inflammatory cells was performed by a blinded observer using 
computer-assisted image analysis at a magnification of 200x (Qwin, Leica Microsystems 
Imaging Solutions, Cambridge, UK). The largest of three biopsy samples was generally 
chosen for quantification.  The number of positively stained inflammatory cells was 
counted in the submucosal area 100 µm under the basement membrane (BM), in a 
total area of 0.1 mm2 per biopsy sample. Additionally, activation of eosinophils and 
mast cells was determined by their degree of degranulation. EPX staining showed 
widely spread distribution of eosinophilic granules, not necessarily in close proximity to 
EPX+ cells. Therefore, degranulation of eosinophils was determined by quantification 
of the EPX immunopositive area by computer-assisted image analysis. AA1 + mast 
cell granules were only observed in close proximity to AA1 + cells and, therefore, the 
percentage of degranulated AA1+ cells was determined by counting (Carroll, N.G. et 
al. Eur. Respir. J., 2002. 19:879-885). In short, positively stained nucleated mast cells 
were classified as intact if they were dense, compact, had unbroken boundaries, and 
did not have any surrounding positively stained granules. All other nucleated AA1+ 
cells were classified as degranulated. 
BM thickness was calculated by dividing the BM surface area by the BM length. Epithelial 
integrity was determined using hematoxylin and eosin-stained biopsy sections and 
expressed as a percentage of the BM covered with : (1) normal epithelium (a layer of 
basal and ciliated columnar epithelial cells without detachment from the BM), (2) basal 
epithelial cells only, (3) no epithelium: denuded BM, or (4) metaplastic epithelium 
(multilayered epithelium covered by a flattened layer of squamous epithelial cells and 
absence of ciliated cells). 
The number of goblet cells was counted on PAS-stained biopsy sections and expressed 
per mm of BM. Additionally, the number of PAS-positive pixels was determined in the 
epithelium and expressed as the percentage of mucus-positive epithelium per biopsy 
section. Epithelial thickness was determined by dividing the epithelial surface area 
by the BM length. Epithelial proliferation was determined by counting the number of 
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Ki67-positive epithelial nuclei in intact and basal epithelium. Expression of collagen 
3 was measured by computer-assisted image analysis in the submucosal area 200 
µm under the BM, and was expressed as the percentage of positive tissue per biopsy 
section. 
STATISTICS 
Principal component analysis was used to determine the inter-relationships between 
different variables that might determine asthma control, i .e. questionnaires, lung 
function inflammation, and remodeling. Exploratory principal component analysis 
included the following variables: postbronchodilator FEV1/VC ( %),  postbronchodilator 
reversibility ( %  predicted), morning PEF ( %  predicted) ,  Asthma Quality of Life 
Questionnaire(AQLQ) total score, AQLQ symptoms score, self-reported rescue 
medication usage, daytime symptoms, and night-time awakenings, slope AMP, alveolar 
NO (ppb),  smoking history in pack-years, inhaled corticosteroid (ICS) use, atopy 
( Phadiatop ratio) , number of eosinophils in blood, sputum (number) and bronchial 
biopsy (EPX immunopositivity) ,  bronchial mast cells (number), and intact epithelium 
(%). Two tailed p-values < 0 . 05 were considered statistically significant. 
ONLINE SUPPLEMENT: RESULTS 
M U LTIPLE LOGISTIC REGRESSION ON ASTH MA CONTROL 
Multivariate logistic regression analysis was used to reveal which variables determine 
the level of control of asthma. However, due to multi-co-linearity, not all the variables 
related to eosinophilic inflammation (alveolar NO, slope AMP, eosinophils in sputum 
and EPX pixels in biopsies) could be entered simultaneously into the model. We 
therefore created an alternative model including sex, age, Phadiatop ratio, inhaled 
corticosteroid (ICS) use and FEV1/VC. We entered the following variables separately 
into this model : alveolar NO, blood eosinophils, slope AMP, EPX-positive pixels or the 
percentage intact epithelium. In most models ( 4 out of 5) Phadiatop ratio and ICS use 
were found to be significant determinants of asthma control. The two exceptions were 
when alveolar NO was entered, ICS use was no longer a significant determinant, and 
when slope AMP was entered, Phadiatop ratio was no longer a significant determinant 
for asthma control . Importantly, the AMP slope (odds ratio (OR) 0. 39; 95% confidence 
interval (CI) 0. 24-0.63) and EPX-positive pixels (OR 0. 32; 95%CI: 0.13-0. 79) were 
also found to be significant determinants for asthma control. 
PRINCIPAL COMPON ENT ANALYSIS 
Due to the multi-co-linearity, we decided to explore our dataset using principal 
component analysis for inter-relationships between the different variables that might 
determine asthma control, i.e. questionnaires, lung function, and airway inflammation. 
Principal component analyses yielded six separate factors that accounted for 66.9% of 
the total variance. Factor 1 comprised the AQLQ total score, AQLQ symptoms score, self­
reported daytime symptoms, and night-time awakenings. Factor 2 included eosinophils 
in blood (number), sputum (number) and bronchial biopsy (EPX immunopositivity) ,  
alveolar N O  (ppb) ,  and self-reported rescue medication usage. Factor 3 contained 
postbronchodilator FEV1/VC ( % )  and morning PEF ( %  predicted). Factor 4 included 
atopy ( Phadiatop ratio) ,  slope AMP and postbronchodilator reversibility ( %  predicted) .  
Factor 5 contained intact epithelium ( % ) ,  bronchial mast cells (number),  and ICS use. 




TABLE El. FAILURE OF ASTHMA CONTROL DURING 4 WEEKS FOLLOW-UP 
Criteria No of patients Median (range) 
of asthma control that failed the criteria q, values per group 
Totally Well Total Well No Total Well No 
Controlled Controlled (n=22) (n=47) (n=42} 
During 4 weeks All of: Two or more of: 
Daytime None � 2 days with 0 26 (55) 12 (29) o""" 0. 1 8  1 .0 
symptoms n (%) 1 (0-4.0)*** ttt### score > 1 (0- 1 .4) 
Rescue beta-2 None � 2 days & � 4 0 9 ( 19) 20 (48) OM 0 0.4 
agonist use n (%) 1 (0-3.3) *** ttt### occasions (0-2) 
Morning PEF (%) 1 � 80% pred. � 80% pred. 0 24 (5 1 )  32 (76) 97 87 8 1  
eve!)'. day eve!)'. day (88- 124f (41 - 128) ( 40-99)***### 
AND each week all of the following 
Night-time None None 0 0 2 1  (50) 0 0 2 
awakening+ (0-41)  *** ttt### 
Exacerbations+ None None 0 0 0 0 0 0 
Emergency visits+ None None 0 0 0 0 0 0 
Treatment-related None enforcing None enforcing 0 0 0 0 0 0 
AEs+ change in asthma change in asthma 
thera12y thera12y 
'!'Numbers of occasions that patients failed to fulfil the criteria of totally controlled or well controlled. Values in the well controlled asthma group are the number of occasions 
that patients do not fulfil the criteria of total control. Values in the uncontrolled asthma group are the number of occasions that patients do not fulfil the criteria of being well 
controlled. � average per day; + number of events during 4 weeks. Daytime symptom score: symptoms for 1 short period during the day ( overall scale: 0 [none] to 5 [severe]). 
Exacerbations: deterioration in asthma requiring treatment with oral corticosteroid or visit to emergency department, hospitalization, or both. AE adverse event; *** p<O.O I 
versus controlled; ttt p<0.00 l versus well-control; ## p<O.O l or ### p<0.00 l versus totally control; IV\ p<O.O l or
= 

















































TABLE E2: INFLAMMATION IN SPUTUM 
Controlled Asthma 
Totally controlled Well controlled 
(n=22) (n=47) 
Sputum evaluable 1 3  (59%) 34 (72%) 
Total cells (x1 06/mL) 0.47 (0.07 - 1 .79) 0.54 (0.05 - 3 .00) 
Neutrophils (%) 60.9 (2 1 .6 - 84.9) 59.7 ( 1 5 .6 - 94.0) 
Macrophages (%) 34. 1 ( 1 3 . 1  - 76.5) 3 6.3 (4.9 - 82.5) 
Eosinophils (%) 1 .4 (0.0 - 5 .7) 0.8 (0.0 - 38.6) 





33  (79%) 
0.37 (0. 14 - 3 .86) 
55 .8 ( 1 6.8 - 88.8) 
3 5 . 1  (9. 1 - 66.7) 
1 .2 (0.0 - 67. 1 )  
0 . 3  (0.0 - 5 .7) 
Values are medians (ranges). No significant differences between controlled versus uncontrolled groups, or 
between totally controlled versus wel l  controlled. Absolute numbers of inflammatory cells in sputum were also 
similar between the three groups. 
TABLE E3: REMODELING IN BRONCHIAL BIOPSIES 
Epithelium Goblet cells (N) 
Mucus (%) 
Intact epithelium (%) 
Basal epithelium (%) 
Denuded BM (%) 
Metaplasia (%) 
Thickness (µm) 
Ki67+ (% intact) 
Ki67+ (% basal) 
Submucosa Collagen 3 (%) 
Values are medians (ranges). N=number 




Totally controlled Well controlled 
(n= l 9) (n=33) 
37 (4-85) 35 (2-92) 
8 (0.8-2 1 .2) 13  (0.9-33 .9) 
13 (0-32.8) 10.5  (0-65 .3) 
37.2 ( 14.7-74.3) 40.9 (5 . 1 -80.2) 
16 (0-58 .8) 9.6 (0.7-47.6) 
0 (0-26.2) 0 (0- 1 8 .2) 
1 7.3 ( 1 1 .2-36.8) 20.4 (7.5-9 1 .4) 
5 . 1 (0.4- 1 1 .2) 4.4 (0.9-20. 1 )  
2.7 (0-8 .5) 5 . 1  (0.4-28.9) 





39 (9- 1 1 9) 
9.4 (0.2-46. 1 )  
5 . 6  (0-47.6)* 
42.5 ( 1 8.5-72.2) 
17 .5  (2. 1 -63 .2) 
0 (0- 19.4) 
17 .6 (7 .9-48. 1 )  
4.0 (0- 1 5 .5) 
3.8 (0-25.5) 
42 ( 15 .5-64.9) 
Summary a nd Discussion  
Chapter 8 
T he aim of this thesis was to gain more insight in processes underlying progression 
and remission of asthma. T he research was focussed on inflammation and remodeling,  
effects of  smoking, and surrogate markers of  asthma control. 
REMISSION OF ASTHMA 
To investigate if remission of asthma really exists we tested markers of airway 
inflammation and remodeling in steroid naive, non-smoking subjects meeting the criteria 
for complete asthma remission. Complete asthma remission was defined by absence of 
asthma symptoms and medication, combined with a normal lung function and absence 
of bronchial hyperresponsiveness. 
We compared inflammatory cells in induced sputum in current asthmatics and former 
asthmatics who had complete remission (Chapter 2). No differences in sputum 
inflammatory cell percentages were found between both groups. T his lack of difference 
may have been caused by the mild disease in the current asthma group that was 
responsive to histamine but nevertheless did not use inhaled steroids. Interestingly, we 
found differences between subjects with current asthma and complete asthma remission 
when percentages of sputum inflammatory cells after AMP provocation were compared. 
A significant increase in the percentage of sputum eosinophils was observed in current 
asthmatics, even in those without hyperresponsiveness to AMP, i.e. in the situation 
that they inhaled comparably high concentrations of AMP as those who had asthma in 
complete remission and hence no response to AMP. In contrast, no increase in sputum 
eosinophils was found in subjects meeting criteria for complete asthma remission. 
Although group sizes were relatively small, the lack of induction of sputum eosinophilia 
by the AMP provocation in this group was promising as to our concept of complete 
asthma remission. It was therefore a logical and important step for the study to assess 
if subjects meeting the criteria for complete asthma remission really had outgrown their 
asthma, as shown by normal airway wall tissue. 
In the third chapter, the concept of complete asthma remission was further investigated 
with the addition of bronchial biopsy data. A larger group of individuals meeting the criteria 
for complete asthma remission was included. Subjects with complete asthma remission 
were compared with subjects in clinical remission, i.e. asthmatics without asthma 
symptoms or medication, and with subjects having current asthma. T his time, smokers 
were included as well. In the group with current asthma, both subjects with and without 
inhaled corticosteroid use were investigated. T he first main finding was that eosinophil 
numbers were significantly lower in bronchial biopsy tissue and in peripheral blood in 
the group with complete asthma remission. Just as observed in the second chapter, no 
differences in sputum eosinophil percentages were found. T he second important finding 
was that basement membrane thickness was comparable in complete and clinical asthma 
remission. In contrast, subjects with current asthma using inhaled corticosteroids had 
reduced basement membrane thickness. T his finding is in line with previous studies 
showing that inhaled corticosteroids reduce basement membrane thickness(1;2) . 
Thus, it seems that complete remission of asthma does exist in the context of remaining 
remodeling features, given the observed persistence of basement membrane thickening. 
It is intriguing that, in our study, loss of bronchial hyperresponsiveness exists despite the 
presence of this remodeling marker. It is thus likely that active eosinophilic inflammation 
with associated epithelial damage, edema and a primed stated of the inflammatory 
response system contributes more to bronchial hyperresponsiveness than basement 
membrane thickness itself. T his is supported by the higher eosinophil peroxidase (EPX) 
immunopositivity in the airway wall of current asthmatics, which we found. Additionally, 
differences in the volume of airway smooth muscle or the absence of activated mast 
cells between smooth muscle bundles could have contributed to loss of bronchial 
hyperresponsiveness in complete remission of asthma. T hese differences were not 
further investigated in our studies. 
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AMP RESPONSIVENESS 
In chapter two and chapter four we investigated the characteristics of current asthma 
patients with respect to presence or absence of AMP responsiveness. In chapter two we 
noticed that current asthma patients who were hyperresponsive to histamine but not 
to AMP showed less increase in sputum eosinophil percentages after an AMP challenge 
compared to asthma patients who were responsive to both provocation tests. This 
increase in eosinophil percentage was significantly higher in AMP responsive asthmatics 
despite inhaling a lower cumulative dose of AMP as compared to AMP unresponsive 
asthmatics. The prevalence of atopy was significantly higher in AMP responsive subjects, 
as well as the level of atopy as assessed by the Phadiatop test. 
In chapter four we showed that eosinophils were significantly more present in bronchial 
biopsies from the AMP responsive group. Additionally, the basement membrane was 
thicker in AMP responsive asthmatics. More severe AMP responsiveness was associated 
with higher percentages of eosinophils in the airway wall, whereas the number of mast 
cells in bronchial submucosa was similar between both groups. Likewise, the severity of 
AMP responsiveness and basement membrane thickness were significantly correlated. 
However, a direct causal relation between the latter two is uncertain, since both could 
well be markers of increased (eosinophilic) airway inflammation. 
To our knowledge, the study described in chapter is the first investigating bronchial 
biopsies in relation to AMP responsiveness. In our small group of asthma patients 
we show that a positive AMP responsiveness is not only related to markers of airway 
inflammation like elevated eosinophils in sputum and higher EPX immunopositivity in 
bronchial mucosa, but also to markers of airway remodeling like metaplastic epithelium 
and increased basement membrane thickness. This could imply that positive AMP 
responsiveness in asthma patients may be an extra factor in the decision for treatment 
with inhaled corticosteroids. First, because positive AMP hyperresponsiveness is 
associated with increased eosinopinilic inflammation and active remodeling, and second 
because this same eosinophilic type of inflammation is usually associated with a good 
response to corticosteroids. 
Another important observation in these chapters was made in asthma patients who are 
unresponsive to AMP, despite a positive response to histamine. These AMP unresponsive 
asthmatics had lower eosinophilic inflammation, less thickening of basement membrane 
and less metaplastic epithelium compared to AMP responsive asthmatics. This observation 
could imply that unresponsiveness to AMP is a marker of mild inflammatory asthmatic 
disease. However, not all AMP unresponsive individuals show this low eosinophilic 
inflammation and remodeling. Thus, further research is needed to determine if absence 
of AMP responsiveness also has clinical consequences for individual asthma patients. 
DECLINE IN LUNG FUNCTION 
In chapter five, we compared asthma patients meeting the clinical criteria for complete 
asthma remission with current asthma patients having either slow or fast decline in 
lung function. Slow decline was arbitrary defined as < 30 ml/year decline in FEVl and 
fast decline as > 30 ml/year. In patients with complete asthma remission the mean 
decline in lung function was very small, only 8 ml/year. Current asthma patients with a 
slow decline in FEVl had a mean decline of 18.6 ml/year and those with a fast decline 
50.3 ml/year. Current asthma patients with a fast decline in FEVl, had more severe 
hyperresponsiveness to AMP, more eosinophilia in blood and sputum, and higher sputum 
ECP levels compared to slow decliners and the complete remission group. However, 
in bronchial biopsies, no differences were foud in inflammatory cells and markers for 
remodeling. 
Sputum eosinophilia and ECP were significantly correlated with an accelerated decline 
in FEV1. A positive association between blood eosinophils and FEVl decline in asthma 
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has been described earlier(3). In contrast, the present study showed no association 
between an accelerated decline and the number of airway wall eosinophils and basement 
membrane thickness. Both latter findings are in line with observations by Van Rensen 
et al. In a 7. 5-year follow-up study in 32 asthma patients, no association was found 
between annual decline in post-bronchodilator FEVl and thickness of the reticular layer 
or eosinophil counts in bronchial biopsies( 4 ). Thickening of the basement membrane 
is already observed in childhood asthma and to a similar extent as seen in adults with 
asthma( S). Thus, basement membrane thickening may be an early feature of asthmatic 
airway remodeling, yet it seems to be unrelated to decline in FEVl in asthma. 
A possible explanation for the lack of association between inflammatory cells in bronchial 
mucosa and an accelerated decline in lung function is the following. An accelerated 
decline in FEVl may be associated with increased recruitment of eosinophils from the 
bone marrow to the blood. Possibly, these eosinophils move straight from the blood to 
the luminal space of the lung and they are possibly not retained in the airway wall e.g. 
due to epithelial damage. In other words: bronchial biopsies give only a snap-shot of the 
cellular composition of the airway wall which is not identical to the traffic of inflammatory 
cells through the airway wall. 
Together, our findings support the importance of measuring sputum eosinophils in asthma 
in being a predictor for accelerated decline in FEV1. In line with findings described above, 
treatment with inhaled corticosteroids should be seriously considered in these patients. 
ASTHMA AND SMOKING 
In chapter six we investigated effects of smoking in a large group of asthma patients, 
including smokers, ex-smokers, and never-smokers. Research was focused on symptoms, 
inflammation and markers of remodeling. We found that cigarette smoking was associated 
with airway remodeling and that this airway remodeling correlated with the severity of self­
reported asthma symptoms. Eosinophil numbers were decreased and mast cell numbers 
increased in current smokers compared to never smokers. Interestingly, ex-smokers did 
not have increased airway remodeling and mast cell numbers were significantly lower 
than in current smokers. Surprisingly, airway remodeling and mast cell numbers were 
similar to never-smokers, which suggests that smoke induced damage can be reversed 
when patients q uit smoking. 
The main difference between ex-smokers and never-smokers was the increased number 
of eosinophils in never-smokers compared to both other groups. In ex-smokers, the 
number of eosinophils was positively correlated with the duration of smoking cessation . 
This suggests that the down-regulatory effect of smoking on the number of eosinophils 
disappears after smoking cessation. 
ASTHMA CONTROL, INFLAMMATION AND QUALITY OF LIFE 
Markers of asthma control, inflammation and quality of life were integrated in chapter 
seven. A total of 69 asthma patients with controlled asthma (total and well control 
according to GOAL criteria) were compared to 42 asthma patients with uncontrolled 
asthma. We showed that patients with controlled asthma had lower median blood 
eosinophil numbers, slope of hyperresponsiveness to AMP, and alveolar nitric oxide 
levels than the subjects with uncontrolled asthma. Biopsies from subjects with controlled 
asthma had fewer eosinophilic granules, and more intact epithelium than uncontrolled 
subjects. These findings are very important, because the use of the clinical definition of 
asthma control by GOAL criteria is now supported by lower inflammation and remodeling 
in bronchial biopsies. 
Health-related q uality of life in our patients with controlled asthma was significantly 
better than in those with uncontrolled asthma. As the difference between the two groups 
was higher than the minimal, clinically important, difference of 0. 5 point, it is also more 
attractive from a patients' perspective to aim for a better level of control. 
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fUTURE PERSPECTIVES 
An important observation in our studies that needs to be investigated further is the 
persistent basement membrane thickening in patients meeting the clinical criteria for 
complete asthma remission. Is this thickening just a marker of damage that has occurred 
in the past or also an indicator of future relapse of asthma? Longitudinal follow-up studies 
are required in this group of asthma patients who are in objective clinical remission. If 
relapse does not occur and decline in lung function is comparable to that found in healthy 
controls, it may be possible to refrain from treating them with corticosteroids because 
the treatment has no clinical consequences. However, if relapse does occur and/or the 
decline in lung function is increased in (a subgroup of) these patients, further clinical 
follow-up and treatment is needed. 
Another interesting finding is the observation that some steroid-na'ive asthma patients 
are unresponsive to AMP, despite being hyperresponsive to histamine. These AMP 
unresponsive asthmatics had lower eosinophilic inflammation in sputum and bronchial 
mucosa, less thickening of basement membrane and less meta plastic epithelium compared 
to AMP responsive asthmatics. This observation could imply that there is less need for 
treatment with corticosteroids in AMP unresponsive asthmatics. Clearly further studies 
are needed to prove this concept in larger cohorts and also to gather longitudinal data 
in this specific group of asthma patients. Also, longitudinal studies will have to elucidate 
whether AMP unresponsiveness in asthma indicates an intermediate state between 
asthma and asthma remission and which factors drive to remission or persistence. 
In our studies, the presence of a positive hyperresponsiveness test to AMP in steroid­
na'ive asthma patients was associated with eosinophilic inflammation, thickened 
basement membrane and faster decline of lung function. These findings implicate that 
steroid-na'ive asthma patients with hyperresponsiveness to AMP are at risk for pulmonary 
damage. Since eosinophilic inflammation usually responds well to treatment with inhaled 
corticosteroids, this treatment should be given to these patients. It would be interesting 
to investigate if the dose of inhaled corticosteroids can be titrated according to bronchial 
hyperresponsiveness to AMP. If so, AMP guided therapy should be compared to other 
markers of airway inflammation used for treatment guidance, as hyperresponsiveness 
to methacholine(l), inflammatory cells in induced sputum(6), and levels of exhaled 
N0(7) . 
Another interesting question is if treatment with inhaled corticosteroids affects the 
decline in lung function in this group of patients. Lange et al. found that treatment 
with res was associated with a decreased decline in of FEVl in both women and men, 
as well as in non-smokers and smokers in a 10-year follow up study(8). In contrast, 
in a 23-year follow-up study, Dijkstra et al. found that treatment with res was only 
associated with a reduction in the decline in FEVl in men who had smoked less than 5 
pack years. No effect on decline in FEVl was found in women or in men with >5  pack 
years of smoking(9). We hypothesize that treatment with inhaled corticosteroids reduces 
the decline in FEVl in AMP responsive and steroid na'ive asthma patients, because in 
our study AMP responsiveness was associated with eosinophilic inflammation and an 
accelerated decline in FEVl. Prospective, longitudinal studies could investigate if this 
hypothesis is valid. 
Our study on smoking and asthma contributed to better understanding the link between 
smoking induced changes in the airway wall and symptoms of asthma. We found 
that cigarette smoking increased airway remodeling and that this airway remodeling 
correlated with self-reported asthma symptoms. Also, an important finding was that 
these smoking induced changes may well be reversible after cessation of smoking. Thus, 
longitudinal studies are needed to investigate the effects of smoking cessation on decline 
of lung function in this group of asthma patients. Does the decline in lung function 
decrease to levels observed in never-smoking asthma patients, or to levels found in 
healthy controls? 
It is also interesting to test if ex-smokers restore responsiveness to treatment with 
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inhaled corticosteroids, as steroid resistance is a known problem in asthma patients who 
smoke( l O). Chaudhuri et al. also found, in a small group of 10 ex-smokers with asthma, 
that peak expiratory flow levels increased after treatment with oral corticosteroids, 
which supports reversibility of steroid resistance(10). More research should increase 
our understanding of steroid unresponsiveness in asthmatic smokers and perhaps 
reversibility of responsiveness after smoking cessation. It would be interesting to 
compare factors associated with steroid unresponsiveness as increased glucocorticoid 
receptor 13 expression, increased histone deacetylase-2 activity and increased expression 
of nuclear factor KB(11) between ( our) groups of never-smokers, ex-smokers and current 
smokers. 
In non-smoking asthmatics, eosinophilic inflammation is associated with steroid 
responsiveness. Treatment with steroids in these patients reduces the numbers of 
eosinophils and decreases asthma symptoms(6). In contrast, smoking in asthma also 
decreases eosinophil numbers, but is associated with increased inflammation, remodeling 
and an increase in asthma symptoms(11). Thus, suppression of the number of eosinophils 
can not explain the different effects on the clinical expression of asthma. Possibly, 
bacterial lipopolysaccharide ( LPS) in cigarette smoke increases airway inflammation, 
because LPS is a known activator of nuclear factor KB(12). Probably, LPS and other 
compounds in inhaled cigarette smoke change the lower airways epithelium into a 
different pathological phenotype. Indeed, in our study smokers had more goblet cells, 
mucous positive epithelium, more epithelial proliferation, and a thicker epithelial layer 
compared to never-smokers. These changes in the airway epithelium may also increase 
airway m ucosa! permeability. Together with increased mucous production this may impair 
the deposition of inhaled antigens as well as corticosteroids within the airways. Thus, 
further investigation of smoke induced changes of the airway epithelium in asthma may 
well add to our understanding of steroid unresponsiveness in this group of patients. 
In asthma, it is suggested that a structurally and functionally defective lower airway 
epithelium underlies abnormal responses to the inhaled environment leading to enhanced 
signalling between the airway epithelium and underlying structural and immune cells. 
Activation of this epithelial-mesenchymal trophic unit might also be responsible for 
tissue remodeling(13). Further research on this epithelial-mesenchymal trophic unit 
could increase our understanding of the different courses of asthma, e.g. stable disease, 
progression or remission, relapse, and responses to environmental factors as cigarette 
smoke. 
It would be interesting to know if epithelial integrity restores in asthma remission. Is there 
still increased epithelial shedding? Are the epithelial tight junctions intact? Additionally, 
can we find markers for chronic repair in asthma remission? What is the expression of 
CD44 or the epithelial growth factor receptor (EGFR)? Are markers for cell proliferation 
as Ki-67 and proliferation cel l  nuclear antigen ( PCNA) reduced? Comparison between 
asthma remission and healthy controls should be made. If longitudinal studies show 
that relapse occurs in a subgroup of patients with complete asthma remission, further 
research may reveal which factors can identify patients who really are in remission or not. 
Maybe, the absence or presence of markers for chronic epithelial inflammation and repair 
can discriminate between patients in real remission and patients at risk for relapse. 
The same factors for epithelial integrity and chronic repair in combination with alterations 
in mesenchymal stroma might help to understand differences between current- and ex­
smokers, and an accelerated decline in lung function. The nature of the matrix that 
surrounds airway smooth muscle probably plays a role in differences in decline of lung 
function. Comparing bronchial smooth muscle and matrix proteins as, i.e. collagens, 
fibronectin, elastin, tenascin, decorin, and laminin, may increase our understanding of 
the different courses of asthma as found in our cohorts. 
Genetic studies may add to our understanding of the heterogeneity of asthma. Also in 
our studies, large individual differences in airway inflammation and remodeling were 
found, even within clinically well-defined subgroups. Genetic studies in these subgroups, 
like asthma in remission, progressive asthma, severe corticosteroid insensitive asthma, 
and asthma with systemic inflammation, may gain more insight into which genetic and 
environmental risk factors contribute to the course of asthma over a life span. The 
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current improvements in the application of genome-wide association scans, genome­
wide expression, microRNA studies, and new epigenetic insights will undoubtedly result 
in a substantial step forward to understand the mechanisms underlying asthma(14). 
Our results suggest that aiming for clinical control of asthma indeed is associated with 
suppression of the underlying airway inflammation. We found that PC20AMP, eosinophils, 
and epithelial integrity were independent factors contributing to the level of asthma 
control in our cross-sectional study. Randomized intervention studies with a longitudinal 
study design are needed to further demonstrate a more causal and specific relationship 
between these markers of inflammation and asthma control. The health-related q uality 
of life in patients with controlled asthma was significantly better than in those with 
uncontrolled asthma. In contrast to a previous study(15)( , we found a significantly higher 
percentage of ICS users and dose of ICS used in the uncontrolled group. An "unhealthy 
ICS" effect may well have been present in our study since it is well-known that some 
asthmatics do not respond well to corticosteroids(16; 17). Longitudinal studies could further 
investigate which surrogate markers for asthma control and/or airway inflammation can 
predict responsiveness to treatment with inhaled corticosteroids. Possibly, there may 
also be a role for the "electronic nose" in assessing asthma control in the future. T he 
electronic nose analyses volatile organic compounds in exhaled breath. Recently, using 
32 sensors, the electronic nose was able to discriminate patients with asthma fro m  
controls, but was less accurate i n  distinguishing asthma severities (18) . Treatment with 
inhaled corticosteroids should be recommended in patients with uncontrolled asthma 
and combined with interventions to improve medication adherence. Which interventions 
are best in improving medication adherence are still not clear(19) . If the use of inhaled 
corticosteroids can be increased in patients who are likely to respond to this treatment, 
we may expect a further increase in quality of life, a decrease in the number of asthma 
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H ET BELOOP VAN ASTMA 
Astma is een chronische ontsteking van de luchtwegen en gaat vaak gepaard met 
een wisselende vernauwing van de luchtwegen. Bij patienten met (chronisch) astma 
kunnen de klachten leiden tot een verminderde kwaliteit van leven. De astmaklachten 
worden waarschijnlijk veroorzaakt door toegenomen activiteit van ontstekingscellen in 
de luchtwegen. Deze ontstekingscellen scheiden verschillende stoffen uit en deze zorgen 
o.a .  voor luchtwegvernauwing en toegenomen slijmproductie. Tegelijkertijd zorgt deze 
chronische ontstekingsreactie voor veranderingen in de luchtwegwand en omringend 
weefsel zoals verlittekening ,  verdikking van spierweefsel en groei van nieuwe bloedvaten. 
Uiteindelijk kunnen deze processen leiden tot blijvende schade en continue vernauwing 
van de luchtwegen. Hiertegenover staat dat sommige 
astmapatienten over hun astma heen lijken te groeien en na verloop van tijd geen 
klachten meer aangeven terwijl ze geen astmamedicijnen meer gebruiken. Dit wordt wel 
remissie van astma genoemd. Of remissie van astma echt bestaat is onduidelijk. 
Bij eerdere onderzoeken naar remissie van astma werd nog vaak toegenomen ontsteking 
in de luchtwegen gevonden. Ook reageerden de luchtwegen van deze patienten nog vaak 
met luchtwegvernauwing op ademhalingstesten, dit wordt ook wel overgevoeligheid 
van de luchtwegen genoemd. Deze bevindingen suggereren dat bij (een deel van) 
deze mensen toch nog steeds astma aanwezig is. Eerder is bedacht om deze patienten 
zonder klachten verder onder te verdelen in een groep met patienten zonder medicijnen 
en klachten, maar wel met luchtwegafwijkingen. Dit zijn patienten in klinische astma 
remissie .  De andere groep heeft ook geen medicijnen en klachten, maar daarnaast ook 
geen functionele luchtwegafwijkingen. Deze patienten zijn in complete astma remissie. 
Of complete remissie ook betekent dat er geen ontsteking van de luchtwegen meer is, 
werd niet eerder onderzocht. 
f ACTOREN DIE VAN INVLOED ZIJN Bil HET BELOOP VAN ASTMA 
Er is nog steeds weinig bekend over factoren die bepalen of astma in ernst zal toenemen 
of juist zal verbeteren. Het lijkt er op dat de duur van astma belangrijker is voor het 
ontstaan van permanente schade aan de luchtwegen dan de leeftijd van de patient. Eerdere 
studies hebben meerdere risicofactoren laten zien voor een versnelde achteruitgang in 
longfunctie zoals een matige longfunctie op jonge leeftijd, matige reactie op medicijnen 
die de vernauwing van de luchtwegen moeten tegengaan (beta-agonisten) ,  toegenomen 
overgevoeligheid van de luchtwegen, toegenomen slijm productie, mannelijk geslacht 
en roken. 
Een aantal van deze risicofactoren is ook gerelateerd aan veranderingen in de 
luchtwegwand en ontsteking zoals een dikkere luchtwegwand, een dikker basaal 
membraan, verlittekening van de luchtwegen, toename van aantal en grootte van de 
slijmbekercellen en het aantal (eosinofiele) ontstekingscellen in het bloed. 
Aan de andere kant blijkt in lange studies dat soms tot 25% van de astmapatienten 
over hun ziekte heen lijkt te groeien. Een jongere leeftijd bij het van ontstaan van 
astma, het hebben van een vrijwel normale longfunctie en weinig overgevoeligheid van 
de luchtwegen zijn geassocieerd met verdwijnen van astma en van de overgevoeligheid 
van de luchtwegen op latere leeftijd. 
Om het beloop van astma te kunnen bepalen, is meting van longfunctie belangrijk. 
Bij de bepaling van de longfunctie is van belang te weten dat de longfunctie steeds 
toeneemt tot het bereiken van een plateaufase op ± 20 jarige leeftijd en vanaf ± 30 
jaar weer afneemt. De longfunctie die we vaak gebruiken is de FEV1 waarde, te weten 
de hoeveelheid lucht die een astmapatient na volledige inademing binnen 1 seconde kan 
uitblazen. Dit is een maat voor de hoeveelheid vernauwing van de luchtwegen. 
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ONTSTEKING VAN DE LUCHTWEGEN 
Astma wordt gekenmerkt door ontsteking van de luchtwegen waarbij veel cellen 
een rol spelen. Dit zijn o.a. epitheelcellen (binnenbekleding van de luchtwegen), 
endotheelcellen (binnenbekleding van bloedvaten), fibroblasten (cellen in staat tot 
vorming van littekenweefsel), zenuwen en verschillende typen ontstekingscellen zeals 
eosinofiele cellen en mestcellen. In de luchtwegen van astmapatienten ontstaat een 
ontstekingsreactie, bijvoorbeeld na inademen van pollen in de lucht, die een allergische 
reactie oproepen. Deze ontstekingsreactie veroorzaakt uiteindelijk schade aan de 
luchtwegen. De allergische reactie begint over het algemeen vanuit mestcellen die 
geactiveerd raken door allergische prikkels. De mestcellen stoten dan allerlei stofjes 
uit (o.a. histamine, prostaglandine) die op hun beurt zorgen voor luchtwegvernauwing, 
slijmsecretie en zwelling van de luchtwegwand. Ook eosinofiele ontstekingscellen raken 
hierdoor geactiveerd waardoor hun aantal toeneemt in de long. Geactiveerde eosinofiele 
ontstekingscellen stoten stoffen uit die in staat zijn de luchtwegwand te beschadigen. 
De gevoeligheid van allergische prikkels wordt mogelijk ook verhoogd door veranderingen 
in de epitheelcellen bij astmapatienten. Mogelijk is de laag epitheelcellen overgevoelig 
voor allergische prikkels en zorgt op zichzelf via uitstoot van stofjes (cytokinen) voor een 
toegenomen ontstekingsreactie. Ook is bekend dat de laag epitheelcellen in de longen van 
astmapatienten niet geheel sluitend is en dat via openingen in deze laag (allergische) 
stoffen makkelijker de (ontstekings)cellen in de long kunnen prikkelen. De gedachte is 
dat door voortdurende prikkeling, het epitheel uiteindelijk terechtkomt in een continue 
staat van ontsteking welke uiteindelijk zorgt voor blijvende schade aan de luchtwegen. 
Deze schade uit zich o.a. door een veranderde samenstelling van de luchtwegwand. 
VERANDERINGEN VAN DE LUCHTWEGWAND 
Onderzoek bij patienten met ernstig astma heeft aangetoond dat ernstig astma 
gekarakteriseerd wordt door een toegenomen dikte van de luchtwegwand in vergelijking 
tot milder astma. Factoren die geassocieerd warden met een dikkere luchtwegwand zijn 
o.a. meer slijmbekercellen, onrustige epitheelcellen, een dikker basaalmembraan (laagje 
weefsel ender de epitheelcellen), verlittekening, dikkere luchtwegspieren, toegenomen 
aantal bloedvaten en veranderingen in de kleinere luchtwegen (richting longblaasjes). 
ASTMA EN R0KEN 
In Nederland werd in een jonge groep astmapatienten met een gemiddelde leeftijd van 
24. 7 jaar gevonden dat 33% rookte ! Dit percentage is hoog en vergelijkbaar met het 
aantal rokers in de algemene bevolking. Het beloop van astma wordt namelijk negatief 
be'invloed door roken. In vergelijking met niet rokende astmapatienten, hebben rokers 
meer astmasymptomen, meer astma aanvallen, meer ziekenhuisopnames door astma, 
een versnelde achteruitgang van longfunctie en meer sterfte door astma. Roken zorgt 
ook voor meer ontsteking in de long. Deze ontsteking is qua type deels vergelijkbaar met 
niet rokende astmapatienten, maar kent ook verschillen zeals een grater aantal andere 
typen ontstekingscellen zeals neutrofiele granulocyten en macrofagen. Belangrijk is ook 
dat roken bij astmapatienten leidt tot meer veranderingen in de samenstelling van de 
luchtwegwand dan bij niet-rokende astmapatienten. 
Momenteel is weinig bekend over de mechanismen die verantwoordelijk zijn voor 
de slechte uitkomst van astma door roken. Dit komt omdat in veel studies rokende 
astmapatienten warden uitgesloten omdat ze soms ook longemfyseem hebben. 
BEPALEN VAN DE MATE VAN 0NTSTEKING IN DE LUCHTWEGEN 
De mate van ontsteking in de luchtwegen is rechtstreeks te meten door biopten 
(kleine hapjes) uit de luchtwegwand te nemen via een kijkonderzoek van de longen 
(bronchoscopie). Dit is echter voor patienten een belastend onderzoek en daardoor 
niet geschikt om de behandeling van astma te sturen. Een aantal indirecte metingen 
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wordt gebruikt om een inschatting te maken van de hoeveelheid ontsteking van de 
luchtwegen. 
M ETING VAN LUCHTWEGOVERGEVOELIGH EID DOOR INADEMEN VAN HISTAMINE OF 
M ETHACHOLIN E 
Histamine en methacholine zorgen rechtstreeks voor samentrekken van de spieren 
rondom astmatische luchtwegen en zorgen zo voor luchtwegvernauwing. Bij deze test 
wordt histamine of methacholine ingeademd door de patient. Begonnen wordt met 
een hele lage dosis en deze wordt geleidelijk verhoogd. Na elke dosis wordt de FEV1 
gemeten. Als de FEV1 met 20% is gedaald en de luchtwegen dus fors vernauwd zijn 
geraakt wordt de test beeindigd. De patient krijgt dan een medicijn (beta-agonist) 
om de luchtwegen weer te verwijden. Hoe sneller de luchtwegen vernauwd raken, en 
dus bij een lagere dosis histamine of methacholine, hoe overgevoeliger de luchtwegen 
zijn. Uit eerdere studies is gebleken dat de mate van overgevoeligheid voor histamine 
of methacholine gerelateerd is aan de mate van ontsteking van de luchtwegen. Deze 
relatie is echter niet heel sterk en matig gevoelig voor veranderingen in de intensiteit 
van ontsteking in de luchtwegen. 
M ETING VAN LUCHTWEGOVERGEVOELIGH EID DOOR INADEMEN VAN ADENOSINE-'5-
MONOPHOSPHATE (AM P) 
Net als met histamine of methacholine kan de overgevoeligheid van luchtwegen ook 
gemeten warden aan de hand van inademingstesten met AMP. Ook nu wordt begonnen 
met een inademen van een lage dos is en kijkt men bij welke dosis de met FEV1 met 20% 
is gedaald. In tegenstelling tot histamine of methacholine werkt AMP niet rechtstreeks 
op de spieren random de luchtwegen. AMP valt na inademing uiteen tot adenosine en 
adenosine op zijn beurt activeert mestcellen. Een geactiveerde mestcel stoot ender 
andere histamine uit wat dan weer zorgt voor samentrekken van de spieren random 
astmatische luchtwegen. Uit eerder onderzoek is gebleken dat de inademingstest met 
AMP, beter dan de inademingstest met histamine of methacholine, de hoeveelheid 
ontsteking in de luchtwegen van astmapatienten weergeeft. Ook verandert de 
gevoeligheid voor inademing van AMP sneller bij veranderingen in de hoeveelheid 
ontsteking in de luchtwegen, bijvoorbeeld na inademing van ontstekingsremmende 
medicijnen. 
M ETING VAN DE HOEVEELHEID STIKSTOF MONO-OXIDE (NO) IN DE UITADEMINGSLUCHT 
Bij ontstekingsprocessen wordt NO geproduceerd. NO komt bij ontsteking in de long 
vrij in de uitademingslucht en kan gemeten warden. Eerdere studies hebben laten zijn 
dat de ernst van astma samen gaat met de hoeveelheid uitgeademd NO. Ook daalt de 
hoeveelheid NO in de uitademingslucht na behandeling met ontstekingsremmers. Er 
is in eerdere studies geprobeerd de behandeling van astma met ontstekingsremmers 
te sturen aan de hand van de hoeveelheid NO in de uitademingslucht. Slechts 1 van 
de 6 studies liet hiervan positieve resultaten zien 
ONTSTEKINGSCELLEN IN LUCHTWEGSLIJM 
Het is mogelijk onstekingscellen te meten in opgehoest slijm uit de longen. Dit 
gebeurt door astmapatienten enige minuten een nevel van zout water in te laten 
ademen. Dit zoute water trekt in de long ontstekingscellen aan, zodat na ophoesten 
deze ontstekingscellen gemeten kunnen word en. Ee rd ere studies hebben laten zien 
dat de behandeling van astma met ontstekingsremmers te sturen is aan de hand van 
de hoeveelheid eosinofiele ontstekingscellen in het luchtwegslijm. Deze gestuurde 
behandeling leidde tot minder astma-aanvallen en ziekenhuisopnames dan in de 
controlegroep. Ook bij onderzoek met behulp van biopten bleek de ontsteking in de 
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luchtwegwand duidelijk minder bij de gestuurde behandeling dan bij de controlegroep. 
ASTMA CONTROLE 
In de ( GINA) astma richtlijnen van 2006 wordt benadrukt dat controle van de ziekte 
astma heel belangrijk is. Patienten moeten zo min mogelijk astmasymptomen hebben, 
daarnaast geen astma-aanvallen, geen achteruitgang van longfunctie en zo weinig 
mogelijk bijwerkingen van de astmamedicijnen. The GOAL (Gaining Optimal Asthma 
control) studie in 2004 heeft met behulp van het bijhouden van dagboekjes met daarin 
astmaklachten, de frequentie van gebruik van luchtwegverwijders en een simpele 
longfunctietest, geprobeerd controle van astma te definieren en zo de behandeling van 
astma te verbeteren. Als patienten te veel astmasymptomen hadden, werd de medicatie 
aangepast met het doel bij zo veel mogelijk patienten controle van astma te bereiken. 
Voor een groot aantal patienten in deze studie bleek het inderdaad mogelijk om zo hun 
astma onder controle te krijgen. 
Er zijn ook een aantal vragenlijsten beschikbaar die de mate van astma controle 
kunnen meten. Deze vragenlijsten zijn de asthma controle questionnaire {ACQ), de 
asthma related quality of life questionnaire {AQLQ) en de asthma control test {ACT). 
Er is niet goed bekend of meer controle van astma zoals gemeten met een vragenlijst 
ook samengaat met minder ontsteking van de luchtwegen. Wei is eerder een relatie 
gevonden tussen de mate van controle volgens de ACQ vragenlijst en de hoeveelheid 
eosinofiele ontstekingscellen in luchtwegslijm en overgevoeligheid van de luchtwegen 
voor methacholine. Andere studies vonden ook een verband tussen controle volgens 
astma vragenlijsten en de hoeveelheid NO in de uitademingslucht. 
Tot nu toe zijn er geen studies geweest die astma controle volgens vragenlijsten hebben 
vergeleken met de hoeveelheid ontsteking in biopten uit de luchtwegwand. 
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1. Te onderzoeken of ontsteking van de luchtwegen en veranderingen van de 
luchtwegwand verdwenen zijn bij (voormalig) astmapatienten die voldoen aan de 
criteria voor complete astma remissie (Hoofdstuk 2 en 3). 
2. Te onderzoeken of er verschillen bestaan in ontsteking van de luchtwegen en 
veranderingen van de luchtwegwand tussen astmapatienten die adenosine-5'-mono 
phoshate (AMP) gevoelig of ongevoelig zijn (Hoofdstuk 4). 
3. Te onderzoeken of er verschillen bestaan in ontsteking van de luchtwegen en 
veranderingen van de luchtwegwand tussen astmapatienten in remissie en 
astmapatienten met een trage en snelle achteruitgang van longfunctie 
(Hoofdstuk 5). 
4. Te onderzoeken welke factoren i n  de luchtwegen een rol spelen bij schade aan de 
luchtwegen van astmapatienten door roken (Hoofdstuk 6). 
5. Te onderzoeken of er een relatie is tussen de (klinische) mate van astmacontrole en 
directe of indirecte metingen van ontsteking in de luchtwegen en veranderingen aan 
de luchtwegwand (Hoofdstuk 7) 
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RESULTATEN VAN DE STUDIES 
REMISSIE VAN ASTMA 
Om te onderzoeken of remissie van astma echt bestaat, hebben we onderzoek gedaan 
naar ontsteking in de luchtwegen en structurele veranderingen in de luchtwegwand. Dit 
hebben we onderzocht bij patienten die geen ontstekingsremmende (astma)medicijnen 
gebruikten ( of hebben gebruikt) en die nooit hebben gerookt. Een grate groep 
astmapatienten die eerder onderzocht was, hebben we opnieuw opgeroepen om te 
zoeken naar patienten die voldeden aan de criteria van complete astma remissie. De 
criteria voor complete astma remissie zijn : geen astmaklachten, geen astmamedicijnen, 
geen permanente vernauwing van de luchtwegen en geen overgevoelige luchtwegen. 
Deze groep mensen werd vergeleken met astmapatienten die nag wel overgevoelige 
luchtwegen hadden. Beide groepen ondergingen de AMP ademtest. Van deze test weten 
we dat als we overgevoelige luchtwegen bij astmapatienten gaan prikkelen door AMP 
in te laten ademen, dit leidt tot een ontstekingsreactie in de long en daarnaast tot 
luchtwegvernauwing . 
In hoofdstuk 2 hebben we vergeleken of ontstekingscellen in luchtwegslijm oak 
verschilden tussen patienten die nag steeds astma hadden en patienten die over hun 
astma heengegroeid leken en voldeden aan de criteria van complete astma remissie. 
De ontstekingscellen werden vergeleken voor inademen van AMP en na inademen van 
AMP. We vonden dat er voor inademen van AMP geen verschil was in de hoeveelheid 
ontstekingscellen tussen de beide groepen. Echter, na het inademen van AMP zag 
je een toename van ontstekingscellen in de groep astmapatienten met nag steeds 
overgevoelige luchtwegen, maar niet bij de patienten met de kenmerken van complete 
astma remissie. 
Hierin vonden we ondersteuning voor de gedachte dat bij vroegere astmapatienten die 
over hun astma heengegroeid leken en daarnaast geen overgevoelige luchtwegen meer 
hadden, oak daadwerkelijk minder ontsteking in de luchtwegen was. Dit zou erop kunnen 
wijzen dat deze groep oak echt volledig over hun astma heengegroeid was. 
In hoofdstuk 3 hebben we complete remissie van astma verder onderzocht. Nu hebben 
we oak gekeken naar ontsteking van de luchtwegwand zelf. Hiervoor hebben we via een 
kijkonderzoek biopten uit de luchtwegwand genomen om deze ender de microscoop te 
onderzoeken. We vergeleken hierbij patienten met complete astma remissie met patienten 
in klinische remissie en patienten met blijvend astma. Oak rokende astmapatienten 
deden nu mee aan deze studie. We vonden dat eosinofiele ontstekingscellen minder 
aanwezig waren in de luchtwegwand en in het bleed van patienten met complete astma 
remissie. Zeals eerder genoemd zijn eosinofiele ontstekingscellen zeer kenmerkend voor 
astma en zorgen door het uitscheiden van stofjes waarschijnlijk voor (veel) schade aan 
de luchtwegen. 
Daarnaast vonden we dat een bepaalde laag van de luchtwegwand, het basaalmembraan, 
net zo dik was bij astmapatienten met complete remissie als bij patienten met blijvend 
astma. Hierbij valt op dat dit kenmerk tussen deze beide groepen wel hetzelfde is, maar 
dat de ene groep (complete remissie) geen overgevoelige luchtwegen meer heeft en de 
andere groep (blijvend astma) wel. We denken dat vooral de ontsteking met eosinofiele 
ontstekingscellen dus bepalend is voor overgevoelige luchtwegen en dus niet zozeer de 
opbouw van de luchtwegwand. 
AMP GEVOELIGH EID 
We weten dat prikkeling van de luchtwegen door inademen van AMP zorgt voor 
luchtwegvernauwing bij de meeste astma patienten. Nu zijn niet alle patienten gevoelig 
voor AMP en is het nag niet goed bekend waardoor dit komt. Om te bewijzen dat onze AMP 
ongevoelige astmapatienten wel degelijk astma hadden, kregen ze een extra ademtest 
met histamine. Van histamine weten we dat eigenlijk elke astmapatient reageert met 
luchtwegvernauwing . Dit was oak bij de AMP ongevoelige astmapatienten in onze studies 
het geval. 
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In hoofdstuk 2 en 4 hebben we onderzoek gedaan naar de kenmerken van astmapatienten 
die wel of niet gevoelig zijn voor AMP. In hoofdstuk 2 vonden we dat AMP ongevoelige 
astma patienten minder eosinofiele ontstekingscellen in luchtwegslijm hadden zitten dan 
AMP gevoelige astmapatienten. Dit verschil was ook significant. Daarnaast waren de AMP 
gevoelige astmapatienten vaker (en meer) allergisch dan AMP ongevoelige patienten. 
In hoofdstuk 4 vonden we dat er meer eosinofiele ontstekingscellen in de luchtwegwand 
waren van astmapatienten die AMP gevoelig waren dan bij astmapatienten die AMP 
ongevoelig waren. Ook de basaalmembraan van de luchtwegwand was dikker bij AMP 
gevoelige patienten. De mate van AMP gevoeligheid nam toe met meer eosinofiele 
ontstekingscellen in de luchtwegwand en daarnaast ook met een dikkere basaalmembraan. 
Ook tussen de hoeveelheid eosinofiele ontstekingscellen in de luchtwegwand en dikte 
van het basaalmembraan was een positief verband. 
Dat AMP gevoeligheid samen gaat met meer eosinofiele ontsteking pleit ervoor dat 
we AMP gevoelige astmapatienten misschien eerder moeten gaan behandelen met 
ontstekingsremmende medicijnen . Ten eerste omdat eosinofiele ontstekking samen lijkt 
te gaan met (blijvende?) veranderingen van de luchtwegenwand. Ten tweede omdat we 
uit eerder onderzoek weten dat patienten met eosinofiele ontstekingscellen vaak geed 
verbeteren na behandeling met ontstekingsremmers. 
Aan de andere kant zagen we dat er bij AMP ongevoelige patienten minder eosinofiele 
ontstekingscellen aanwezig waren en minder verdikking was van de basaal membraan. 
Dit zou kunnen betekenen dat AMP ongevoelige astmapatienten misschien wel een milde 
vorm van astma hebben. Echter de beperkte hoeveelheid ontsteking werd niet bij elk 
individu uit de AMP ongevoelige groep gezien. Dat betekent dat AMP ongevoeligheid 
individueel dus (nog) geen betekenis heeft voor de dagelijkse praktijk. 
ACHTERUITGANG VAN LONG FU NCTIE 
In hoofdstuk 5 hebben we (voormalige?) astmapatienten met complete rem1ss1e 
vergeleken met huidige astmapatienten met een trage ( < 30 ml/jaar) en een snelle ( > 30 
ml/jaar) achteruitgang in longfunctie. In de groep patienten met complete astma remissie 
was de achteruitgang in longfunctie gemiddeld 8 ml/jaar, bij huidige astmapatienten met 
een trage achteruitgang 18.6 ml/jaar en met een snelle achteruitgang 50. 3 ml/jaar. 
Huidige astmapatienten met een snelle achteruitgang in longfunctie waren gevoeliger 
voor AMP en hadden meer eosinofiele ontstekingscellen in bleed en luchtwegslijm in 
vergelijking met de twee andere groepen. Ook leken de eosinofiele ontstekingscellen 
actiever en hierdoor meer in staat tot de uitstoot van, voor de luchtweg, schadelijke 
stoffen. Opvallend was dat we in de luchtwegwand zelf geen verschil konden vinden in de 
hoeveelheid (en soort) ontstekingscellen tussen de drie groepen. Ook de samenstelling 
van de luchtwegwand was idem tussen de drie groepen. 
Over alle groepen gezamenlijk, zagen we dat de mate van achteruitgang van longfunctie 
toenam bij meer eosinofiele ontstekingscellen in luchtwegslijm. 
Mogelijk kan het ontbreken van verschillen in de mate van ontsteking in de luchtwegwand 
zelf tussen de groepen wordt veroorzaakt doordat (eosinofiele) ontstekingscellen 
rechtstreeks van het bleed naar het luchtwegslijm gaan en niet blijven hangen in de 
luchtwegwand. Dit benadrukt het belang van het meten van ontstekingscellen in het 
luchtwegslijm omdat de hoeveelheid van deze cellen in het luchtwegslijm was gekoppeld 
aan een toegenomen achteruitgang in longfunctie. Dus ook de bevindingen uit deze 
studie pleiten voor behandeling met ontstekingsrem mende medicatie bij astmapatienten 
met een toegenomen aantal eosinofiele ontstekingscellen in luchtwegslijm. 
ASTMA E N  ROKEN 
In hoofdstuk 6 hebben we de effecten van roken bestudeerd bij een grote groep 
astmapatienten. We vergeleken rokers met ex-rokers en nooit-rokers. In deze groepen 
hebben we astmasymptomen, ontsteking en veranderingen in de luchtwegwand 
onderzocht. We vonden een verband tussen roken en toegenomen verandering in de 
samenstelling van de luchtwegwand. Daarnaast was er een verband tussen toename van 
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veranderingen in de luchtwegwand en toename van astmaklachten zeals aangegeven 
door de patient zelf. Bij actieve rokers werden minder eosinofiele ontstekingscellen 
en mestcellen gevonden dan bij nooit-rokers. Dit is eerder gevonden en betekent dat 
andere factoren dan eosinofiele ontstekingscellen bij rokers zorgen voor de versnelde 
achteruitgang van longfunctie. Tot onze verrassing was het aantal mestcellen en de 
mate van verandering van de luchtwegwand gelijk tussen ex-rokers en nooit rokers. 
Dit suggereert dat schade door sigarettenrook (deels) omkeerbaar is na stoppen met 
roken. 
Het belangrijkste verschil tussen ( ex-)rokers en nooit-rokers was het toegenomen 
aantal eosinofiele ontstekingscellen bij nooit rokers in vergelijkingen tot beide andere 
groepen. Het aantal eosinofiele ontstekingscellen nam toe met duur van stoppen van 
roken in de groep van ex-rokers. Dit suggereert dat het onderdrukken van eosinofiele 
ontsteking door roken verdwijnt na stoppen met roken. Dit zou voro de patienten 
gunstig kunnen zijn, omdat eosinofiele ontsteking vaak goed reageert op behandeling 
met ontstekingsremmers. 
ASTMA CONTROLE 
In hoofdstuk 7 werd onderzocht of er een verband was tussen verschillende 
manieren van het meten van astma controle en de gemeten mate van ontsteking 
in de luchtwegen en kwaliteit van leven. We vergeleken 69 patienten die hun astma 
voldoende ender controle hadden (volgens de GOAL criteria) met 42 patienten die hun 
astma niet ender controle hadden. We vonden dat patienten met gecontroleerd astma 
minder eosinofiele ontstekingscellen hadden in het bleed, minder gevoelig waren 
voor AMP en minder stikstofmonoxide in de uitademingslucht hadden dan patienten 
met ongecontroleerd astma. Ook in biopten van de luchtwegwand van patienten 
met gecontroleerd astma vonden we minder actieve eosinofiele ontstekingscel len en 
minder schade aan het epitheel dan in ongecontroleerd astma. 
Deze bevindingen zijn belangrijk omdat de mate van astma controle werd vastgesteld 
met behulp van een simpel dagboek met symptomen en een eenvoudige blaastest 
(GOAL criteria). Nu blijkt dat deze relatief eenvoudig uit te voeren bepaling van astma 
controle oak echt samen gaat met de mate van ontsteking in de luchtwegen en de 
hoeveelheid veranderingen van de luchtwegwand van astmapatienten. Dit ondersteunt 
dus deze manier van meten van astma controle. 
De gemeten kwaliteit van leven volgens de AQLQ vragenlijst was hoger bij patienten 
met gecontroleerd astma dan bij de groep met ongecontroleerd astma. Dit geeft aan 
dat streven naar een betere astma controle met behulp van de GOAL criteria oak 
daadwerkelijk voor patient een merkbaar verschil maakt. 
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1. Bij (voormalig) astmapatienten die voldoen aan de criteria van complete astma 
remissie wordt er geen toename van ontstekingscellen gezien in luchtwegslijm na 
inademen van AMP. Bij astmapatienten met nog steeds overgevoelige luchtwegen 
wordt deze toename van ontstekingcellen wel gezien ( Hoofdstuk 2). 
2 .  Bij (voormalig) astmapatienten die voldoen aan de criteria van complete astma 
remissie wordt er een lager aantal eosinofiele ontstekingscellen in de luchtwegwand 
gemeten dan bij astmapatienten in klinische remissie en bij astmapatienten met 
nog steeds astmasymptomen ( Hoofdstuk 3). 
3. De dikte van de basaalmembraan is gelijk bij (voormalig) astmapatienten die 
voldoen aan de criteria van complete astma remissie, astmapatienten in klinische 
remissie en astmapatienten met nog steeds astmasymptomen ( Hoefdstuk 3). 
4. Astmapatienten die geveelig zijn veer AMP hebben meereesinefiele ontstekingscellen 
en een dikkere basaalmembraan dan AMP engevoelige astmapatienten ( Hoofdstuk 
4). 
5. Bij (veormalig) astmapatienten die voldeen aan de criteria van complete astma 
remissie worden evenveel eesinofiele ontstekingscellen gevenden in luchtwegslijm 
en luchtwegbiopten als bij astmapatienten met een langzame achteruitgang in 
longfunctie. Astmapatienten met een snelle achteruitgang in longfunctie hadden 
meer eosinofiele entstekingscellen in de luchtwegen dan deze beide andere greepen 
( Heofdstuk 5). 
6. Rokende astma patienten hebben veranderingen in de luchtwegwand die gerelateerd 
zijn aan astmasymptemen zoals kertademigheid en hoesten ( Hoofdstuk 6). 
7. Astmapatienten die met roken gestept zijn hebben een vergelijkbare samenstelling 
van de luchtwegwand als astmapatienten die nooit gerookt hebben ( Hoofdstuk 
6). 
8. De mate van astmacentrole zeals gemeten met vragenlijsten en longfunctietesten 
is gerelateerd aan de heeveelheden entsteking in de luchtwegen zeals gemeten bij 
directe en indirecte testen ( Hoefdstuk 7). 
9. De mate van astmacentrole is gerelateerd aan de kwaliteit van leven bij 
astmapatienten ( Hoefdstuk 7). 
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Dankwoord 
Na 6 jaren van noeste arbeid zit het erop .  Het proefschrift is af! 
De uitdrukking mede mogel ijk gemaakt door: . . . is op d it proefschrift zeker van toepassing .  
In d i t  laatste hoofdstuk w i l  ik graag iedereen bedanken d ie  mijn  werk en  daarmee het 
proefschrift mogelijk heeft gemaakt. 
Eerst nog even dit :  Een i nternist bij de longziekten komt dat wel goed? Net aangenomen 
voor de opleid ing i nterne geneeskunde en dan onderzoek doen bij de longziekten omdat 
een kl in ische studie naar de effecten van roken bij astma zo leuk l ijkt .  Grote kans dat 
i k  tot inzicht zou komen en toch longarts zou wil len worden . . . .  U iteindel ijk ben ik n iet 
bekeerd, maar wat m ij betreft is het kenmerk van de intern ist het brede interessegebied 
en daar hoort longziekten (en astma in het bijzonder) ook absoluut bij !  
Beste Dirkje, mijn eerste promoter, i k  w i l  je hartelijk danken voor de fijne samenwerking 
de afgelopen jaren .  Je scherpte, energie en daadkracht zijn bewonderenswaard ig .  De 
gezamenl ijke besprekingen en bra instormsessies heb ik zeer gewaardeerd en hebben 
steeds geleid tot een "strak" n ieuw plan met u iteindel ij k  oak mooie resultaten .  Ik  heb 
een dikke 3 jaar fu l lt ime onderzoek mogen doen, d it b leek voor deze forse kl in ische 
studies te krap om snel tot een proefschrift te komen . Daarna eiste de opleid ing interne 
geneeskunde ook de nod ige tijd op. U iteindel ijk  heeft het 6 jaar geduurd voor het 
proefschrift naar de leescommissie g ing . Af en toe heb je h iervoor het nodige geduld 
moeten opbrengen, maar v ia subtiele, d ip lomatieke wegen (N ick) wist je de beweg ing er 
wel  steeds in te houden . Inmiddels l igt h iervan het tastbaar resu ltaat in  handen !  
Beste Wim,  mijn tweede promoter, onze eerste kenn ismaking was a l  tijdens de 
sol l icitatiegesprekken voor het promotietraject. I k  had woensdagmiddag v ia  e-mai l  
m ijn interesse voor onderzoek kenbaar gemaakt. 2 dagen later zaten j ij ,  N ick en ik 
a l  gezamenl ijk  aan tafel voor de sol l icitatie .  Na de verkenn ing beiderzijds was b innen 
1 week de zaak  beklonken .  I k  wil je graag bedanken voor de prettige samenwerking 
tijdens het onderzoek .  We hadden mooie kl inische studies i n  handen waarbij zeer veel 
materiaa l  werd verzameld voor verdere ana lyses in het laboratorium .  De gezamenl ijk  
w i l  om met d i t  kostbare materiaal tot resu ltaten te  komen was  sterk en de u itgebreide 
mogelijkheden die je hiertoe gecreeerd hebt, hebben, denk ik, zeker hun vruchten 
afgeworpen .  
Beste N ick, mijn  co- promoter. De  afgelopen jaren en  zeker de  eerste 3 hebben we 
i ntensief samengewerkt. De ochtend na m ijn  eerste sol l icitatiemai l  was jij degene die 
me d irect belde en zie waar d it toe geleid heeft! Het samenwerken met jou was zeer 
plezierig . De i nteresse voor onderzoek wist je zeker over te brengen en de ru imte die 
ik kreeg voor overleg en eigen inbreng heb ik  zeer gewaardeerd . Ik  heb bewondering 
voor je creativiteit van denken .  J ij wist, i n  mijn  ogen,  bekende paden in een hee l  n ieuw 
dagl icht te zetten waarbij onverwacht nieuwe wegen voor onderzoek werden gevonden . 
Oak de omgang en geze l l igheid bu iten het onderzoek tijdens congressen en eten bij ju l l ie 
thuis z ijn mij warm bijgebleven .  Je had af en toe de dankbare taak  om als bemiddelaar te 
fungeren  a ls er wat te wein ig progressie vanu it m ijn  kant l eek te z ijn . Je begrip, subti l iteit 
en hu lp  hebben er zeker toe bijgedragen dat het proefschrift nu afgerond is. 
M ijn col lega's van de longfunctie afdel ing in  Beatrixoord . Beste Therese, Monica , Aly, 
Door, E l ly, Henk, N ienke, Margrietha en Maria ,hartel ijk  dank voor de prettige tijd die ik in 
Beatrixoord heb gehad . Het patientenonderzoek vond grotendeels plaats in Beatrixoord 
en zo hebben we jaren lang intensief contact gehad . Dank  voor de gezel l igheid en de 
prettige samenwerking .  Hard werken,  maar oak lekker l unchen samen i n  de zon op het 
terras.  De wil om goed onderzoek te doen was in Beatrixoord sterk aanwezig en dit heeft 
tot prachtige inclusieresu ltaten geleid .  Zander ju l l ie  hu lp  b ij p lann ingen, mai l ingen, data­
invoer, recruteri ng, etc. was het onderzoek nooit zo ver gekomen . Hiervoor nogmaals 
mijn  hartel ijk dank!  
Beste Monique.  Dank  voor je bijdrage aan het onderzoek . Dank voor de tal loze keren dat 
je vanu it het UMCG naar Beatrixoord heen en weer bent gereisd voor verwerken van het 
sputum .  Dank voor je nauwkeurigheid van werken waardoor het onderzoek en ana lyses 
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steeds goed op gang konden blijven. 
I would like to thank Prof.cir. I. D. Pavord, Prof.cir H .J. Kauffman and Prof.cir. J .A. M. 
Raaymakers for their willingness to be a member of the review committee of this 
thesis. 
Beste Huib en Rob, graag wil ik jullie bedanken voor het doen van het grootste deel van 
de bronchoscopieen voor het onderzoek. Onderzoekscopieen is een aparte tak van sport, 
dankzij jullie toewijding hebben we hierin prachtige resultaten geboekt waarop inmiddels 
veel van onze belangrijkste onderzoeksconclusies gebaseerd zijn. 
Alie Smid, hartelijk dank voor je assistentie tijdens vrijwel alle scopieen. Dank voor je 
hulp om de planning met deze scopieen telkens weer rond te krijgen. 
Beste Machteld, hartelijk dank voor je bijdrage aan de "rokend astma besprekingen" en 
de artikelen. Het was fijn en leerzaam om met jou te mogen samenwerken. 
Beste Judith Vonk, mag ik jou hartelijk danken voor je ondersteuning bij de analyses van 
het onderzoek. Jouw hulp bij de statistiek en grote kennis van de onderzoekscohorten 
heeft mijn werk een stuk makkelijker gemaakt. 
Graag wil ik mijn collega onderzoeker danken voor de gezellige tijd, luisterend oor en 
steun tijdens de onderzoekstijd. Beste Wouter, Judith, Margot, Toby, Renske, Naomi, 
Erik, Fransien, Hester, Sandra, Linda, Eef, Marieke, Corry Anke, Anne, Cleo, Juliet en Jan 
Willem, ik hoop jullie te zien op mijn promotie! 
Beste Martine, het onderzoeksstokje dat in mijn handen vooral klinisch was heb jij 
met verve meegenomen het laboratorium in. Goede resultaten uit het bioptmateriaal 
hebben de weg vrijgemaakt voor mooie publicaties. Hartelijk dank voor de prettige 
samenwerking ! 
Collega's van de longfunctie in het UMCG. Beste Martijn, Jose, Sindy en Karin dank voor 
jullie hulp en gezellige samenwerking tijdens de NO metingen in het U MCG. 
Jan Bouwman, hartelijk dank voor de mogelijkheden die je ons gegeven om met een 
forse personele bezetting vanuit de longfunctie het onderzoek te kunnen doen. 
Johan Wempe en Peter Vennik wil ik graag bedanken voor het waarnemen van het 
patientenonderzoek in Beatrixoord. Dankzij jullie kon de inclusie doorgaan, ook op dagen 
dat ik in het UMCG aanwezig moest zijn. 
Beste leden van de G RIAC die ik niet allemaal bij naam durf te noemen gezien de kans 
iemand te vergeten . . .  Onze wekelijkse bespreking waren heel leerzaam en gaven mij de 
mogelijkheid het blikveld te verruimen. Dank voor jullie bijdragen ! 
Beste Anne, hartelijk dank voor je hulp om dit boekje klaar te maken voor de drukker. 
Het secretariaat longziekten wil graag bedanken voor hun hulp en prettige samenwerking. 
Met name Evelyn en Trudy, die als kostbare link steeds weer een gezamenlijke afspraak 
wisten te creeren tussen alle (bijna) volgeboekte agenda's. 
Alie deelnemers aan de onderzoeken wil ik van harte bedanken voor hun bijdrage. 
Gemiddeld zagen wij elkaar 5-6 keer voor de metingen voor het onderzoek. Het was een 
intensief programma en zonder jullie toewijding waren we nu nog net zover als aan het 
begin van de studie! Mijn respect en dank is groot! 
Beste Bas en Maarten, fijn dat jullie mij willen bijstaan op dit bijzonder moment! Samen 
moeten we in staat zijn links van rechts te onderscheiden . . .  
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Lieve Antje, dank voor je tijd en scherpe blik in de tekstuele beoordeling van mijn 
proefschrift. 
Lieve vrienden en familie, dank voor jullie gezelligheid en steun. Misschien wordt een 
afspraak in de agenda nu iets makkelijker .. . .  13 december kan er alvast in! 
Mijn lieve ouders, dank voor jullie trouwe steun door de jaren heen en zeker in de 
hectiek tijdens de laatste loodjes. Wat het onderzoek inhield was grotendeels ver van 
jullie bed, maar tijdens julllie hulp bij de tekstuele beoordeling van de nederlandse 
samenvatting zijn mijn bezigheden een stuk duidelijk geworden. 0 ja, beloop is, denk 
ik, gewoon medisch jargon en deze dokter is wel eens eigenwijs . . .  
Lieve schoonouders . . .  T ijd voor onderzoek moest gemaakt warden en zonder jullie 
geweldige hulp was dit nooit gelukt. Dank voor jullie liefde en inzet om gezin en 
huishouden draaiende te houden terwij l aan dit proefschrift werd gewerkt! 
Lieve, lieve Kirsten, samen staan we sterk en zonder jou was dit proefschrift er nooit 
gekomen. Ze zeggen dat er na de promotie een en ander verandert, aan plannen om 
dit in te vullen hebben wij gelukkig nooit gebrek .. .  
Mijn mooie mannen. Lieve Lars, Stijn en Jort: Papa zal nag steeds af en toe thuis 
moeten werken . . .  maar wel een stuk minder ! 
Beste lezer, hier houdt het proefschrift op. Dank voor de interesse ! 
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